<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">gastro-j</journal-id><journal-title-group><journal-title xml:lang="ru">Российский журнал гастроэнтерологии, гепатологии, колопроктологии</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Gastroenterology, Hepatology, Coloproctology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1382-4376</issn><issn pub-type="epub">2658-6673</issn><publisher><publisher-name>«Gastro» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.22416/1382-4376-2025-35-1-94-152</article-id><article-id custom-type="elpub" pub-id-type="custom">gastro-j-1461</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ РОССИЙСКОЙ ГАСТРОЭНТЕРОЛОГИЧЕСКОЙ АССОЦИАЦИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL GUIDELINES OF THE RUSSIAN GASTROENTEROLOGICAL ASSOCIATION</subject></subj-group></article-categories><title-group><article-title>Клинические рекомендации Российского общества по изучению печени, Российской гастроэнтерологической ассоциации, Российского общества профилактики неинфекционных заболеваний, Российской ассоциации эндокринологов, Российского научного медицинского общества терапевтов, Национального общества профилактической кардиологии, Российской ассоциации геронтологов и гериатров по неалкогольной жировой болезни печени</article-title><trans-title-group xml:lang="en"><trans-title>Clinical Guidelines of the Russian Society for the Study of the Liver, Russian Gastroenterological Association, Russian Society for the Prevention of Non-Communicable Diseases, Russian Association of Endocrinologists, Russian Scientific Medical Society of Therapists, National Society of Preventive Cardiology, Russian Association of Gerontologists and Geriatricians on Non-Alcoholic Fatty Liver Disease</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6815-6015</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ивашкин</surname><given-names>В. Т.</given-names></name><name name-style="western" xml:lang="en"><surname>Ivashkin</surname><given-names>V. T.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ивашкин Владимир Трофимович  —  доктор медицинских наук, профессор, академик РАН, заведующий кафедрой пропедевтики внутренних болезней, гастроэнтерологии и гепатологии </p><p>119435, г. Москва, ул. Погодинская, 1, стр. 1. </p></bio><bio xml:lang="en"><p>Vladimir T. Ivashkin — Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences, Head of the Department of Propaedeutics of Internal Diseases, Gastroenterology and  Hepatology </p><p>119435, Moscow, Pogodinskaya str., 1, build. 1.</p></bio><email xlink:type="simple">ivashkin_v_t@staff.sechenov.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4453-8430</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Драпкина</surname><given-names>О. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Drapkina</surname><given-names>O. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Драпкина Оксана Михайловна — доктор медицинских наук, профессор, академик РАН, директор </p><p>101000, г. Москва, Петроверигский пер., 10, стр. 3. </p></bio><bio xml:lang="en"><p>Оksana M. Drapkina — Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences, Director </p><p>101000, Moscow, Petroverginskiy lane, 10, build. 3.</p></bio><email xlink:type="simple">drapkina@bk.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8913-140X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Маевская</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Maevskaya</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Маевская Марина Викторовна — доктор медицинских наук, профессор </p><p>119435, г. Москва, ул. Погодинская, 1, стр. 1. </p></bio><bio xml:lang="en"><p>Marina V. Maevskaya — Dr. Sci. (Med.), Professor </p><p>119435, Moscow, Pogodinskaya str., 1, build. 1.</p></bio><email xlink:type="simple">maevskaya_m_v@staff.sechenov.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8821-6142</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Райхельсон</surname><given-names>К. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Raikhelson</surname><given-names>K. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Райхельсон Карина Леонидовна — доктор медицинских наук, профессор Научно-клинического и образовательного центра гастроэнтерологии и гепатологии </p><p>199034, г. Санкт-Петербург, Университетская наб., 7/9. </p></bio><bio xml:lang="en"><p>Karina L. Raikhelson — Dr. Sci. (Med.), Professor of the Scientific, Clinical and Educational Centre of Gastroenterology and Hepatology </p><p>199034, Saint Petersburg, Universitetskaya embankment, 7/9.</p></bio><email xlink:type="simple">kraikhelson@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4294-5531</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Оковитый</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Okovityi</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Оковитый Сергей Владимирович — доктор медицинских наук, профессор, заведующий кафедрой фармакологии и клинической фармакологии </p><p>197022, г. Санкт-Петербург, ул. Профессора Попова, 14а. </p></bio><bio xml:lang="en"><p>Sergey V. Okovityi — Dr. Sci. (Med.), Professor, Head of the Department of Pharmacology and Clinical Pharmacology </p><p>197022, Saint Petersburg, Professora Popova str., 14А.</p></bio><email xlink:type="simple">sergey.okovity@pharminnotech.com</email><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5939-1032</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Жаркова</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Zharkova</surname><given-names>M. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Жаркова Мария Сергеевна — кандидат медицинских наук, заведующая отделением гепатологии Клиники пропедевтики внутренних болезней, гастроэнтерологии, гепатологии им. В.Х. Василенко </p><p>119048, г. Москва, ул. Трубецкая, 8, стр. 2. </p></bio><bio xml:lang="en"><p>Maria S. Zharkova — Cand. Sci. (Med.), Head of the Hepatology Department, V.Kh. Vasilenko Clinic of Internal Disease Propaedeutics, Gastroenterology and Hepatology </p><p>119048, Moscow, Trubetskaya str., 8/2.</p></bio><email xlink:type="simple">zharkova_m_s@staff.sechenov.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3851-626X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гречишникова</surname><given-names>В. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Grechishnikova</surname><given-names>V. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гречишникова Василиса Романовна — аспирант, ассистент кафедры пропедевтики внутренних болезней, гастроэнтерологии и гепатологии Института клинической медицины им. Н.В. Склифосовского </p><p>119435, г. Москва, ул. Погодинская, 1, стр. 1. </p></bio><bio xml:lang="en"><p>Vasilisa R. Grechishnikova — Postgraduate, Teaching Assistant of the Department of Internal Disease Propaedeutics, Gastroenterology and Hepatology, N.V. Sklifosovsky Institute of Clinical Medicine </p><p>119435, Moscow, Pogodinskaya str., 1, build. 1.</p></bio><email xlink:type="simple">korneeva_v_r@staff.sechenov.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7069-2725</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Абдулганиева</surname><given-names>Д. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Abdulganieva</surname><given-names>D. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Абдулганиева Диана Ильдаровна — доктор медицинских наук, профессор, заведующая кафедрой госпитальной терапии </p><p>420012, г. Казань, ул. Бутлерова, 49. </p></bio><bio xml:lang="en"><p>Diana I. Abdulganieva — Dr. Sci. (Med.), Professor, Head of the Department of Hospital Therapy </p><p>420012, Kazan, Butlerova str., 49</p></bio><email xlink:type="simple">diana_s@mail.ru</email><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1724-9980</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Алексеенко</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Alekseenko</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Алексеенко Сергей Алексеевич — доктор медицинских наук, профессор, заведующий кафедрой госпитальной терапии </p><p>680000, г. Хабаровск, ул. Муравьева-Амурского, 35. </p></bio><bio xml:lang="en"><p>Sergei A. Alekseenko — Dr. Sci. (Med.), Professor, Head of the Department of Hospital Therapy </p><p>680000, Khabarovsk, Muravyova-Amurskogo str., 35</p></bio><email xlink:type="simple">sa.alexeenko@gmail.com</email><xref ref-type="aff" rid="aff-6"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8069-0368</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ардатская</surname><given-names>М. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Ardatskaya</surname><given-names>M. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ардатская Мария Дмитриевна — доктор медицинских наук, профессор </p><p>121359, г. Москва, ул. Маршала Тимошенко, 19, стр. 1А. </p></bio><bio xml:lang="en"><p>Maria D. Ardatskaya — Dr. Sci. (Med.), Professor </p><p>121359, Moscow, Marshala Timoshenko str., 19, build. 1A.</p></bio><email xlink:type="simple">ma@uni-med.ru</email><xref ref-type="aff" rid="aff-7"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6151-2021</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бакулин</surname><given-names>И. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Bakulin</surname><given-names>I. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бакулин Игорь Геннадьевич — доктор медицинских наук, профессор, заведующий кафедрой пропедевтики внутренних болезней, гастроэнтерологии и диетологии им. С.М. Рысса </p><p>191015, г. Санкт-Петербург, ул. Кирочная, 41. </p></bio><bio xml:lang="en"><p>Igor G. Bakulin — Dr. Sci. (Med.), Professor, Head of  the Department of Propaedeutics of Internal Medicine, Gastroenterology and Dietetics named after S.M. Ryss </p><p>191015, Saint Petersburg, Kirochnaya str., 41.</p></bio><email xlink:type="simple">igbakulin@yandex.ru</email><xref ref-type="aff" rid="aff-8"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4075-4096</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бакулина</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Bakulina</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бакулина Наталья Валерьевна — доктор медицинских наук, профессор, проректор по науке и инновационной деятельности, заведующая кафедрой внутренних болезней, клинической фармакологии и нефрологии </p><p>191015, г. Санкт-Петербург, ул. Кирочная, 41.</p></bio><bio xml:lang="en"><p>Natalia V. Bakulina — Dr. Sci. (Med.), Head of the Department of Internal Medicine, Nephrology, General and Clinical Pharmacology with a course in Pharmacy </p><p>191015, Saint Petersburg, Kirochnaya str., 41.</p></bio><email xlink:type="simple">natalya.bakulina@szgmu.ru</email><xref ref-type="aff" rid="aff-8"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2346-1216</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Богомолов</surname><given-names>П. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Bogomolov</surname><given-names>P. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Богомолов Павел Олегович — кандидат медицинских наук, доцент кафедры пропедевтики внутренних болезней и гастроэнтерологии; руководитель отделения и ведущий научный сотрудник гепатологического отделения </p><p>129110, г. Москва, ул. Щепкина, 61/2.</p></bio><bio xml:lang="en"><p>Pavel O. Bogomolov — Cand. Sci. (Med.), Associate Professor of the Department of Propaedeutics of Internal Medicine and  Gastroenterology; Head of the Department of Hepatology </p><p>129110, Moscow, Shchepkina str., 61/2.</p></bio><email xlink:type="simple">Bpo73@list.ru</email><xref ref-type="aff" rid="aff-9"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6244-4294</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бредер</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Breder</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бредер Валерий Владимирович — доктор медицинских наук, заведующий отделом лекарственного лечения </p><p>115478, г. Москва, Каширское шоссе, 24. </p></bio><bio xml:lang="en"><p>Valeriy V. Breder — Dr. Sci. (Med.), Head of the Department of  Drug Treatment </p><p>115478, Moscow, Kashirskoe highway, 24.</p></bio><email xlink:type="simple">vbreder@yandex.ru</email><xref ref-type="aff" rid="aff-10"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0344-8375</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Винницкая</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vinnitskaya</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Винницкая Елена Владимировна — доктор медицинских наук, заведующая отделом гепатологии </p><p>111123, г. Москва, шоссе Энтузиастов, 86.</p></bio><bio xml:lang="en"><p>Elena V. Vinnitskaya — Dr. Sci. (Med.), Head of the Department of Hepatology </p><p>111123, Moscow, Entuziastov highway, 86.</p></bio><email xlink:type="simple">evinn@mail.ru</email><xref ref-type="aff" rid="aff-11"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5920-5703</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гейвандова</surname><given-names>Н. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Geyvandova</surname><given-names>N. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гейвандова Наталья Иогановна — доктор медицинских наук, профессор </p><p>355017, г. Ставрополь, ул. Мира, 310.</p></bio><bio xml:lang="en"><p>Natalia I. Geyvandova — Dr. Sci. (Med.), Professor of the Department of Hospital Therapy </p><p>355017, Stavropol, Mira str., 310.</p></bio><email xlink:type="simple">ngeyvandova@yandex.ru</email><xref ref-type="aff" rid="aff-12"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8034-5329</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Голованова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Golovanova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Голованова Елена Владимировна — доктор медицинских наук, профессор кафедры терапии и профилактической медицины </p><p>127473, г. Москва, ул. Делегатская, 20, стр. 1.</p></bio><bio xml:lang="en"><p>Elena V. Golovanova — Dr. Sci. (Med.), Professor of the Department of Therapy and Preventive Medicine </p><p>127473, Moscow, Delegatskaya str., 20, build. 1.</p></bio><email xlink:type="simple">golovanovaev@mail.ru</email><xref ref-type="aff" rid="aff-13"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1095-8787</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гриневич</surname><given-names>В. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Grinevich</surname><given-names>V. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гриневич Владимир Борисович — доктор медицинских наук, профессор, заведующий 2-й кафедрой (терапии усовершенствования врачей) </p><p>194044, г. Санкт-Петербург, ул. Академика Лебедева, 6. </p></bio><bio xml:lang="en"><p>Vladimir B. Grinevich — Dr. Sci. (Med.), Professor, Head of the 2nd Department of Therapy </p><p>194044, Saint Petersburg, Akademika Lebedeva str., 6.</p></bio><email xlink:type="simple">vb_grinevich@mail.ru</email><xref ref-type="aff" rid="aff-14"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8874-4108</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дощицин</surname><given-names>В. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Doshchitsin</surname><given-names>V. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Дощицин Владимир Леонидович — доктор медицинских наук, профессор, профессор кафедры кардиологии </p><p>117997, г. Москва, ул. Островитянова, 1.</p></bio><bio xml:lang="en"><p>Vladimir L. Doshchitsin — Dr. Sci. (Med.), Professor, Professor of the Department of Cardiology </p><p>117997, Moscow, Ostrovityanova str., 1.</p></bio><email xlink:type="simple">vlad.dos@mail.ru</email><xref ref-type="aff" rid="aff-15"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7891-6850</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дудинская</surname><given-names>Е. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Dudinskaya</surname><given-names>E. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Дудинская Екатерина Наильевна — доктор медицинских наук, заведующая лабораторией возрастных метаболических и эндокринных нарушений, обособленное структурное подразделение «Российский геронтологический научно-клинический центр», профессор кафедры болезней старения факультета дополнительного профессионального образования </p><p>129226, г. Москва, ул. 1-я Леонова, 16.</p></bio><bio xml:lang="en"><p>Ekaterina N. Dudinskaya — Dr. Sci. (Med.), Head of the Laboratory of Age-Related Metabolic Endocrinological Disorders, Russian Gerontological Scientific and Clinical Center, Professor of the Department of Aging Diseases of the Faculty of Continuing Professional Education </p><p>129226, Moscow, 1-ya Leonova str., 16.</p></bio><email xlink:type="simple">katharina.gin@gmail.com</email><xref ref-type="aff" rid="aff-15"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6220-4397</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ершова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ershova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ершова Екатерина Владимировна — кандидат медицинских наук, ведущий научный сотрудник отдела терапевтической эндокринологии </p><p>117292, г. Москва, ул. Дмитрия Ульянова, 11.</p></bio><bio xml:lang="en"><p>Ekaterina V. Ershova — Cand. Sci. (Med.), Leading Researcher of the Department of Therapeutic Endocrinology </p><p>117292, Moscow, Dmitriya Ulyanova str., 11.</p></bio><email xlink:type="simple">yu99pol06@rambler.ru</email><xref ref-type="aff" rid="aff-16"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7510-6553</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кодзоева</surname><given-names>Х. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Kodzoeva</surname><given-names>K. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кодзоева Хава Багаудиновна — врач-терапевт терапевтического отделения </p><p>119435, г. Москва, ул. Погодинская, 1, стр. 1. </p></bio><bio xml:lang="en"><p>Khava B. Kodzoeva — Physician of the Therapeutic Department </p><p>119435, Moscow, Pogodinskaya str., 1, build. 1.</p></bio><email xlink:type="simple">kod_eva@bk.ru</email><xref ref-type="aff" rid="aff-17"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5056-4504</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Козлова</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kozlova</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Козлова Ирина Вадимовна — доктор медицинских наук, профессор </p><p>410012, г. Саратов, ул. Большая Казачья, 112. </p></bio><bio xml:lang="en"><p>Irina V. Kozlova — Dr. Sci. (Med.), Professor </p><p>410012, Saratov, Bolshaya Kazachya str., 112.</p></bio><email xlink:type="simple">kozlova@inbox.ru</email><xref ref-type="aff" rid="aff-18"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6624-2374</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Комшилова</surname><given-names>К. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Komshilova</surname><given-names>K. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Комшилова Ксения Андреевна — кандидат медицинских наук, врач-эндокринолог отделения терапии заболеваний щитовидной железы, надпочечников и ожирения отдела терапевтической эндокринологии </p><p>117292, г. Москва, ул. Дмитрия Ульянова, 11. </p></bio><bio xml:lang="en"><p>Kseniya A. Komshilova — Cand. Sci. (Med.), Endocrinologist at the Department of Therapy of Thyroid Gland Diseases, Adrenal Glands and Obesity, Department of Therapeutic Endocrinology </p><p>117292, Moscow, Dmitriya Ulyanova str., 11.</p></bio><email xlink:type="simple">kom-ksusha@rambler.ru</email><xref ref-type="aff" rid="aff-16"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4786-2041</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Конев</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Konev</surname><given-names>Yu. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Конев Юрий Владимирович — доктор медицинских наук, профессор кафедры поликлинической терапии </p><p>127473, г. Москва, ул. Делегатская, 20, стр. 1. </p></bio><bio xml:lang="en"><p>Yuri V. Konev — Dr. Sci. (Med.), Professor of the Department of Outpatient Therapy </p><p>127473, Moscow, Delegatskaya str., 20, build. 1.</p></bio><email xlink:type="simple">ukonev@rambler.ru</email><xref ref-type="aff" rid="aff-13"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5538-9418</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Корочанская</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Korochanskaya</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Корочанская Наталья Всеволодовна — доктор медицинских наук, профессор </p><p>350063, г. Краснодар, ул. Митрофана Седина, 4. </p></bio><bio xml:lang="en"><p>Natalia V. Korochanskaya — Dr. Sci. (Med.), Professor </p><p>350063, Krasnodar, Mitrofana Sedina str., 4.</p></bio><email xlink:type="simple">nvk-gastro@mail.ru</email><xref ref-type="aff" rid="aff-19"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1628-5093</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Котовская</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kotovskaya</surname><given-names>Yu. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Котовская Юлия Викторовна — доктор медицинских наук, профессор, заместитель директора по научной работе, обособленное структурное подразделение «Российский геронтологический научно-клинический центр» </p><p>129226, г. Москва, ул. 1-я Леонова, 16.</p></bio><bio xml:lang="en"><p>Yulia V. Kotovskaya — Dr. Sci. (Med.), Professor, Deputy Director for Research, Russian Gerontological Scientific and  Clinical Center </p><p>129226, Moscow, 1-ya Leonova str., 16.</p></bio><email xlink:type="simple">kotovskaya_yv@rgnkc.ru</email><xref ref-type="aff" rid="aff-15"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8347-0531</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кравчук</surname><given-names>Ю. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kravchuk</surname><given-names>Yu. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кравчук Юрий Алексеевич — доктор медицинских наук, профессор </p><p>194044, г. Санкт-Петербург, ул. Академика Лебедева, 6. </p></bio><bio xml:lang="en"><p>Yuri A. Kravchuk — Dr. Sci. (Med.), Professor </p><p>194044, Saint Petersburg, Akademika Lebedeva str., 6.</p></bio><email xlink:type="simple">kravchuk2003@mail.ru</email><xref ref-type="aff" rid="aff-14"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3681-4132</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лоранская</surname><given-names>И. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Loranskaya</surname><given-names>I. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лоранская Ирина Дмитриевна — доктор медицинских наук, профессор, декан терапевтического факультета, заведующая кафедрой гастроэнтерологии </p><p>123242, г. Москва, Баррикадная ул., 2/1, корп. 1. </p></bio><bio xml:lang="en"><p>Irina D. Loranskaya — Dr. Sci. (Med.), Professor, Dean of the Faculty of Therapy, Head of the Department of Gastroenterology of  the Faculty of Therapy </p><p>123242, Moscow, Barrikadnaya str., 2/1, build. 1.</p></bio><email xlink:type="simple">gastrormapo@yandex.ru</email><xref ref-type="aff" rid="aff-20"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6114-564X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Маев</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Maev</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Маев Игорь Вениаминович — доктор медицинских наук, профессор, академик РАН, заведующий кафедрой пропедевтики внутренних болезней и гастроэнтерологии </p><p>127473, г. Москва, ул. Делегатская, 20, стр. 1. </p></bio><bio xml:lang="en"><p>Igor V. Maev — Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences, Head of the Department of Internal Disease Propaedeutics and Gastroenterology </p><p>127473, Moscow, Delegatskaya str., 20, build. 1.</p></bio><email xlink:type="simple">igormaev@rambler.ru</email><xref ref-type="aff" rid="aff-13"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2839-7292</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мартынов</surname><given-names>А. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Martynov</surname><given-names>A. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мартынов Анатолий Иванович — доктор медицинских наук, академик РАН, профессор кафедры госпитальной терапии № 1 лечебного факультета </p><p>127473, г. Москва, ул. Делегатская, 20, стр. 1.</p></bio><bio xml:lang="en"><p>Anatoliy I. Martynov — Dr. Sci. (Med.), Academician of the Russian Academy of Sciences, Professor of the Department of Hospital Therapy No. 1 of the Faculty of Medicine </p><p>127473, Moscow, Delegatskaya str., 20, build. 1.</p></bio><email xlink:type="simple">anatmartynov@mail.ru</email><xref ref-type="aff" rid="aff-13"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7367-9219</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мехтиев</surname><given-names>С. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Mekhtiev</surname><given-names>S. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мехтиев Сабир Насрединович — доктор медицинских наук, профессор </p><p>197022, г. Санкт-Петербург, ул. Льва Толстого, 6-8</p></bio><bio xml:lang="en"><p>Sabir N. Mekhtiev — Dr. Sci. (Med.), Professor </p><p>197022, Saint Petersburg, L’va Tolstogo str., 6-8.</p></bio><email xlink:type="simple">sabirm@mail.ru</email><xref ref-type="aff" rid="aff-21"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5371-8708</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мишина</surname><given-names>Е. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Mishina</surname><given-names>E. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мишина Екатерина Евгеньевна — кандидат медицинских наук, научный сотрудник, врач-эндокринолог </p><p>117292, г. Москва, ул. Дмитрия Ульянова, 11.</p></bio><bio xml:lang="en"><p>Ekaterina E. Mishina — Cand. Sci. (Med.), Researcher, Endocrinologist </p><p>117292, Moscow, Dmitriya Ulyanova str., 11.</p></bio><email xlink:type="simple">eka-mi@rambler.ru</email><xref ref-type="aff" rid="aff-16"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1210-2528</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Надинская</surname><given-names>М. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Nadinskaia</surname><given-names>M. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Надинская Мария Юрьевна — кандидат медицинских наук, доцент кафедры пропедевтики внутренних болезней, гастроэнтерологии и гепатологии </p><p>119048, г. Москва, ул. Трубецкая, 8, стр. 2. </p></bio><bio xml:lang="en"><p>Maria Yu. Nadinskaia — Cand. Sci. (Med.), Associate Professor of the Department of Propaedeutics of Internal Diseases </p><p>119048, Moscow, Trubetskaya str., 8/2.</p></bio><email xlink:type="simple">nadinskaya_m_yu@staff.sechenov.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1699-0881</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Никитин</surname><given-names>И. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Nikitin</surname><given-names>I. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Никитин Игорь Геннадьевич — доктор медицинских наук, профессор, заведующий кафедрой госпитальной терапии им. академика Г.И. Сторожакова Института клинической медицины </p><p>117997, г. Москва, ул. Островитянова, 1. </p></bio><bio xml:lang="en"><p>Igor G. Nikitin — Dr. Sci. (Med.), Professor, Head of the Department of Hospital Therapy named after Academician G.I.  Storozhakov, Institute of Clinical Medicine </p><p>117997, Moscow, Ostrovityanova str., 1.</p></bio><email xlink:type="simple">igor.nikitin.64@mail.ru</email><xref ref-type="aff" rid="aff-22"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5156-2842</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Осипенко</surname><given-names>М. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Osipenko</surname><given-names>M. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Осипенко Марина Федоровна — доктор медицинских наук, профессор, заведующая кафедрой пропедевтики внутренних болезней </p><p>630091, г. Новосибирск, Красный просп., 52. </p></bio><bio xml:lang="en"><p>Marina F. Osipenko — Dr. Sci. (Med.), Professor, Head of the Department of Internal Diseases Propedeutics </p><p>630091, Novosibirsk, Krasnyi ave., 52.</p></bio><email xlink:type="simple">ngma@bk.ru</email><xref ref-type="aff" rid="aff-23"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0795-8225</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Остроумова</surname><given-names>О. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Ostroumova</surname><given-names>O. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Остроумова Ольга Дмитриевна — доктор медицинских наук, профессор, заведующая кафедрой терапии и полиморбидной патологии им. академика М.С. Вовси </p><p>123242, г. Москва, Баррикадная ул., 2/1, корп. 1.</p></bio><bio xml:lang="en"><p>Olga D. Ostroumova — Dr. Sci. (Med.), Professor, Head of the Department of Therapy and Polymorbid Pathology named after Academician M.S. Vovsi </p><p>123242, Moscow, Barrikadnaya str., 2/1, build. 1.</p></bio><email xlink:type="simple">ostroumova.olga@mail.ru</email><xref ref-type="aff" rid="aff-20"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5031-9798</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Павлов</surname><given-names>Ч. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Pavlov</surname><given-names>Ch. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Павлов Чавдар Савов — доктор медицинских наук, профессор, заведующий кафедрой терапии Института профессионального образования, заместитель директора по научно-организационной работе Института клинической медицины им. Н.В. Склифосовского; руководитель клиники терапии </p><p>252844, г. Москва, 2-й Боткинский проезд, 5.</p></bio><bio xml:lang="en"><p>Chavdar S. Pavlov — Dr. Sci. (Med.), Professor, Head of the Department of Therapy at the Institute of Professional Education, Deputy Director for Scientific and Organizational Work at the  N.V.  Sklifosovsky Institute of Clinical Medicine; Head of the Therapy Clinic </p><p>252844, Moscow, 2-y Botkinsky lane, 5.</p></bio><email xlink:type="simple">chpavlov@mail.ru</email><xref ref-type="aff" rid="aff-24"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4165-804X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Погосова</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Pogosova</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Погосова Нана Вачиковна — доктор медицинских наук, профессор, заместитель генерального директора по научно-аналитической работе и профилактической кардиологии </p><p>121552, г. Москва, ул. Академика Чазова, 15а, стр. 1.</p></bio><bio xml:lang="en"><p>Nana V. Pogosova — Dr. Sci. (Med.), Professor, Deputy Director General for Scientific and Analytical Work and   Preventive Cardiology </p><p>121552, Moscow, Akademika Chazova str., 15a, build. 1.</p></bio><email xlink:type="simple">nanapogosova@gmail.com</email><xref ref-type="aff" rid="aff-25"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2964-9167</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Радченко</surname><given-names>В. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Radchenko</surname><given-names>V. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Радченко Валерий Григорьевич — доктор медицинских наук, профессор, профессор 2-й кафедры (терапии усовершенствования врачей) </p><p>194044, г. Санкт-Петербург, ул. Академика Лебедева, 6. </p></bio><bio xml:lang="en"><p>Valery G. Radchenko — Dr. Sci. (Med.), Professor, Professor of the 2nd Department of Therapy </p><p>194044, Saint Petersburg, Akademika Lebedeva str., 6.</p></bio><email xlink:type="simple">radchenkovalery@mail.ru</email><xref ref-type="aff" rid="aff-14"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0514-9114</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ройтберг</surname><given-names>Г. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Roytberg</surname><given-names>G. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ройтберг Григорий Ефимович — доктор медицинских наук, профессор, академик РАН </p><p>117997, г. Москва, ул. Островитянова, 1. </p></bio><bio xml:lang="en"><p>Grigory E. Roytberg — Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences </p><p>117997, Moscow, Ostrovityanova str., 1.</p></bio><email xlink:type="simple">contact@medicina.ru</email><xref ref-type="aff" rid="aff-15"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2839-100X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сайфутдинов</surname><given-names>Р. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Saifutdinov</surname><given-names>R. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сайфутдинов Рафик Галимзянович — доктор медицинских наук, профессор, заведующий кафедрой госпитальной и поликлинической терапии </p><p>420012, г. Казань, ул. Бутлерова, 36. </p></bio><bio xml:lang="en"><p>Rafik G. Saifutdinov — Dr. Sci. (Med.), Professor, Head of the  Department of Hospital and Polyclinic Therapy </p><p>420012, Kazan, Butlerova str., 36.</p></bio><email xlink:type="simple">rgsbancorp@mail.ru</email><xref ref-type="aff" rid="aff-26"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5617-7110</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Самсонов</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Samsonov</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Самсонов Алексей Андреевич — доктор медицинских наук, профессор кафедры пропедевтики внутренних болезней и  гастроэнтерологии </p><p>127473, г. Москва, ул. Делегатская, 20, стр. 1. </p></bio><bio xml:lang="en"><p>Aleksey A. Samsonov — Dr. Sci. (Med.), Professor of the Department of Propaedeutics of Internal Medicine and Gastroenterology </p><p>127473, Moscow, Delegatskaya str., 20, build. 1.</p></bio><email xlink:type="simple">aleksey.samsonov@gmail.com</email><xref ref-type="aff" rid="aff-13"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5623-4226</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Селиверстов</surname><given-names>П. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Seliverstov</surname><given-names>P. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Селиверстов Павел Васильевич — кандидат медицинских наук, доцент 2-й кафедры (терапии усовершенствования врачей) </p><p>194044, г. Санкт-Петербург, ул. Академика Лебедева, 6. </p></bio><bio xml:lang="en"><p>Pavel V. Seliverstov — Cand. Sci. (Med.), Associate Professor of the 2nd Department of Therapy </p><p>194044, Saint Petersburg, Akademika Lebedeva str., 6.</p></bio><email xlink:type="simple">seliverstov-pv@yandex.ru</email><xref ref-type="aff" rid="aff-14"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0331-0963</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ситкин</surname><given-names>С. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Sitkin</surname><given-names>S. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ситкин Станислав Игоревич — кандидат медицинских наук, доцент кафедры пропедевтики внутренних болезней, гастроэнтерологии и диетологии им. С.М. Рысса; заведующий научно-исследовательской группой эпигенетики и метагеномики Института перинатологии и педиатрии </p><p>197341, г. Санкт-Петербург, ул. Аккуратова, 2. </p></bio><bio xml:lang="en"><p>Stanislav I. Sitkin — Cand. Sci. (Med.), Associate Professor of the Department of Propaedeutics of Internal Medicine, Gastroenterology and Dietetics named after S.M. Ryss; Head of the Research Group of Epigenetics and Metagenomics of the Institute of Perinatology and Pediatrics </p><p>197341, Saint Petersburg, Akkuratova str., 2.</p></bio><email xlink:type="simple">sitkins@mail.ru</email><xref ref-type="aff" rid="aff-27"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1496-0689</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тарасова</surname><given-names>Л. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Tarasova</surname><given-names>L. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Тарасова Лариса Владимировна — доктор медицинских наук, профессор </p><p>428015, г. Чебоксары, Московский просп., 15. </p></bio><bio xml:lang="en"><p>Larisa V. Tarasova — Dr. Sci. (Med.), Professor </p><p>428015, Cheboksary, Moskovsky ave., 15.</p></bio><email xlink:type="simple">Tlarisagast18@mail.ru</email><xref ref-type="aff" rid="aff-28"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9536-8307</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тарзиманова</surname><given-names>А. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Tarzimanova</surname><given-names>A. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Тарзиманова Аида Ильгизовна — доктор медицинских наук, профессор кафедры факультетской терапии № 2 </p><p>119048, г. Москва, ул. Ефремова, 24.</p></bio><bio xml:lang="en"><p>Aida I. Tarzimanova — Dr. Sci. (Med.), Professor of the Department of Faculty Therapy No. 2 </p><p>119048, Moscow, Efremova str., 24.</p></bio><email xlink:type="simple">tarzimanova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4193-688X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ткачева</surname><given-names>О. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Tkacheva</surname><given-names>O. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ткачева Ольга Николаевна — доктор медицинских наук, профессор, член-корреспондент РАН, директор Российского геронтологического научно-клинического центра; главный внештатный гериатр Министерства здравоохранения Российской Федерации. </p><p>129226, г. Москва, ул. 1-я Леонова, 16.</p></bio><bio xml:lang="en"><p>Olga N. Tkacheva — Dr. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences, Director of  the  Russian Gerontological Scientific and Clinical Center; Chief Freelance Geriatrician of the Ministry of Health of  the Russian Federation.</p><p>129226, Moscow, 1-ya Leonova str., 16.</p></bio><email xlink:type="simple">tkacheva@rgnkc.ru</email><xref ref-type="aff" rid="aff-29"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-4123-4649</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ткаченко</surname><given-names>Е. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Tkachenko</surname><given-names>E. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ткаченко Евгений Иванович — доктор медицинских наук, профессор, профессор 2-й кафедры (терапии усовершенствования врачей) </p><p>194044, г. Санкт-Петербург, ул. Академика Лебедева, 6. </p></bio><bio xml:lang="en"><p>Evgeny I. Tkachenko — Dr. Sci. (Med.), Professor of the 2nd Department of Therapy </p><p>194044, Saint Petersburg, Akademika Lebedeva str., 6.</p></bio><email xlink:type="simple">tkachenkoe@mail.ru</email><xref ref-type="aff" rid="aff-14"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8520-8702</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Трошина</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Troshina</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Трошина Екатерина Анатольевна — доктор медицинских наук, профессор, член-корреспондент РАН, директор Института клинической эндокринологии, заместитель директора </p><p>117292, г. Москва, ул. Дмитрия Ульянова, 11. </p></bio><bio xml:lang="en"><p>Ekaterina A. Troshina — Dr. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences, Head of the Institute of Clinical Endocrinology, Deputy Director </p><p>17292, Moscow, Dmitriya Ulyanova str., 11.</p></bio><email xlink:type="simple">troshina@inbox.com</email><xref ref-type="aff" rid="aff-16"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8844-2465</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Туркина</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Turkina</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Туркина Светлана Владимировна — доктор медицинских наук, профессор </p><p>400131, г. Волгоград, пл. Павших борцов, 1. </p></bio><bio xml:lang="en"><p>Svetlana V. Turkina — Dr. Sci. (Med.), Professor </p><p>400131, Volgograd, Pavshikh Bortsov square, 1.</p></bio><email xlink:type="simple">turkinasv@rambler.ru</email><xref ref-type="aff" rid="aff-30"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6434-1267</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Успенский</surname><given-names>Ю. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Uspenskiy</surname><given-names>Yu. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Успенский Юрий Павлович — доктор медицинских наук, профессор, профессор кафедры внутренних болезней стоматологического факультета; заведующий кафедрой факультетской терапии им. профессора В.А. Вальдмана </p><p>194100, г. Санкт-Петербург, Литовская ул., 2.</p></bio><bio xml:lang="en"><p>Yury P. Uspenskiy — Dr. Sci. (Med.), Professor, Professor of the Department of Internal Diseases, Faculty of Dentistry; Head of the Department of Faculty Therapy named after Professor V.A. Valdman </p><p>194100, Saint Petersburg, Litovskaya str., 2.</p></bio><email xlink:type="simple">uspenskiy65@mail.ru</email><xref ref-type="aff" rid="aff-31"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2436-3813</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фоминых</surname><given-names>Ю. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Fominykh</surname><given-names>Yu. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Фоминых Юлия Александровна — доктор медицинских наук, доцент, заведующая кафедрой пропедевтики внутренних болезней с клиникой; доцент кафедры внутренних болезней стоматологического факультета </p><p>194100, г. Санкт-Петербург, Литовская ул., 2. </p></bio><bio xml:lang="en"><p>Yulia A. Fominykh — Dr. Sci. (Med.), Docent, Head of the Department of Propaedeutics of Internal Medicine with a Clinic; Associate Professor of the Department of Internal Diseases of Dentistry Faculty </p><p>194100, Saint Petersburg, Litovskaya str., 2.</p></bio><email xlink:type="simple">jaf@mail.ru</email><xref ref-type="aff" rid="aff-32"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4860-0112</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хлынова</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Khlynova</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Хлынова Ольга Витальевна — доктор медицинских наук, профессор, член-корреспондент РАН, заведующая кафедрой госпитальной терапии и кардиологии </p><p>614990, г. Пермь, ул. Петропавловская, 26.</p></bio><bio xml:lang="en"><p>Olga V. Khlynova — Dr. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences, Head of the Department of Hospital Therapy and Cardiology </p><p>614990, Perm, Petropavlovskaya str., 26.</p></bio><email xlink:type="simple">olgakhlynova@mail.ru</email><xref ref-type="aff" rid="aff-33"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8339-9496</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Цыганова</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Tsyganova</surname><given-names>Yu. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Цыганова Юлия Вадимовна — кандидат медицинских наук, доцент кафедры госпитальной терапии </p><p>428015, г. Чебоксары, Московский просп., 15.</p></bio><bio xml:lang="en"><p>Yulia V. Tsyganova — Cand. Sci. (Med.), Associate Professor of the Department of Hospital Therapy </p><p>428015, Cheboksary, Moskovsky ave., 15.</p></bio><email xlink:type="simple">aj_00001@mail.ru</email><xref ref-type="aff" rid="aff-28"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3433-0142</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шамхалова</surname><given-names>М. Ш.</given-names></name><name name-style="western" xml:lang="en"><surname>Shamkhalova</surname><given-names>M. Sh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шамхалова Минара Шамхаловна — доктор медицинских наук, профессор, заведующая отделением диабетической болезни почек и посттрансплантационной реабилитации </p><p>117292, г. Москва, ул. Дмитрия Ульянова, 11.</p></bio><bio xml:lang="en"><p>Minara Sh. Shamkhalova — Dr. Sci. (Med.), Professor, Head of the Department of Diabetic Kidney Disease and Post-Transplant Rehabilitation </p><p>117292, Moscow, Dmitriya Ulyanova str., 11</p></bio><email xlink:type="simple">shamkhalova@mail.ru</email><xref ref-type="aff" rid="aff-16"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8527-4681</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шархун</surname><given-names>О. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Sharkhun</surname><given-names>O. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шархун Ольга Олеговна — доктор медицинских наук, профессор </p><p>117997, г. Москва, ул. Островитянова, 1. </p></bio><bio xml:lang="en"><p>Olga O. Sharkhun — Dr. Sci. (Med.), Professor </p><p>117997, Moscow, Ostrovityanova str., 1.</p></bio><email xlink:type="simple">olga_sharkhun@mail.ru</email><xref ref-type="aff" rid="aff-15"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5057-127X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шестакова</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shestakova</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шестакова Марина Владимировна — доктор медицинских наук, профессор, академик РАН, заместитель директора </p><p>117292, г. Москва, ул. Дмитрия Ульянова, 11.</p></bio><bio xml:lang="en"><p>Marina V. Shestakova — Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences, Deputy Director </p><p>117292, Moscow, Dmitriya Ulyanova str., 11.</p></bio><email xlink:type="simple">shestakova.mv@gmail.com</email><xref ref-type="aff" rid="aff-16"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov First Moscow State Medical University (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр терапии и профилактической медицины» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center for Therapy and Preventive Medicine</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБОУ ВО «Санкт-Петербургский государственный университет»;&#13;
ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. академика И.П. Павлова» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Saint Petersburg State University;&#13;
Academician I.P. Pavlov First Saint Petersburg State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ФГБОУ ВО «Санкт-Петербургский государственный химико-фармацевтический университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Saint Petersburg State Chemical Pharmaceutical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="ru"><institution>ФГБОУ ВО «Казанский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kazan State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-6"><aff xml:lang="ru"><institution>ФГБОУ ВО «Дальневосточный государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Far-Eastern State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-7"><aff xml:lang="ru"><institution>ФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Central State Medical Academy of the Department of Presidential Affairs</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-8"><aff xml:lang="ru"><institution>ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>North-Western State Medical University named after I.I. Mechnikov</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-9"><aff xml:lang="ru"><institution>ФГБОУ ВО «Российский университет медицины» Министерства здравоохранения Российской Федерации;&#13;
ГБУЗ МО «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Russian University of Medicine;&#13;
Moscow Regional Research Clinical Institute</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-10"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center of Oncology named after N.N. Blokhin</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-11"><aff xml:lang="ru"><institution>ГБУЗ «Московский клинический научно-практический центр им. А.С. Логинова» Департамента здравоохранения города Москвы</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Loginov Moscow Clinical Scientific Center</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-12"><aff xml:lang="ru"><institution>ФГБОУ ВО «Ставропольский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Stavropol State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-13"><aff xml:lang="ru"><institution>ФГБОУ ВО «Российский университет медицины» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Russian University of Medicine</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-14"><aff xml:lang="ru"><institution>ФГБВОУ ВО «Военно-медицинская академия им. С.М. Кирова» Министерства обороны Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kirov Military Medical Academy</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-15"><aff xml:lang="ru"><institution>ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.I. Pirogov Russian National Research Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-16"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Endocrinology Research Centre</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-17"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр трансплантологии и искусственных органов им. академика В.И. Шумакова» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center for Transplantology and Artificial Organs named after Academician V.I. Shumakov</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-18"><aff xml:lang="ru"><institution>ФГБОУ ВО «Саратовский государственный медицинский университет им. В.И. Разумовского» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Saratov State Medical University named after V.I. Razumovsky</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-19"><aff xml:lang="ru"><institution>ФГБОУ ВО «Кубанский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kuban State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-20"><aff xml:lang="ru"><institution>ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Russian Medical Academy of Continuous Professional Education</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-21"><aff xml:lang="ru"><institution>ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. академика И.П. Павлова» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Academician I.P. Pavlov First Saint Petersburg State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-22"><aff xml:lang="ru"><institution>ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Министерства здравоохранения Российской Федерации;&#13;
ФГАУ «Национальный медицинский исследовательский центр «Лечебно-реабилитационный центр» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.I. Pirogov Russian National Research Medical University;&#13;
National Medical Research Center “Treatment and Rehabilitation Center”</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-23"><aff xml:lang="ru"><institution>ФГБОУ ВО «Новосибирский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Novosibirsk State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-24"><aff xml:lang="ru"><institution>ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет);&#13;
ГБУЗ «Московский многопрофильный научно-клинический центр им. С.П. Боткина» Департамента здравоохранения города Москвы</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov First Moscow State Medical University (Sechenov University);&#13;
Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-25"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр кардиологии им. академика Е.И. Чазова» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center of Cardiology named after Academician E.I. Chazov</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-26"><aff xml:lang="ru"><institution>Казанская государственная медицинская академия — филиал ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kazan State Medical Academy — Branch Campus of the Russian Medical Academy of Continuous Professional Education</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-27"><aff xml:lang="ru"><institution>ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Министерства здравоохранения Российской Федерации;&#13;
ФГБУ «Национальный медицинский исследовательский центр им. В.А. Алмазова» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>North-Western State Medical University named after I.I. Mechnikov;&#13;
V.A. Almazov National Medical Research Center</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-28"><aff xml:lang="ru"><institution>ФГБОУ ВО «Чувашский государственный университет им. И.Н. Ульянова» Министерства науки и высшего образования Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Chuvash State University named after I.N. Ulyanov</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-29"><aff xml:lang="ru"><institution>ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.I.  Pirogov Russian National Research Medical University;</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-30"><aff xml:lang="ru"><institution>ФГБОУ ВО «Волгоградский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Volgograd State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-31"><aff xml:lang="ru"><institution>ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. академика И.П. Павлова» Министерства здравоохранения Российской Федерации;&#13;
ФГБОУ ВО «Санкт-Петербургский государственный педиатрический медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Academician I.P. Pavlov First Saint Petersburg State Medical University;&#13;
Saint Petersburg State Pediatric Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-32"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр им. В.А. Алмазова» Министерства здравоохранения Российской Федерации; ФГБОУ ВО «Санкт-Петербургский государственный педиатрический медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Almazov National Medical Research Center; Saint Petersburg State Pediatric Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-33"><aff xml:lang="ru"><institution>ФГБОУ ВО «Пермский государственный медицинский университет им. академика Е.А. Вагнера» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Perm State Medical University named after Academician E.A. Wagner</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>09</day><month>03</month><year>2025</year></pub-date><volume>35</volume><issue>1</issue><fpage>94</fpage><lpage>152</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ивашкин В.Т., Драпкина О.М., Маевская М.В., Райхельсон К.Л., Оковитый С.В., Жаркова М.С., Гречишникова В.Р., Абдулганиева Д.И., Алексеенко С.А., Ардатская М.Д., Бакулин И.Г., Бакулина Н.В., Богомолов П.О., Бредер В.В., Винницкая Е.В., Гейвандова Н.И., Голованова Е.В., Гриневич В.Б., Дощицин В.Л., Дудинская Е.Н., Ершова Е.В., Кодзоева Х.Б., Козлова И.В., Комшилова К.А., Конев Ю.В., Корочанская Н.В., Котовская Ю.В., Кравчук Ю.А., Лоранская И.Д., Маев И.В., Мартынов А.И., Мехтиев С.Н., Мишина Е.Е., Надинская М.Ю., Никитин И.Г., Осипенко М.Ф., Остроумова О.Д., Павлов Ч.С., Погосова Н.В., Радченко В.Г., Ройтберг Г.Е., Сайфутдинов Р.Г., Самсонов А.А., Селиверстов П.В., Ситкин С.И., Тарасова Л.В., Тарзиманова А.И., Ткачева О.Н., Ткаченко Е.И., Трошина Е.А., Туркина С.В., Успенский Ю.П., Фоминых Ю.А., Хлынова О.В., Цыганова Ю.В., Шамхалова М.Ш., Шархун О.О., Шестакова М.В., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Ивашкин В.Т., Драпкина О.М., Маевская М.В., Райхельсон К.Л., Оковитый С.В., Жаркова М.С., Гречишникова В.Р., Абдулганиева Д.И., Алексеенко С.А., Ардатская М.Д., Бакулин И.Г., Бакулина Н.В., Богомолов П.О., Бредер В.В., Винницкая Е.В., Гейвандова Н.И., Голованова Е.В., Гриневич В.Б., Дощицин В.Л., Дудинская Е.Н., Ершова Е.В., Кодзоева Х.Б., Козлова И.В., Комшилова К.А., Конев Ю.В., Корочанская Н.В., Котовская Ю.В., Кравчук Ю.А., Лоранская И.Д., Маев И.В., Мартынов А.И., Мехтиев С.Н., Мишина Е.Е., Надинская М.Ю., Никитин И.Г., Осипенко М.Ф., Остроумова О.Д., Павлов Ч.С., Погосова Н.В., Радченко В.Г., Ройтберг Г.Е., Сайфутдинов Р.Г., Самсонов А.А., Селиверстов П.В., Ситкин С.И., Тарасова Л.В., Тарзиманова А.И., Ткачева О.Н., Ткаченко Е.И., Трошина Е.А., Туркина С.В., Успенский Ю.П., Фоминых Ю.А., Хлынова О.В., Цыганова Ю.В., Шамхалова М.Ш., Шархун О.О., Шестакова М.В.</copyright-holder><copyright-holder xml:lang="en">Ivashkin V.T., Drapkina O.M., Maevskaya M.V., Raikhelson K.L., Okovityi S.V., Zharkova M.S., Grechishnikova V.R., Abdulganieva D.I., Alekseenko S.A., Ardatskaya M.D., Bakulin I.G., Bakulina N.V., Bogomolov P.O., Breder V.V., Vinnitskaya E.V., Geyvandova N.I., Golovanova E.V., Grinevich V.B., Doshchitsin V.L., Dudinskaya E.N., Ershova E.V., Kodzoeva K.B., Kozlova I.V., Komshilova K.A., Konev Y.V., Korochanskaya N.V., Kotovskaya Y.V., Kravchuk Y.A., Loranskaya I.D., Maev I.V., Martynov A.I., Mekhtiev S.N., Mishina E.E., Nadinskaia M.Y., Nikitin I.G., Osipenko M.F., Ostroumova O.D., Pavlov C.S., Pogosova N.V., Radchenko V.G., Roytberg G.E., Saifutdinov R.G., Samsonov A.A., Seliverstov P.V., Sitkin S.I., Tarasova L.V., Tarzimanova A.I., Tkacheva O.N., Tkachenko E.I., Troshina E.A., Turkina S.V., Uspenskiy Y.P., Fominykh Y.A., Khlynova O.V., Tsyganova Y.V., Shamkhalova M.S., Sharkhun O.O., Shestakova M.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.gastro-j.ru/jour/article/view/1461">https://www.gastro-j.ru/jour/article/view/1461</self-uri><abstract><p>Цель: представления клинических рекомендаций заключается в обеспечении информационной поддержки для принятия врачами-гастроэнтерологами, врачами общей практики и врачами-терапевтами решений, способствующих повышению качества оказания медицинской помощи пациенту с неалкогольной жировой болезнью печени с учетом новейших клинических данных и принципов доказательной медицины. Основное содержание. Клинические рекомендации содержат информацию о современных представлениях об этиологии, факторах риска и патогенезе неалкогольной жировой болезни печени, особенностях ее клинического течения. Также в рекомендациях представлена информация об актуальных методах лабораторной и инструментальной, инвазивной и неинвазивной диагностики неалкогольной жировой болезни печени и ее клинических фенотипов, подходах к ее лечению с учетом наличия коморбидностей, особенностей диспансерного наблюдения и профилактики. Приведенная информация проиллюстрирована алгоритмами дифференциального диагноза, действий врача. Помимо этого, присутствует информация для пациента и критерии оценки качества оказания медицинской помощи. Заключение. Осведомленность специалистов в вопросах диагностики, лечения и наблюдения пациентов с неалкогольной жировой болезнью печени способствует своевременной постановке диагноза и инициации лечения, что в перспективе будет существенно влиять на их прогноз и качество жизни.</p></abstract><trans-abstract xml:lang="en"><p>Aim. The clinical guidelines are intended to provide information support for making decisions by gastroenterologists, general practitioners and internists that will improve the quality of medical care for patients with non-alcoholic fatty liver disease, taking into account the latest clinical data and principles of evidence-based medicine. Key points. Clinical guidelines contain information about current views on etiology, risk factors and pathogenesis of nonalcoholic fatty liver disease, peculiarities of its clinical course. Also given recommendations provide information on current methods of laboratory and instrumental diagnostics, invasive and non-invasive tools for nonalcoholic fatty liver disease and its clinical phenotypes assessment, approaches to its treatment, considering the presence of comorbidities, features of dispensary monitoring and prophylaxis. The information is illustrated with algorithms of differential diagnosis and physician's actions. In addition, there is information for the patient and criteria for assessing the quality of medical care. Conclusion. Awareness of specialists in the issues of diagnosis, treatment and follow-up of patients with nonalcoholic fatty liver disease contributes to the timely diagnosis and initiation of treatment, which in the long term will significantly affect their prognosis and quality of life.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>дислипидемии</kwd><kwd>жировая болезнь печени</kwd><kwd>кардиометаболические факторы риска</kwd><kwd>неалкогольный стеатогепатит</kwd><kwd>стеатоз печени</kwd><kwd>стеатогепатит</kwd></kwd-group><kwd-group xml:lang="en"><kwd>dyslipidemia</kwd><kwd>fatty liver disease</kwd><kwd>cardiometabolic risk factors</kwd><kwd>nonalcoholic steatohepatitis</kwd><kwd>liver steatosis</kwd><kwd>steatohepatitis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Rinella M.E., Neuschwander-Tetri B.A., Siddiqui M.S., Abdelmalek M.F., Caldwell S., Barb D., et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797–835. DOI: 10.1097/HEP.0000000000000323</mixed-citation><mixed-citation xml:lang="en">Rinella M.E., Neuschwander-Tetri B.A., Siddiqui M.S., Abdelmalek M.F., Caldwell S., Barb D., et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797–835. DOI: 10.1097/HEP.0000000000000323</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Rinella M.E., Lazarus J.V., Ratziu V., Francque S.M., Sanyal A.J., Kanwal F., et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–86. DOI: 10.1097/HEP.0000000000000520</mixed-citation><mixed-citation xml:lang="en">Rinella M.E., Lazarus J.V., Ratziu V., Francque S.M., Sanyal A.J., Kanwal F., et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–86. DOI: 10.1097/HEP.0000000000000520</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">ICD-11. International Classification of Diseases 11th Revision. URL: https://icd.who.int</mixed-citation><mixed-citation xml:lang="en">ICD-11. International Classification of Diseases 11th Revision. URL: https://icd.who.int</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Singh S., Allen A.M., Wang Z., Prokop L.J., Murad M.H., Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: A systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643–54.e1–9. DOI: 10.1016/j.cgh.2014.04.014</mixed-citation><mixed-citation xml:lang="en">Singh S., Allen A.M., Wang Z., Prokop L.J., Murad M.H., Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: A systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643–54.e1–9. DOI: 10.1016/j.cgh.2014.04.014</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Райхельсон К.Л., Маевская М.В., Жаркова М.С., Гречишникова В.Р., Оковитый С.В., Деева Т.А. и др. Жировая болезнь печени: новая номенклатура и ее адаптация в Российской Федерации. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2024;34(2):35–44. DOI: 10.22416/1382-4376-2024-961</mixed-citation><mixed-citation xml:lang="en">Raikhelson K.L., Maevskaya M.V., Zharkova M.S., Grechishnikova V.R., Okovityi S.V., Deeva T.A., et al. Steatotic liver disease: New nomenclature and its localization in the Russian Federation. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(2):35–44. (In Russ.). DOI: 10.22416/1382-4376-2024-961</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Day C.P., James O.F. Steatohepatitis: A tale of two “hits”? Gastroenterology. 1998;114(4):842–5. DOI: 10.1016/s0016-5085(98)70599-2</mixed-citation><mixed-citation xml:lang="en">Day C.P., James O.F. Steatohepatitis: A tale of two “hits”? Gastroenterology. 1998;114(4):842–5. DOI: 10.1016/s0016-5085(98)70599-2</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Byrne C.D., Targher G. NAFLD: A multisystem disease. J Hepatol. 2015;62(Suppl. 1):S47–64. DOI: 10.1016/j.jhep.2014.12.012</mixed-citation><mixed-citation xml:lang="en">Byrne C.D., Targher G. NAFLD: A multisystem disease. J Hepatol. 2015;62(Suppl. 1):S47–64. DOI: 10.1016/j.jhep.2014.12.012</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Xian Y.X., Weng J.P., Xu F. MAFLD vs. NAFLD: Shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. Chin Med J (Engl). 2020;134(1):8–19. DOI: 10.1097/CM9.0000000000001263</mixed-citation><mixed-citation xml:lang="en">Xian Y.X., Weng J.P., Xu F. MAFLD vs. NAFLD: Shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. Chin Med J (Engl). 2020;134(1):8–19. DOI: 10.1097/CM9.0000000000001263</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Parthasarathy G., Revelo X., Malhi H. Pathogenesis of nonalcoholic steatohepatitis: An overview. Hepatol Commun. 2020;4(4):478–92. DOI: 10.1002/hep4.1479</mixed-citation><mixed-citation xml:lang="en">Parthasarathy G., Revelo X., Malhi H. Pathogenesis of nonalcoholic steatohepatitis: An overview. Hepatol Commun. 2020;4(4):478–92. DOI: 10.1002/hep4.1479</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Haas J.T., Francque S., Staels B. Pathophysiology and mechanisms of nonalcoholic fatty liver disease. Annu Rev Physiol. 2016;78:181–205. DOI: 10.1146/annurev-physiol-021115-105331</mixed-citation><mixed-citation xml:lang="en">Haas J.T., Francque S., Staels B. Pathophysiology and mechanisms of nonalcoholic fatty liver disease. Annu Rev Physiol. 2016;78:181–205. DOI: 10.1146/annurev-physiol-021115-105331</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Basaranoglu M., Basaranoglu G., Bugianesi E. Carbohydrate intake and nonalcoholic fatty liver disease: Fructose as a weapon of mass destruction. Hepatobiliary Surg Nutr. 2015;4(2):109–16. DOI: 10.3978/j.issn.2304-3881.2014.11.05</mixed-citation><mixed-citation xml:lang="en">Basaranoglu M., Basaranoglu G., Bugianesi E. Carbohydrate intake and nonalcoholic fatty liver disease: Fructose as a weapon of mass destruction. Hepatobiliary Surg Nutr. 2015;4(2):109–16. DOI: 10.3978/j.issn.2304-3881.2014.11.05</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Jensen T., Abdelmalek M.F., Sullivan S., Nadeau K.J., Green M., Roncal C., et al. Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. J Hepatol. 2018;68(5):1063–75. DOI: 10.1016/j.jhep.2018.01.019</mixed-citation><mixed-citation xml:lang="en">Jensen T., Abdelmalek M.F., Sullivan S., Nadeau K.J., Green M., Roncal C., et al. Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. J Hepatol. 2018;68(5):1063–75. DOI: 10.1016/j.jhep.2018.01.019</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Birkenfeld A.L., Shulman G.I. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology. 2014;59(2):713–23. DOI: 10.1002/hep.26672</mixed-citation><mixed-citation xml:lang="en">Birkenfeld A.L., Shulman G.I. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology. 2014;59(2):713–23. DOI: 10.1002/hep.26672</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ipsen D.H., Lykkesfeldt J., Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018;75(18):3313–27. DOI: 10.1007/s00018-018-2860-6</mixed-citation><mixed-citation xml:lang="en">Ipsen D.H., Lykkesfeldt J., Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018;75(18):3313–27. DOI: 10.1007/s00018-018-2860-6</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Lambert J.E., Ramos-Roman M.A., Browning J.D., Parks E.J. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 2014;146(3):726–35. DOI: 10.1053/j.gastro.2013.11.049</mixed-citation><mixed-citation xml:lang="en">Lambert J.E., Ramos-Roman M.A., Browning J.D., Parks E.J. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 2014;146(3):726–35. DOI: 10.1053/j.gastro.2013.11.049</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Ter Horst K.W., Serlie M.J. Fructose consumption, lipogenesis, and non-alcoholic fatty liver disease. Nutrients. 2017;9(9):981. DOI: 10.3390/nu9090981</mixed-citation><mixed-citation xml:lang="en">Ter Horst K.W., Serlie M.J. Fructose consumption, lipogenesis, and non-alcoholic fatty liver disease. Nutrients. 2017;9(9):981. DOI: 10.3390/nu9090981</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Shen J., Sakaida I., Uchida K., Terai S., Okita K. Leptin enhances TNF-alpha production via p38 and JNK MAPK in LPS-stimulated Kupffer cells. Life Sci. 2005;77(13):1502–15. DOI: 10.1016/j.lfs.2005.04.004</mixed-citation><mixed-citation xml:lang="en">Shen J., Sakaida I., Uchida K., Terai S., Okita K. Leptin enhances TNF-alpha production via p38 and JNK MAPK in LPS-stimulated Kupffer cells. Life Sci. 2005;77(13):1502–15. DOI: 10.1016/j.lfs.2005.04.004</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Subichin M., Clanton J., Makuszewski M., Bohon A., Zografakis J.G., Dan A. Liver disease in the morbidly obese: A review of 1000 consecutive patients undergoing weight loss surgery. Surg Obes Relat Dis. 2015;11(1):137–41. DOI: 10.1016/j.soard.2014.06.015</mixed-citation><mixed-citation xml:lang="en">Subichin M., Clanton J., Makuszewski M., Bohon A., Zografakis J.G., Dan A. Liver disease in the morbidly obese: A review of 1000 consecutive patients undergoing weight loss surgery. Surg Obes Relat Dis. 2015;11(1):137–41. DOI: 10.1016/j.soard.2014.06.015</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Sasaki A., Nitta H., Otsuka K., Umemura A., Baba S., Obuchi T., et al. Bariatric surgery and non-alcoholic fatty liver disease: Current and potential future treatments. Front Endocrinol (Lausanne). 2014;5:164. DOI: 10.3389/fendo.2014.00164</mixed-citation><mixed-citation xml:lang="en">Sasaki A., Nitta H., Otsuka K., Umemura A., Baba S., Obuchi T., et al. Bariatric surgery and non-alcoholic fatty liver disease: Current and potential future treatments. Front Endocrinol (Lausanne). 2014;5:164. DOI: 10.3389/fendo.2014.00164</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Stojsavljević S., Gomerčić Palčić M., Virović Jukić L., Smirčić Duvnjak L., Duvnjak M. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(48):18070–91. DOI: 10.3748/wjg.v20.i48.18070</mixed-citation><mixed-citation xml:lang="en">Stojsavljević S., Gomerčić Palčić M., Virović Jukić L., Smirčić Duvnjak L., Duvnjak M. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(48):18070–91. DOI: 10.3748/wjg.v20.i48.18070</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Osborn O., Olefsky J.M. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med. 2012;18(3):363–74. DOI: 10.1038/nm.2627</mixed-citation><mixed-citation xml:lang="en">Osborn O., Olefsky J.M. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med. 2012;18(3):363–74. DOI: 10.1038/nm.2627</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Yan F.J., Wang X., Wang S.E., Hong H.T., Lu J., Ye Q., et al. C-Jun/C7ORF41/NF-κB axis mediates hepatic inflammation and lipid accumulation in NAFLD. Biochem J. 2020;477(3):691–708. DOI: 10.1042/BCJ20190799</mixed-citation><mixed-citation xml:lang="en">Yan F.J., Wang X., Wang S.E., Hong H.T., Lu J., Ye Q., et al. C-Jun/C7ORF41/NF-κB axis mediates hepatic inflammation and lipid accumulation in NAFLD. Biochem J. 2020;477(3):691–708. DOI: 10.1042/BCJ20190799</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Jin S., Li Y., Xia T., Liu Y., Zhang S., Hu H., et al. Mechanisms and therapeutic implications of selective autophagy in nonalcoholic fatty liver disease. J Adv Res. 2025:67:317–29. DOI: 10.1016/j.jare.2024.01.027</mixed-citation><mixed-citation xml:lang="en">Jin S., Li Y., Xia T., Liu Y., Zhang S., Hu H., et al. Mechanisms and therapeutic implications of selective autophagy in nonalcoholic fatty liver disease. J Adv Res. 2025:67:317–29. DOI: 10.1016/j.jare.2024.01.027</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Prerna K., Dubey V.K. Beclin1-mediated interplay between autophagy and apoptosis: New understanding. Int J Biol Macromol. 2022;204:258–73. DOI: 10.1016/j.ijbiomac.2022.02.005</mixed-citation><mixed-citation xml:lang="en">Prerna K., Dubey V.K. Beclin1-mediated interplay between autophagy and apoptosis: New understanding. Int J Biol Macromol. 2022;204:258–73. DOI: 10.1016/j.ijbiomac.2022.02.005</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Fromenty B., Roden M. Mitochondrial alterations in fatty liver diseases. J Hepatol. 2023;78(2):415–29. DOI: 10.1016/j.jhep.2022.09.020</mixed-citation><mixed-citation xml:lang="en">Fromenty B., Roden M. Mitochondrial alterations in fatty liver diseases. J Hepatol. 2023;78(2):415–29. DOI: 10.1016/j.jhep.2022.09.020</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Ferré P., Foufelle F. SREBP-1c transcription factor and lipid homeostasis: Clinical perspective. Horm Res. 2007;68(2):72–82. DOI: 10.1159/000100426</mixed-citation><mixed-citation xml:lang="en">Ferré P., Foufelle F. SREBP-1c transcription factor and lipid homeostasis: Clinical perspective. Horm Res. 2007;68(2):72–82. DOI: 10.1159/000100426</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Miserez A.R., Muller P.Y., Barella L., Barella S., Staehelin H.B., Leitersdorf E., et al. Sterol-regulatory element-binding protein (SREBP)-2 contributes to polygenic hypercholesterolaemia. Atherosclerosis. 2002;164(1):15–26. DOI: 10.1016/s0021-9150(01)00762-6</mixed-citation><mixed-citation xml:lang="en">Miserez A.R., Muller P.Y., Barella L., Barella S., Staehelin H.B., Leitersdorf E., et al. Sterol-regulatory element-binding protein (SREBP)-2 contributes to polygenic hypercholesterolaemia. Atherosclerosis. 2002;164(1):15–26. DOI: 10.1016/s0021-9150(01)00762-6</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Iizuka K., Takao K., Yabe D. ChREBP-mediated regulation of lipid metabolism: Involvement of the gut microbiota, liver, and adipose tissue. Front Endocrinol (Lausanne). 2020;11:587189. DOI: 10.3389/fendo.2020.587189</mixed-citation><mixed-citation xml:lang="en">Iizuka K., Takao K., Yabe D. ChREBP-mediated regulation of lipid metabolism: Involvement of the gut microbiota, liver, and adipose tissue. Front Endocrinol (Lausanne). 2020;11:587189. DOI: 10.3389/fendo.2020.587189</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Ma M., Xie W., Li X. Identification of autophagy-related genes in the progression from non-alcoholic fatty liver to non-alcoholic steatohepatitis. Int J Gen Med. 2021;14:3163–76. DOI: 10.2147/IJGM.S317785</mixed-citation><mixed-citation xml:lang="en">Ma M., Xie W., Li X. Identification of autophagy-related genes in the progression from non-alcoholic fatty liver to non-alcoholic steatohepatitis. Int J Gen Med. 2021;14:3163–76. DOI: 10.2147/IJGM.S317785</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Barrientos-Riosalido A., Real M., Bertran L., Aguilar C., Martínez S., Parada D., et al. Increased hepatic ATG7 mRNA and ATG7 protein expression in nonalcoholic steatohepatitis associated with obesity. Int J Mol Sci. 2023;24(2):1324. DOI: 10.3390/ijms24021324</mixed-citation><mixed-citation xml:lang="en">Barrientos-Riosalido A., Real M., Bertran L., Aguilar C., Martínez S., Parada D., et al. Increased hepatic ATG7 mRNA and ATG7 protein expression in nonalcoholic steatohepatitis associated with obesity. Int J Mol Sci. 2023;24(2):1324. DOI: 10.3390/ijms24021324</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Syed-Abdul M.M. Lipid metabolism in metabolic-associated steatotic liver disease (MASLD). Metabolites. 2023;14(1):12. DOI: 10.3390/metabo14010012</mixed-citation><mixed-citation xml:lang="en">Syed-Abdul M.M. Lipid metabolism in metabolic-associated steatotic liver disease (MASLD). Metabolites. 2023;14(1):12. DOI: 10.3390/metabo14010012</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Branković M., Dukić M., Gmizić T., Popadić V., Nikolić N., Sekulić A., et al. New therapeutic approaches for the treatment of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and increased cardiovascular risk. Diagnostics (Basel). 2024;14(2):229. DOI: 10.3390/diagnostics14020229</mixed-citation><mixed-citation xml:lang="en">Branković M., Dukić M., Gmizić T., Popadić V., Nikolić N., Sekulić A., et al. New therapeutic approaches for the treatment of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and increased cardiovascular risk. Diagnostics (Basel). 2024;14(2):229. DOI: 10.3390/diagnostics14020229</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao Y., Zhou Y., Wang D., Huang Z., Xiao X., Zheng Q., et al. Mitochondrial dysfunction in metabolic dysfunction fatty liver disease (MAFLD). Int J Mol Sci. 2023;24(24):17514. DOI: 10.3390/ijms242417514</mixed-citation><mixed-citation xml:lang="en">Zhao Y., Zhou Y., Wang D., Huang Z., Xiao X., Zheng Q., et al. Mitochondrial dysfunction in metabolic dysfunction fatty liver disease (MAFLD). Int J Mol Sci. 2023;24(24):17514. DOI: 10.3390/ijms242417514</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Chen Z., Tian R., She Z., Cai J., Li H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic Biol Med. 2020;152:116–41. DOI: 10.1016/j.freeradbiomed.2020.02.025</mixed-citation><mixed-citation xml:lang="en">Chen Z., Tian R., She Z., Cai J., Li H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic Biol Med. 2020;152:116–41. DOI: 10.1016/j.freeradbiomed.2020.02.025</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Thomson A.W., Knolle P.A. Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol. 2010;10(11):753–66. DOI: 10.1038/nri2858</mixed-citation><mixed-citation xml:lang="en">Thomson A.W., Knolle P.A. Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol. 2010;10(11):753–66. DOI: 10.1038/nri2858</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Lotze M.T., Zeh H.J., Rubartelli A., Sparvero L.J., Amoscato A.A., Washburn N.R., et al. The grateful dead: Damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev. 2007;220:60–81. DOI: 10.1111/j.1600-065X.2007.00579.x</mixed-citation><mixed-citation xml:lang="en">Lotze M.T., Zeh H.J., Rubartelli A., Sparvero L.J., Amoscato A.A., Washburn N.R., et al. The grateful dead: Damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev. 2007;220:60–81. DOI: 10.1111/j.1600-065X.2007.00579.x</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Szabo G., Csak T. Inflammasomes in liver diseases. J Hepatol. 2012;57(3):642–54. DOI: 10.1016/j.jhep.2012.03.035</mixed-citation><mixed-citation xml:lang="en">Szabo G., Csak T. Inflammasomes in liver diseases. J Hepatol. 2012;57(3):642–54. DOI: 10.1016/j.jhep.2012.03.035</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Luedde T., Schwabe R.F. NF-κB in the liver — linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2011;8(2):108–18. DOI: 10.1038/nrgastro.2010.213</mixed-citation><mixed-citation xml:lang="en">Luedde T., Schwabe R.F. NF-κB in the liver — linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2011;8(2):108–18. DOI: 10.1038/nrgastro.2010.213</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Klein I., Cornejo J.C., Polakos N.K., John B., Wuensch S.A., Topham D.J., et al. Kupffer cell heterogeneity: Functional properties of bone marrow derived and sessile hepatic macrophages. Blood. 2007;110(12):4077–85. DOI: 10.1182/blood-2007-02-073841</mixed-citation><mixed-citation xml:lang="en">Klein I., Cornejo J.C., Polakos N.K., John B., Wuensch S.A., Topham D.J., et al. Kupffer cell heterogeneity: Functional properties of bone marrow derived and sessile hepatic macrophages. Blood. 2007;110(12):4077–85. DOI: 10.1182/blood-2007-02-073841</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Fang Y.L., Chen H., Wang C.L., Liang L. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From “two hit theory” to “multiple hit model”. World J Gastroenterol. 2018;24(27):2974–83. DOI: 10.3748/wjg.v24.i27.2974</mixed-citation><mixed-citation xml:lang="en">Fang Y.L., Chen H., Wang C.L., Liang L. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From “two hit theory” to “multiple hit model”. World J Gastroenterol. 2018;24(27):2974–83. DOI: 10.3748/wjg.v24.i27.2974</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Tomita K., Tamiya G., Ando S., Ohsumi K., Chiyo T., Mizutani A., et al. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut. 2006;55(3):415–24. DOI: 10.1136/gut.2005.071118</mixed-citation><mixed-citation xml:lang="en">Tomita K., Tamiya G., Ando S., Ohsumi K., Chiyo T., Mizutani A., et al. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut. 2006;55(3):415–24. DOI: 10.1136/gut.2005.071118</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Kremer M., Hines I.N., Milton R.J., Wheeler M.D. Favored T helper 1 response in a mouse model of hepatosteatosis is associated with enhanced T cell-mediated hepatitis. Hepatology. 2006;44(1):216–27. DOI: 10.1002/hep.21221</mixed-citation><mixed-citation xml:lang="en">Kremer M., Hines I.N., Milton R.J., Wheeler M.D. Favored T helper 1 response in a mouse model of hepatosteatosis is associated with enhanced T cell-mediated hepatitis. Hepatology. 2006;44(1):216–27. DOI: 10.1002/hep.21221</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Ghazarian M., Revelo X.S., Nøhr M.K., Luck H., Zeng K., Lei H., et al. Type I interferon Responses drive intrahepatic T cells to promote metabolic syndrome. Sci Immunol. 2017;2(10):eaai7616. DOI: 10.1126/sciimmunol.aai7616</mixed-citation><mixed-citation xml:lang="en">Ghazarian M., Revelo X.S., Nøhr M.K., Luck H., Zeng K., Lei H., et al. Type I interferon Responses drive intrahepatic T cells to promote metabolic syndrome. Sci Immunol. 2017;2(10):eaai7616. DOI: 10.1126/sciimmunol.aai7616</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Wang M., Li L., Xu Y., Du J., Ling C. Roles of hepatic stellate cells in NAFLD: From the perspective of inflammation and fibrosis. Front Pharmacol. 2022;13:958428. DOI: 10.3389/fphar.2022.958428</mixed-citation><mixed-citation xml:lang="en">Wang M., Li L., Xu Y., Du J., Ling C. Roles of hepatic stellate cells in NAFLD: From the perspective of inflammation and fibrosis. Front Pharmacol. 2022;13:958428. DOI: 10.3389/fphar.2022.958428</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Li Z., Yuan H., Chu H., Yang L. The crosstalk between gut microbiota and bile acids promotes the development of non-alcoholic fatty liver disease. Microorganisms. 2023;11(8):2059. DOI: 10.3390/microorganisms11082059</mixed-citation><mixed-citation xml:lang="en">Li Z., Yuan H., Chu H., Yang L. The crosstalk between gut microbiota and bile acids promotes the development of non-alcoholic fatty liver disease. Microorganisms. 2023;11(8):2059. DOI: 10.3390/microorganisms11082059</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Clemente M.G., Mandato C., Poeta M., Vajro P. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions. World J Gastroenterol. 2016;22(36):8078–93. DOI: 10.3748/wjg.v22.i36.8078</mixed-citation><mixed-citation xml:lang="en">Clemente M.G., Mandato C., Poeta M., Vajro P. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions. World J Gastroenterol. 2016;22(36):8078–93. DOI: 10.3748/wjg.v22.i36.8078</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Ulluwishewa D., Anderson R.C., McNabb W.C., Moughan P.J., Wells J.M., Roy N.C. Regulation of tight junction permeability by intestinal bacteria and dietary components. J Nutr. 2011;141(5):769–76. DOI: 10.3945/jn.110.135657</mixed-citation><mixed-citation xml:lang="en">Ulluwishewa D., Anderson R.C., McNabb W.C., Moughan P.J., Wells J.M., Roy N.C. Regulation of tight junction permeability by intestinal bacteria and dietary components. J Nutr. 2011;141(5):769–76. DOI: 10.3945/jn.110.135657</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Paolella G., Mandato C., Pierri L., Poeta M., Di Stasi M., Vajro P. Gut-liver axis and probiotics: Their role in non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20(42):15518–31. DOI: 10.3748/wjg.v20.i42.15518</mixed-citation><mixed-citation xml:lang="en">Paolella G., Mandato C., Pierri L., Poeta M., Di Stasi M., Vajro P. Gut-liver axis and probiotics: Their role in non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20(42):15518–31. DOI: 10.3748/wjg.v20.i42.15518</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Zorn A.M., Wells J.M. Vertebrate endoderm development and organ formation. Annu Rev Cell Dev Biol. 2009;25:221–51. DOI: 10.1146/annurev.cellbio.042308.113344</mixed-citation><mixed-citation xml:lang="en">Zorn A.M., Wells J.M. Vertebrate endoderm development and organ formation. Annu Rev Cell Dev Biol. 2009;25:221–51. DOI: 10.1146/annurev.cellbio.042308.113344</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Fairfield C.J., Drake T.M., Pius R., Bretherick A.D., Campbell A., Clark D.W., et al. Genome-wide association study of NAFLD using electronic health records. Hepatol Commun. 2022;6(2):297–308. DOI: 10.1002/hep4.1805</mixed-citation><mixed-citation xml:lang="en">Fairfield C.J., Drake T.M., Pius R., Bretherick A.D., Campbell A., Clark D.W., et al. Genome-wide association study of NAFLD using electronic health records. Hepatol Commun. 2022;6(2):297–308. DOI: 10.1002/hep4.1805</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Anstee Q.M., Darlay R., Cockell S., Meroni M., Govaere O., Tiniakos D., et al. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. J Hepatol. 2020;73(3):505–15. DOI: 10.1016/j.jhep.2020.04.003</mixed-citation><mixed-citation xml:lang="en">Anstee Q.M., Darlay R., Cockell S., Meroni M., Govaere O., Tiniakos D., et al. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. J Hepatol. 2020;73(3):505–15. DOI: 10.1016/j.jhep.2020.04.003</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Куртанов Х.А., Сыдыкова Л.А., Павлова Н.И., Филиппова Н.П., Додохов В.В., Апсолихова Г.А. и др. Полиморфизм гена адипонутрина (PNPLA3) у коренных жителей Республики Саха (Якутия), страдающих сахарным диабетом 2-го типа. Альманах клинической медицины. 2018;46(3):258–63. DOI: 10.18786/2072-0505-2018-46-3-258-263</mixed-citation><mixed-citation xml:lang="en">Kurtanov K.A., Sydykova L.A., Pavlova N.I., Filippova N.P., Dodokhov V.V., Apsolikhova G.A., et al. Polymorphism of the adiponutrin gene (PNPLA3) in the indigenous inhabitants of the Republic of Sakha (Yakutia) with type 2 diabetes mellitus. Almanac of Clinical Medicine. 2018;46(3):258–63 (In Russ.). DOI: 10.18786/2072-0505-2018-46-3-258-263</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Кролевец Т.С., Ливзан М.А., Ахмедов В.А., Новиков Д.Г. Исследование полиморфизма гена PNPLA3 у пациентов с неалкогольной жировой болезнью печени и различной стадией фиброза. Экспериментальная и клиническая гастроэнтерология. 2018;11:24–32.</mixed-citation><mixed-citation xml:lang="en">Krolevets T.S., Livzan M.A., Akhmedov V.A., Novikov D.G. Study of PNPLA3 gene polymorphism in patients with non-alcoholic fatty liver disease and various stages of fibrosis. Experimental and Clinical Gastroenterology. 2018;11:24–32. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Райхельсон К.Л., Ковязина В.П., Сидоренко Д.В., Назаров В.Д., Лапин С.В., Эмануэль В.Л. и др. Влияние полиморфизма гена PNPLA3 на течение неалкогольной жировой болезни печени. РМЖ. 2019;12:85–8.</mixed-citation><mixed-citation xml:lang="en">Raikhelson K.L., Kovyazina V.P., Sidorenko D.V., Nazarov V.D., Lapin S.V., Emanuel V.L., et al. PNPLA3 gene polymorphism impact on the nonalcoholic fatty liver disease course. RMJ. 2019;12:85–8. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Дьяконова А.Т., Куртанов Х.А., Павлова Н.И., Соловьева Н.А., Соловьева Ю.А., Филиппова Н.П. и др. Полиморфизм rs58542926 гена TM6SF2 при хронических неинфекционных болезнях печени в якутской популяции. Современные проблемы науки и образования. 2019;6:133. DOI: 10.17513/spno.29334</mixed-citation><mixed-citation xml:lang="en">Dyakonova A.T., Kurtanov K.A., Pavlova N.I., Soloveva N.A., Soloveva Yu.A., Filippova N.P., et al. Polymorphism rs58542926 of the TM6SF2 gene in chronic non-infectious liver diseases in the Yakut population. Modern Problems of Science and Education. 2019;6:133. (In Russ.). DOI: 10.17513/spno.29334</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Cusi K., Isaacs S., Barb D., Basu R., Caprio S., Garvey W.T., et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: Co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28(5):528–62. DOI: 10.1016/j.eprac.2022.03.010</mixed-citation><mixed-citation xml:lang="en">Cusi K., Isaacs S., Barb D., Basu R., Caprio S., Garvey W.T., et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: Co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28(5):528–62. DOI: 10.1016/j.eprac.2022.03.010</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Lonardo A., Ballestri S., Mantovani A., Nascimbeni F., Lugari S., Targher G. Pathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity? Dig Liver Dis. 2019;51(4):462–70. DOI: 10.1016/j.dld.2018.12.014</mixed-citation><mixed-citation xml:lang="en">Lonardo A., Ballestri S., Mantovani A., Nascimbeni F., Lugari S., Targher G. Pathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity? Dig Liver Dis. 2019;51(4):462–70. DOI: 10.1016/j.dld.2018.12.014</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Ramanathan R., Patwa S.A., Ali A.H., Ibdah J.A. Thyroid hormone and mitochondrial dysfunction: Therapeutic implications for metabolic dysfunction-associated steatotic liver disease (MASLD). Cells. 2023;12(24):2806. DOI: 10.3390/cells12242806</mixed-citation><mixed-citation xml:lang="en">Ramanathan R., Patwa S.A., Ali A.H., Ibdah J.A. Thyroid hormone and mitochondrial dysfunction: Therapeutic implications for metabolic dysfunction-associated steatotic liver disease (MASLD). Cells. 2023;12(24):2806. DOI: 10.3390/cells12242806</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Younossi Z.M., Henry L. Understanding the burden of nonalcoholic fatty liver disease: Time for action. Diabetes Spectr. 2024;37(1):9–19. DOI: 10.2337/dsi23-0010</mixed-citation><mixed-citation xml:lang="en">Younossi Z.M., Henry L. Understanding the burden of nonalcoholic fatty liver disease: Time for action. Diabetes Spectr. 2024;37(1):9–19. DOI: 10.2337/dsi23-0010</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Jichitu A., Bungau S., Stanescu A.M.A., Vesa C.M., Toma M.M., Bustea C., et al. Non-alcoholic fatty liver disease and cardiovascular comorbidities: Pathophysiological links, diagnosis, and therapeutic management. Diagnostics (Basel). 2021;11(4):689. DOI: 10.3390/diagnostics11040689</mixed-citation><mixed-citation xml:lang="en">Jichitu A., Bungau S., Stanescu A.M.A., Vesa C.M., Toma M.M., Bustea C., et al. Non-alcoholic fatty liver disease and cardiovascular comorbidities: Pathophysiological links, diagnosis, and therapeutic management. Diagnostics (Basel). 2021;11(4):689. DOI: 10.3390/diagnostics11040689</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О.М., Ивашкин В.Т. Эпидемиологические особенности неалкогольной жировой болезни печени в России (результаты открытого многоцентрового проспективного исследования-наблюдения DIREG L 01903). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2014;24(4):32–8.</mixed-citation><mixed-citation xml:lang="en">Drapkina O.M., Ivashkin V.T. Epidemiological features of non-alcoholic fatty liver disease in Russia (results of an open multi-center prospective observational study DIREG L 01903). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014;24(4):32–8. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Ивашкин В.Т., Драпкина О.М., Маев И.В., Трухманов А.С., Блинов Д.В., Пальгова Л.К. и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015;25(6):31–41.</mixed-citation><mixed-citation xml:lang="en">Ivashkin V.T., Drapkina O.M., Mayev I.V., Trukhmanov A.S., Blinov D.V., Palgova L.K., et al. Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;25(6):31–41. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Евстифеева С.Е., Шальнова С.А., Куценко В.А., Яровая Е.Б., Баланова Ю.А., Имаева А.Э. и др. Распространенность неалкогольной жировой болезни печени среди населения трудоспособного возраста: ассоциации с социально-демографическими показателями и поведенческими факторами риска (данные ЭССЕ-РФ-2). Кардиоваскулярная терапия и профилактика. 2022;21(9):3356. DOI: 10.15829/1728-8800-2022-3356</mixed-citation><mixed-citation xml:lang="en">Evstifeeva S.E., Shalnova S.A., Kutsenko V.A., Yarovaya E.V., Balanova Yu.A., Imaeva A.E., et al. Prevalence of non-alcoholic fatty liver disease among the working-age population: Associations with socio-demographic indicators and behavioral risk factors (ESSE RF-2 data). Cardiovascular Therapy and Prevention. 2022;21(9):3356. (In Russ.). DOI: 10.15829/1728-8800-2022-3356</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Маев И.В., Андреев Д.Н., Кучерявый Ю.А. Распространенность неалкогольной жировой болезни печени в России: метаанализ. Consilium Medicum. 2023;25(5):313–19. DOI: 10.26442/20751753.2023.5.202155</mixed-citation><mixed-citation xml:lang="en">Maev I.V., Andreev D.N., Kucheryavyy Yu.A. Prevalence of non-alcoholic fat disease liver in Russian Federation: Meta-analysis. Consilium Medicum. 2023;25(5):313–19. (In Russ.). DOI: 10.26442/20751753.2023.5.202155</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Povsic M., Wong O.Y., Perry R., Bottomley J. A structured literature review of the epidemiology and disease burden of non-alcoholic steatohepatitis (NASH). Adv Ther. 2019;36(7):1574–94. DOI: 10.1007/s12325-019-00960-3</mixed-citation><mixed-citation xml:lang="en">Povsic M., Wong O.Y., Perry R., Bottomley J. A structured literature review of the epidemiology and disease burden of non-alcoholic steatohepatitis (NASH). Adv Ther. 2019;36(7):1574–94. DOI: 10.1007/s12325-019-00960-3</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Harrison S.A., Gawrieh S., Roberts K., Lisanti C.J., Schwope R.B., Cebe K.M., et al. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. J Hepatol. 2021;75(2):284–91. DOI: 10.1016/j.jhep.2021.02.034</mixed-citation><mixed-citation xml:lang="en">Harrison S.A., Gawrieh S., Roberts K., Lisanti C.J., Schwope R.B., Cebe K.M., et al. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. J Hepatol. 2021;75(2):284–91. DOI: 10.1016/j.jhep.2021.02.034</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Estes C., Anstee Q.M., Arias-Loste M.T., Bantel H., Bellentani S., Caballeria J., et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016– 2030. J Hepatol. 2018;69(4):896–904. DOI: 10.1016/j.jhep.2018.05.036</mixed-citation><mixed-citation xml:lang="en">Estes C., Anstee Q.M., Arias-Loste M.T., Bantel H., Bellentani S., Caballeria J., et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016– 2030. J Hepatol. 2018;69(4):896–904. DOI: 10.1016/j.jhep.2018.05.036</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Huang D.Q., Terrault N.A., Tacke F., Gluud L.L., Arrese M., Bugianesi E., et al. Global epidemiology of cirrhosis — aetiology, trends and predictions. Nat Rev Gastroenterol Hepatol. 2023;20(6):388–98. DOI: 10.1038/s41575-023-00759-2</mixed-citation><mixed-citation xml:lang="en">Huang D.Q., Terrault N.A., Tacke F., Gluud L.L., Arrese M., Bugianesi E., et al. Global epidemiology of cirrhosis — aetiology, trends and predictions. Nat Rev Gastroenterol Hepatol. 2023;20(6):388–98. DOI: 10.1038/s41575-023-00759-2</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Huang D.Q., El-Serag H.B., Loomba R. Global epidemiology of NAFLD-related HCC: Trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18(4):223–38. DOI: 10.1038/s41575-020-00381-6</mixed-citation><mixed-citation xml:lang="en">Huang D.Q., El-Serag H.B., Loomba R. Global epidemiology of NAFLD-related HCC: Trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18(4):223–38. DOI: 10.1038/s41575-020-00381-6</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Ивашкин В.Т., Маевская М.В., Жаркова М.С., Жигалова С.Б., Киценко Е.А., Манукьян Г.В. и др. Цирроз и фиброз печени: клинические рекомендации. М.; 2021.</mixed-citation><mixed-citation xml:lang="en">Ivashkin V.T., Maevskaya M.V., Zharkova M.S., Zhigalova S.B., Kitsenko E.A., Manukyan G.V., et al. Liver cirrhosis and fibrosis: Clinical guidelines. Moscow; 2021. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Muthiah M.D., Cheng Han N., Sanyal A.J. A clinical overview of non-alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications — What the non-specialist needs to know. Diabetes Obes Metab. 2022;24(Suppl. 2):3–14. DOI: 10.1111/dom.14521</mixed-citation><mixed-citation xml:lang="en">Muthiah M.D., Cheng Han N., Sanyal A.J. A clinical overview of non-alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications — What the non-specialist needs to know. Diabetes Obes Metab. 2022;24(Suppl. 2):3–14. DOI: 10.1111/dom.14521</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Cook N., Geier A., Schmid A., Hirschfield G., Kautz A., Schattenberg J.M., et al. The patient perspectives on future therapeutic options in NASH and patient needs. Front Med (Lausanne). 2019;6:61. DOI: 10.3389/fmed.2019.00061</mixed-citation><mixed-citation xml:lang="en">Cook N., Geier A., Schmid A., Hirschfield G., Kautz A., Schattenberg J.M., et al. The patient perspectives on future therapeutic options in NASH and patient needs. Front Med (Lausanne). 2019;6:61. DOI: 10.3389/fmed.2019.00061</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Liebe R., Esposito I., Bock H.H., Vom Dahl S., Stindt J., Baumann U., et al. Diagnosis and management of secondary causes of steatohepatitis. J Hepatol. 2021;74(6):1455–71. DOI: 10.1016/j.jhep.2021.01.045</mixed-citation><mixed-citation xml:lang="en">Liebe R., Esposito I., Bock H.H., Vom Dahl S., Stindt J., Baumann U., et al. Diagnosis and management of secondary causes of steatohepatitis. J Hepatol. 2021;74(6):1455–71. DOI: 10.1016/j.jhep.2021.01.045</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Ивашкин В.Т. Пропедевтика внутренних болезней: учебник. 2-е изд. М.: ГЭОТАР-Медиа; 2023.</mixed-citation><mixed-citation xml:lang="en">Ivashkin V.T. Propaedeutics of internal diseases: textbook. 2nd ed. Moscow: GEOTAR-Media Publ.; 2023. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Ивашкин В.Т., Маевская М.В., Жаркова М.С., Котовская Ю.В., Ткачева О.Н., Трошина Е.А. и др. Клинические рекомендации Российского общества по изучению печени, Российской гастроэнтерологической ассоциации, Российской ассоциации эндокринологов, Российской ассоциации геронтологов и гериатров и Национального общества профилактической кардиологии по диагностике и лечению неалкогольной жировой болезни печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;32(4):104–40. DOI: 10.22416/1382-4376-2022-32-4-104-140</mixed-citation><mixed-citation xml:lang="en">Ivashkin V.T., Maevskaya M.V., Zharkova M.S., Kotovskaya Yu.V., Tkacheva O.N., Troshina E.A., et al. Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(4):104–40. (In Russ). DOI: 10.22416/1382-4376-2022-32-4-104-140</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Obika M., Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res. 2012;2012:145754. DOI: 10.1155/2012/145754</mixed-citation><mixed-citation xml:lang="en">Obika M., Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res. 2012;2012:145754. DOI: 10.1155/2012/145754</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Павлов Ч.С., Глушенков Д.В., Коновалова О.Н., Ивашкин В.Т. Сфера клинического применения неинвазивных методов оценки фиброза печени: результаты собственных исследований в многопрофильном стационаре. Клиническая медицина. 2009;87(11):40–5.</mixed-citation><mixed-citation xml:lang="en">Pavlov Ch.S., Glushenkov D.V., Konovalova O.N., Ivashkin V.T. The scope of clinical application of noninvasive methods for assessing liver fibrosis: Results of our own studies in a multidisciplinary hospital. Clinical Medicine. 2009;87(11):40–5. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Sorbi D., Boynton J., Lindor K.D. The ratio of aspartate aminotransferase to alanine aminotransferase: Potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol. 1999;94(4):1018–22. DOI: 10.1111/j.1572-0241.1999.01006.x</mixed-citation><mixed-citation xml:lang="en">Sorbi D., Boynton J., Lindor K.D. The ratio of aspartate aminotransferase to alanine aminotransferase: Potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol. 1999;94(4):1018–22. DOI: 10.1111/j.1572-0241.1999.01006.x</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Шестакова М.В., Майоров А.Ю., Шамхалова М.Ш., Сухарева О.Ю., Галстян Г.Р. и др. Сахарный диабет 2-го типа у взрослых: клинические рекомендации. М.; 2022.</mixed-citation><mixed-citation xml:lang="en">Dedov I.I., Shestakova M.V., Mayorov A.Yu., Shamkhalova M.Sh., Sukhareva O.Yu., Galstyan G.R., et al. Type 2 diabetes mellitus in adults: Clinical guidelines. Moscow; 2022. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Fujii H., Kawada N.; Japan Study Group Of Nafld Jsg-Nafld. The role of insulin resistance and diabetes in nonalcoholic fatty liver disease. Int J Mol Sci. 2020;21(11):3863. DOI: 10.3390/ijms21113863</mixed-citation><mixed-citation xml:lang="en">Fujii H., Kawada N.; Japan Study Group Of Nafld Jsg-Nafld. The role of insulin resistance and diabetes in nonalcoholic fatty liver disease. Int J Mol Sci. 2020;21(11):3863. DOI: 10.3390/ijms21113863</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363(14):1341–50. DOI: 10.1056/NEJMra0912063</mixed-citation><mixed-citation xml:lang="en">Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363(14):1341–50. DOI: 10.1056/NEJMra0912063</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">Кутишенко Н.П., Марцевич С.Ю., Лерман О.В., Балашов И.С., Невзорова В.А., Резник И.И. и др. Повышение эффективности гиполипидемической терапии у пациентов высокого сердечно-сосудистого риска с сочетанной патологией печени (результаты дополнительного анализа исследования РАКУРС). Рациональная фармакотерапия в кардиологии. 2015;11(3):297–303. DOI: 10.20996/1819-6446-2015-11-3-297-303</mixed-citation><mixed-citation xml:lang="en">Kutishenko N.P., Martsevich S.Yu., Lerman O.V., Balashov I.S., Nevzorova V.A., Reznik I.I., et al. The improvement of lipid-lowering therapy effectiveness in patients with high cardiovascular risk and concomitant liver disease (results of additional analysis of the RAKURS study). Rational Pharmacotherapy in Cardiology. 2015;11(3):297–303. (In Russ.). DOI: 10.20996/1819-6446-2015-11-3-297-303</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">Ежов М.В., Кухарчук В.В., Сергиенко И.В., Алиева А.С., Анциферов М.Б., Аншелес А.А. и др. Нарушения липидного обмена: клинические рекомендации. М.; 2023.</mixed-citation><mixed-citation xml:lang="en">Ezhov M.V., Kukharchuk V.V., Sergienko I.V., Alieva A.S., Antsiferov M.B., Ansheles A.A., et al. Lipid metabolism disorders: Clinical guidelines. Moscow; 2023. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit84"><label>84</label><citation-alternatives><mixed-citation xml:lang="ru">Spinosa M., Stine J.G. Nonalcoholic fatty liver disease — evidence for a thrombophilic state? Curr Pharm Des. 2020;26(10):1036–44. DOI: 10.2174/1381612826666200131101553</mixed-citation><mixed-citation xml:lang="en">Spinosa M., Stine J.G. Nonalcoholic fatty liver disease — evidence for a thrombophilic state? Curr Pharm Des. 2020;26(10):1036–44. DOI: 10.2174/1381612826666200131101553</mixed-citation></citation-alternatives></ref><ref id="cit85"><label>85</label><citation-alternatives><mixed-citation xml:lang="ru">Verrijken A., Francque S., Mertens I., Prawitt J., Caron S., Hubens G., et al. Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2014;59(1):121–9. DOI: 10.1002/hep.26510</mixed-citation><mixed-citation xml:lang="en">Verrijken A., Francque S., Mertens I., Prawitt J., Caron S., Hubens G., et al. Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2014;59(1):121–9. DOI: 10.1002/hep.26510</mixed-citation></citation-alternatives></ref><ref id="cit86"><label>86</label><citation-alternatives><mixed-citation xml:lang="ru">Balta G., Altay C., Gurgey A. PAI-1 gene 4G/5G genotype: A risk factor for thrombosis in vessels of internal organs. Am J Hematol. 2002;71(2):89–93. DOI: 10.1002/ajh.10192</mixed-citation><mixed-citation xml:lang="en">Balta G., Altay C., Gurgey A. PAI-1 gene 4G/5G genotype: A risk factor for thrombosis in vessels of internal organs. Am J Hematol. 2002;71(2):89–93. DOI: 10.1002/ajh.10192</mixed-citation></citation-alternatives></ref><ref id="cit87"><label>87</label><citation-alternatives><mixed-citation xml:lang="ru">Northup P.G., Argo C.K., Shah N., Caldwell S.H. Hypercoagulation and thrombophilia in nonalcoholic fatty liver disease: Mechanisms, human evidence, therapeutic implications, and preventive implications. Semin Liver Dis. 2012;32(1):39–48. DOI: 10.1055/s-0032-1306425</mixed-citation><mixed-citation xml:lang="en">Northup P.G., Argo C.K., Shah N., Caldwell S.H. Hypercoagulation and thrombophilia in nonalcoholic fatty liver disease: Mechanisms, human evidence, therapeutic implications, and preventive implications. Semin Liver Dis. 2012;32(1):39–48. DOI: 10.1055/s-0032-1306425</mixed-citation></citation-alternatives></ref><ref id="cit88"><label>88</label><citation-alternatives><mixed-citation xml:lang="ru">Skurk T., Hauner H. Obesity and impaired fibrinolysis: Role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord. 2004;28(11):1357–64. DOI: 10.1038/sj.ijo.0802778</mixed-citation><mixed-citation xml:lang="en">Skurk T., Hauner H. Obesity and impaired fibrinolysis: Role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord. 2004;28(11):1357–64. DOI: 10.1038/sj.ijo.0802778</mixed-citation></citation-alternatives></ref><ref id="cit89"><label>89</label><citation-alternatives><mixed-citation xml:lang="ru">Kotronen A., Joutsi-Korhonen L., Sevastianova K., Bergholm R., Hakkarainen A., Pietiläinen K.H., et al. Increased coagulation factor VIII, IX, XI and XII activities in non-alcoholic fatty liver disease. Liver Int. 2011;31(2):176–83. DOI: 10.1111/j.1478-3231.2010.02375.x</mixed-citation><mixed-citation xml:lang="en">Kotronen A., Joutsi-Korhonen L., Sevastianova K., Bergholm R., Hakkarainen A., Pietiläinen K.H., et al. Increased coagulation factor VIII, IX, XI and XII activities in non-alcoholic fatty liver disease. Liver Int. 2011;31(2):176–83. DOI: 10.1111/j.1478-3231.2010.02375.x</mixed-citation></citation-alternatives></ref><ref id="cit90"><label>90</label><citation-alternatives><mixed-citation xml:lang="ru">Ciardullo S., Ballabeni C., Trevisan R., Perseghin G. Liver stiffness, albuminuria and chronic kidney disease in patients with NAFLD: A systematic review and meta-analysis. Biomolecules. 2022;12(1):105. DOI: 10.3390/biom12010105</mixed-citation><mixed-citation xml:lang="en">Ciardullo S., Ballabeni C., Trevisan R., Perseghin G. Liver stiffness, albuminuria and chronic kidney disease in patients with NAFLD: A systematic review and meta-analysis. Biomolecules. 2022;12(1):105. DOI: 10.3390/biom12010105</mixed-citation></citation-alternatives></ref><ref id="cit91"><label>91</label><citation-alternatives><mixed-citation xml:lang="ru">Sun D.Q., Jin Y., Wang T.Y., Zheng K.I., Rios R.S., Zhang H.Y., et al. MAFLD and risk of CKD. Metabolism. 2021;115:154433. DOI: 10.1016/j.metabol.2020.154433</mixed-citation><mixed-citation xml:lang="en">Sun D.Q., Jin Y., Wang T.Y., Zheng K.I., Rios R.S., Zhang H.Y., et al. MAFLD and risk of CKD. Metabolism. 2021;115:154433. DOI: 10.1016/j.metabol.2020.154433</mixed-citation></citation-alternatives></ref><ref id="cit92"><label>92</label><citation-alternatives><mixed-citation xml:lang="ru">Бобкова И.Н., Ватазин А.В., Ветчинникова О.Н., Волгина Г.В., Голубев Р.В., Горелова Е.А. и др. Хроническая болезнь почек (ХБП): клинические рекомендации. М.; 2021.</mixed-citation><mixed-citation xml:lang="en">Bobkova I.N., Vatazin A.V., Vetchinnikova O.N., Volgina G.V., Golubev R.V., Gorelova E.A., et al. Chronic kidney disease (CKD): Clinical guidelines. Moscow; 2021. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit93"><label>93</label><citation-alternatives><mixed-citation xml:lang="ru">Маевская М.В., Котовская Ю.В., Ивашкин В.Т., Ткачева О.Н., Трошина Е.А., Шестакова М.В. и др. Национальный Консенсус для врачей по ведению взрослых пациентов с неалкогольной жировой болезнью печени и ее основными коморбидными состояниями. Терапевтический архив. 2022;94(2):216–53. DOI: 10.26442/00403660.2022.02.201363</mixed-citation><mixed-citation xml:lang="en">Maevskaya M.V., Kotovskaya Yu.V., Ivashkin V.T., Tkacheva O.N., Troshina E.A., Shestakova M.V., et al. The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. Terapevticheskii Arkhiv. 2022;94(2):216–53. (In Russ.). DOI: 10.26442/00403660.2022.02.201363</mixed-citation></citation-alternatives></ref><ref id="cit94"><label>94</label><citation-alternatives><mixed-citation xml:lang="ru">Darmawan G., Hamijoyo L., Hasan I. Association between serum uric acid and non-alcoholic fatty liver disease: A meta-analysis. Acta Med Indones. 2017;49(2):136–47.</mixed-citation><mixed-citation xml:lang="en">Darmawan G., Hamijoyo L., Hasan I. Association between serum uric acid and non-alcoholic fatty liver disease: A meta-analysis. Acta Med Indones. 2017;49(2):136–47.</mixed-citation></citation-alternatives></ref><ref id="cit95"><label>95</label><citation-alternatives><mixed-citation xml:lang="ru">Lombardi R., Pisano G., Fargion S. Role of serum uric acid and ferritin in the development and progression of NAFLD. Int J Mol Sci. 2016;17(4):548. DOI: 10.3390/ijms17040548</mixed-citation><mixed-citation xml:lang="en">Lombardi R., Pisano G., Fargion S. Role of serum uric acid and ferritin in the development and progression of NAFLD. Int J Mol Sci. 2016;17(4):548. DOI: 10.3390/ijms17040548</mixed-citation></citation-alternatives></ref><ref id="cit96"><label>96</label><citation-alternatives><mixed-citation xml:lang="ru">Аверкина Н.А., Багаева М.Э., Батышева Т.Т., Быкова О.В., Вашакмадзе Н.Д., Волынец Г.В. и др. Нарушения обмена меди (болезнь Вильсона): клинические рекомендации. М.; 2021.</mixed-citation><mixed-citation xml:lang="en">Averkina N.A., Bagaeva M.E., Batysheva T.T., Bykova O.V., Vashakmadze N.D., Volynets G.V., et al. Copper metabolism disorders (Wilson’s disease): Clinical guidelines. Moscow; 2021. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit97"><label>97</label><citation-alternatives><mixed-citation xml:lang="ru">Ивашкин В.Т., Ющук Н.Д., Богомолов П.О., Волчкова Е.В., Дмитриев А.С., Жаркова М.С. и др. Хронический вирусный гепатит С: клинические рекомендации. М.; 2021.</mixed-citation><mixed-citation xml:lang="en">Ivashkin V.T., Yushchuk N.D., Bogomolov P.O., Volchkova E.V., Dmitriev A.S., Zharkova M.S., et al. Chronic viral hepatitis C: Clinical recommendations. Moscow; 2021. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit98"><label>98</label><citation-alternatives><mixed-citation xml:lang="ru">Ивашкин В.Т., Маевская М.В., Жаркова М.С., Тихонов И.Н., Федосьина Е.А., Павлов Ч.С. Алгоритмы диагностики и лечения в гепатологии: справочные материалы. М.: МЕДпресс-информ; 2016.</mixed-citation><mixed-citation xml:lang="en">Ivashkin V.T., Maevskaya M.V., Zharkova M.S., Tikhonov I.N., Fedosina E.A., Pavlov Ch.S. Algorithms for diagnosis and treatment in hepatology: Reference materials. Moscow: MEDpress-inform Publ.; 2016. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit99"><label>99</label><citation-alternatives><mixed-citation xml:lang="ru">Petzold G. Role of ultrasound methods for the assessment of NAFLD. J Clin Med. 2022;11(15):4581. DOI: 10.3390/jcm11154581</mixed-citation><mixed-citation xml:lang="en">Petzold G. Role of ultrasound methods for the assessment of NAFLD. J Clin Med. 2022;11(15):4581. DOI: 10.3390/jcm11154581</mixed-citation></citation-alternatives></ref><ref id="cit100"><label>100</label><citation-alternatives><mixed-citation xml:lang="ru">Ferraioli G., Soares Monteiro L.B. Ultrasound-based techniques for the diagnosis of liver steatosis. World J Gastroenterol. 2019;25(40):6053–62. DOI: 10.3748/wjg.v25.i40.6053</mixed-citation><mixed-citation xml:lang="en">Ferraioli G., Soares Monteiro L.B. Ultrasound-based techniques for the diagnosis of liver steatosis. World J Gastroenterol. 2019;25(40):6053–62. DOI: 10.3748/wjg.v25.i40.6053</mixed-citation></citation-alternatives></ref><ref id="cit101"><label>101</label><citation-alternatives><mixed-citation xml:lang="ru">Hernaez R., Lazo M., Bonekamp S., Kamel I., Brancati F.L., Guallar E., et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-analysis. Hepatology. 2011;54(3):1082–90. DOI: 10.1002/hep.24452</mixed-citation><mixed-citation xml:lang="en">Hernaez R., Lazo M., Bonekamp S., Kamel I., Brancati F.L., Guallar E., et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-analysis. Hepatology. 2011;54(3):1082–90. DOI: 10.1002/hep.24452</mixed-citation></citation-alternatives></ref><ref id="cit102"><label>102</label><citation-alternatives><mixed-citation xml:lang="ru">European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis — 2021 update. J Hepatol. 2021;75(3):659–89. DOI: 10.1016/j.jhep.2021.05.025</mixed-citation><mixed-citation xml:lang="en">European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis — 2021 update. J Hepatol. 2021;75(3):659–89. DOI: 10.1016/j.jhep.2021.05.025</mixed-citation></citation-alternatives></ref><ref id="cit103"><label>103</label><citation-alternatives><mixed-citation xml:lang="ru">Petroff D., Blank V., Newsome P.N., Shalimar, Voican C.S., Thiele M., et al. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: An individual patient data meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(3):185–98. DOI: 10.1016/S2468-1253(20)30357-5</mixed-citation><mixed-citation xml:lang="en">Petroff D., Blank V., Newsome P.N., Shalimar, Voican C.S., Thiele M., et al. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: An individual patient data meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(3):185–98. DOI: 10.1016/S2468-1253(20)30357-5</mixed-citation></citation-alternatives></ref><ref id="cit104"><label>104</label><citation-alternatives><mixed-citation xml:lang="ru">Pu K., Wang Y., Bai S., Wei H., Zhou Y., Fan J., et al. Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: A systematic review and meta-analysis. BMC Gastroenterol. 2019;19(1):51. DOI: 10.1186/s12876-019-0961-9</mixed-citation><mixed-citation xml:lang="en">Pu K., Wang Y., Bai S., Wei H., Zhou Y., Fan J., et al. Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: A systematic review and meta-analysis. BMC Gastroenterol. 2019;19(1):51. DOI: 10.1186/s12876-019-0961-9</mixed-citation></citation-alternatives></ref><ref id="cit105"><label>105</label><citation-alternatives><mixed-citation xml:lang="ru">Gu J., Liu S., Du S., Zhang Q., Xiao J., Dong Q., et al. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: A meta-analysis. Eur Radiol. 2019;29(7):3564–73. DOI: 10.1007/s00330-019-06072-4</mixed-citation><mixed-citation xml:lang="en">Gu J., Liu S., Du S., Zhang Q., Xiao J., Dong Q., et al. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: A meta-analysis. Eur Radiol. 2019;29(7):3564–73. DOI: 10.1007/s00330-019-06072-4</mixed-citation></citation-alternatives></ref><ref id="cit106"><label>106</label><citation-alternatives><mixed-citation xml:lang="ru">Verhaegh P., Bavalia R., Winkens B., Masclee A., Jonkers D., Koek G. Noninvasive tests do not accurately differentiate nonalcoholic steatohepatitis from simple steatosis: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16(6):837–61. DOI: 10.1016/j.cgh.2017.08.024</mixed-citation><mixed-citation xml:lang="en">Verhaegh P., Bavalia R., Winkens B., Masclee A., Jonkers D., Koek G. Noninvasive tests do not accurately differentiate nonalcoholic steatohepatitis from simple steatosis: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16(6):837–61. DOI: 10.1016/j.cgh.2017.08.024</mixed-citation></citation-alternatives></ref><ref id="cit107"><label>107</label><citation-alternatives><mixed-citation xml:lang="ru">Kleiner D.E., Brunt E.M. Nonalcoholic fatty liver disease: Pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis. 2012;32(1):3–13. DOI: 10.1055/s-0032-1306421</mixed-citation><mixed-citation xml:lang="en">Kleiner D.E., Brunt E.M. Nonalcoholic fatty liver disease: Pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis. 2012;32(1):3–13. DOI: 10.1055/s-0032-1306421</mixed-citation></citation-alternatives></ref><ref id="cit108"><label>108</label><citation-alternatives><mixed-citation xml:lang="ru">Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21. DOI: 10.1002/hep.20701</mixed-citation><mixed-citation xml:lang="en">Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21. DOI: 10.1002/hep.20701</mixed-citation></citation-alternatives></ref><ref id="cit109"><label>109</label><citation-alternatives><mixed-citation xml:lang="ru">Bedossa P. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014;60(2):565–75. DOI: 10.1002/hep.27173</mixed-citation><mixed-citation xml:lang="en">Bedossa P. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014;60(2):565–75. DOI: 10.1002/hep.27173</mixed-citation></citation-alternatives></ref><ref id="cit110"><label>110</label><citation-alternatives><mixed-citation xml:lang="ru">Bedossa P. Current histological classification of NAFLD: Strength and limitations. Hepatol Int. 2013;7(Suppl. 2):765–70. DOI: 10.1007/s12072-013-9446-z</mixed-citation><mixed-citation xml:lang="en">Bedossa P. Current histological classification of NAFLD: Strength and limitations. Hepatol Int. 2013;7(Suppl. 2):765–70. DOI: 10.1007/s12072-013-9446-z</mixed-citation></citation-alternatives></ref><ref id="cit111"><label>111</label><citation-alternatives><mixed-citation xml:lang="ru">Harrison S.A., Torgerson S., Hayashi P., Ward J., Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003;98(11):2485–90. DOI: 10.1111/j.1572-0241.2003.08699.x</mixed-citation><mixed-citation xml:lang="en">Harrison S.A., Torgerson S., Hayashi P., Ward J., Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003;98(11):2485–90. DOI: 10.1111/j.1572-0241.2003.08699.x</mixed-citation></citation-alternatives></ref><ref id="cit112"><label>112</label><citation-alternatives><mixed-citation xml:lang="ru">Xiao G., Zhu S., Xiao X., Yan L., Yang J., Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. Hepatology. 2017;66(5):1486–501. DOI: 10.1002/hep.29302</mixed-citation><mixed-citation xml:lang="en">Xiao G., Zhu S., Xiao X., Yan L., Yang J., Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. Hepatology. 2017;66(5):1486–501. DOI: 10.1002/hep.29302</mixed-citation></citation-alternatives></ref><ref id="cit113"><label>113</label><citation-alternatives><mixed-citation xml:lang="ru">McPherson S., Hardy T., Dufour J.F., Petta S., Romero-Gomez M., Allison M., et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol. 2017;112(5):740–51. DOI: 10.1038/ajg.2016.453</mixed-citation><mixed-citation xml:lang="en">McPherson S., Hardy T., Dufour J.F., Petta S., Romero-Gomez M., Allison M., et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol. 2017;112(5):740–51. DOI: 10.1038/ajg.2016.453</mixed-citation></citation-alternatives></ref><ref id="cit114"><label>114</label><citation-alternatives><mixed-citation xml:lang="ru">Bril F., McPhaul M.J., Caulfield M.P., Clark V.C., Soldevilla-Pico C., Firpi-Morell R.J., et al. Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes. Diabetes Care. 2020;43(2):290–7. DOI: 10.2337/dc19-1071</mixed-citation><mixed-citation xml:lang="en">Bril F., McPhaul M.J., Caulfield M.P., Clark V.C., Soldevilla-Pico C., Firpi-Morell R.J., et al. Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes. Diabetes Care. 2020;43(2):290–7. DOI: 10.2337/dc19-1071</mixed-citation></citation-alternatives></ref><ref id="cit115"><label>115</label><citation-alternatives><mixed-citation xml:lang="ru">Ratziu V., Massard J., Charlotte F., Messous D., Imbert-Bismut F., Bonyhay L., et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006;6:6. DOI: 10.1186/1471-230X-6-6</mixed-citation><mixed-citation xml:lang="en">Ratziu V., Massard J., Charlotte F., Messous D., Imbert-Bismut F., Bonyhay L., et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006;6:6. DOI: 10.1186/1471-230X-6-6</mixed-citation></citation-alternatives></ref><ref id="cit116"><label>116</label><citation-alternatives><mixed-citation xml:lang="ru">Vali Y., Lee J., Boursier J., Spijker R., Verheij J., Brosnan M.J., et al. FibroTest for evaluating fibrosis in non-alcoholic fatty liver disease patients: A systematic review and meta-analysis. J Clin Med. 2021;10(11):2415. DOI: 10.3390/jcm10112415</mixed-citation><mixed-citation xml:lang="en">Vali Y., Lee J., Boursier J., Spijker R., Verheij J., Brosnan M.J., et al. FibroTest for evaluating fibrosis in non-alcoholic fatty liver disease patients: A systematic review and meta-analysis. J Clin Med. 2021;10(11):2415. DOI: 10.3390/jcm10112415</mixed-citation></citation-alternatives></ref><ref id="cit117"><label>117</label><citation-alternatives><mixed-citation xml:lang="ru">Papatheodoridi M., Hiriart J.B., Lupsor-Platon M., Bronte F., Boursier J., Elshaarawy O., et al. Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. J Hepatol. 2021;74(5):1109–16. DOI: 10.1016/j.jhep.2020.11.050</mixed-citation><mixed-citation xml:lang="en">Papatheodoridi M., Hiriart J.B., Lupsor-Platon M., Bronte F., Boursier J., Elshaarawy O., et al. Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. J Hepatol. 2021;74(5):1109–16. DOI: 10.1016/j.jhep.2020.11.050</mixed-citation></citation-alternatives></ref><ref id="cit118"><label>118</label><citation-alternatives><mixed-citation xml:lang="ru">De Franchis R., Bosch J., Garcia-Tsao G., Reiberger T., Ripoll C. Baveno VII — Renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959–74. DOI: 10.1016/j.jhep.2021.12.022</mixed-citation><mixed-citation xml:lang="en">De Franchis R., Bosch J., Garcia-Tsao G., Reiberger T., Ripoll C. Baveno VII — Renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959–74. DOI: 10.1016/j.jhep.2021.12.022</mixed-citation></citation-alternatives></ref><ref id="cit119"><label>119</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization. WHO guidelines on physical activity and sedentary behaviour. URL: https://iris.who.int/bitstream/handle/10665/336656/9789240015128-eng.pdf</mixed-citation><mixed-citation xml:lang="en">World Health Organization. WHO guidelines on physical activity and sedentary behaviour. URL: https://iris.who.int/bitstream/handle/10665/336656/9789240015128-eng.pdf</mixed-citation></citation-alternatives></ref><ref id="cit120"><label>120</label><citation-alternatives><mixed-citation xml:lang="ru">Keating S.E., Hackett D.A., George J., Johnson N.A. Exercise and non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Hepatol. 2012;57(1):157–66. DOI: 10.1016/j.jhep.2012.02.023</mixed-citation><mixed-citation xml:lang="en">Keating S.E., Hackett D.A., George J., Johnson N.A. Exercise and non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Hepatol. 2012;57(1):157–66. DOI: 10.1016/j.jhep.2012.02.023</mixed-citation></citation-alternatives></ref><ref id="cit121"><label>121</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Мокрышева Н.Г., Мельниченко Г.А., Трошина Е.А., Мазурина Н.В., Ершова Е.В. и др. Ожирение: клинические рекомендации. М.; 2020.</mixed-citation><mixed-citation xml:lang="en">Dedov I.I., Mokrysheva N.G., Melnichenko G.A., Troshina E.A., Mazurina N.V., Ershova E.V., et al. Obesity: Clinical guidelines. Moscow; 2020. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit122"><label>122</label><citation-alternatives><mixed-citation xml:lang="ru">Hashida R., Kawaguchi T., Bekki M., Omoto M., Matsuse H., Nago T., et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. J Hepatol. 2017;66(1):142–52. DOI: 10.1016/j.jhep.2016.08.023</mixed-citation><mixed-citation xml:lang="en">Hashida R., Kawaguchi T., Bekki M., Omoto M., Matsuse H., Nago T., et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. J Hepatol. 2017;66(1):142–52. DOI: 10.1016/j.jhep.2016.08.023</mixed-citation></citation-alternatives></ref><ref id="cit123"><label>123</label><citation-alternatives><mixed-citation xml:lang="ru">Katsagoni C.N., Georgoulis M., Papatheodoridis G.V., Panagiotakos D.B., Kontogianni M.D. Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis. Metabolism. 2017;68:119–32. DOI: 10.1016/j.metabol.2016.12.006</mixed-citation><mixed-citation xml:lang="en">Katsagoni C.N., Georgoulis M., Papatheodoridis G.V., Panagiotakos D.B., Kontogianni M.D. Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis. Metabolism. 2017;68:119–32. DOI: 10.1016/j.metabol.2016.12.006</mixed-citation></citation-alternatives></ref><ref id="cit124"><label>124</label><citation-alternatives><mixed-citation xml:lang="ru">Golabi P., Locklear C.T., Austin P., Afdhal S., Byrns M., Gerber L., et al. Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: Systematic review. World J Gastroenterol. 2016;22(27):6318–27. DOI: 10.3748/wjg.v22.i27.6318</mixed-citation><mixed-citation xml:lang="en">Golabi P., Locklear C.T., Austin P., Afdhal S., Byrns M., Gerber L., et al. Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: Systematic review. World J Gastroenterol. 2016;22(27):6318–27. DOI: 10.3748/wjg.v22.i27.6318</mixed-citation></citation-alternatives></ref><ref id="cit125"><label>125</label><citation-alternatives><mixed-citation xml:lang="ru">Smart N.A., King N., McFarlane J.R., Graham P.L., Dieberg G. Effect of exercise training on liver function in adults who are overweight or exhibit fatty liver disease: A systematic review and meta-analysis. Br J Sports Med. 2018;52(13):834–43. DOI: 10.1136/bjsports-2016-096197</mixed-citation><mixed-citation xml:lang="en">Smart N.A., King N., McFarlane J.R., Graham P.L., Dieberg G. Effect of exercise training on liver function in adults who are overweight or exhibit fatty liver disease: A systematic review and meta-analysis. Br J Sports Med. 2018;52(13):834–43. DOI: 10.1136/bjsports-2016-096197</mixed-citation></citation-alternatives></ref><ref id="cit126"><label>126</label><citation-alternatives><mixed-citation xml:lang="ru">Cheng S., Ge J., Zhao C., Le S., Yang Y., Ke D., et al. Effect of aerobic exercise and diet on liver fat in pre-diabetic patients with non-alcoholic-fatty-liver-disease: A randomized controlled trial. Sci Rep. 2017;7(1):15952. DOI: 10.1038/s41598-017-16159-x</mixed-citation><mixed-citation xml:lang="en">Cheng S., Ge J., Zhao C., Le S., Yang Y., Ke D., et al. Effect of aerobic exercise and diet on liver fat in pre-diabetic patients with non-alcoholic-fatty-liver-disease: A randomized controlled trial. Sci Rep. 2017;7(1):15952. DOI: 10.1038/s41598-017-16159-x</mixed-citation></citation-alternatives></ref><ref id="cit127"><label>127</label><citation-alternatives><mixed-citation xml:lang="ru">Hallsworth K., Thoma C., Hollingsworth K.G., Cassidy S., Anstee Q.M., Day C.P., et al. Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: A randomized controlled trial. Clin Sci (Lond). 2015;129(12):1097–105. DOI: 10.1042/CS20150308</mixed-citation><mixed-citation xml:lang="en">Hallsworth K., Thoma C., Hollingsworth K.G., Cassidy S., Anstee Q.M., Day C.P., et al. Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: A randomized controlled trial. Clin Sci (Lond). 2015;129(12):1097–105. DOI: 10.1042/CS20150308</mixed-citation></citation-alternatives></ref><ref id="cit128"><label>128</label><citation-alternatives><mixed-citation xml:lang="ru">Rector R.S., Thyfault J.P., Morris R.T., Laye M.J., Borengasser S.J., Booth F.W., et al. Daily exercise increases hepatic fatty acid oxidation and prevents steatosis in Otsuka Long-Evans Tokushima Fatty rats. Am J Physiol Gastrointest Liver Physiol. 2008;294(3):G619–26. DOI: 10.1152/ajpgi.00428.2007</mixed-citation><mixed-citation xml:lang="en">Rector R.S., Thyfault J.P., Morris R.T., Laye M.J., Borengasser S.J., Booth F.W., et al. Daily exercise increases hepatic fatty acid oxidation and prevents steatosis in Otsuka Long-Evans Tokushima Fatty rats. Am J Physiol Gastrointest Liver Physiol. 2008;294(3):G619–26. DOI: 10.1152/ajpgi.00428.2007</mixed-citation></citation-alternatives></ref><ref id="cit129"><label>129</label><citation-alternatives><mixed-citation xml:lang="ru">Rinella M.E., Neuschwander-Tetri B.A., Siddiqui M.S., Abdelmalek M.F., Caldwell S., Barb D., et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797–835. DOI: 10.1097/HEP.0000000000000323</mixed-citation><mixed-citation xml:lang="en">Rinella M.E., Neuschwander-Tetri B.A., Siddiqui M.S., Abdelmalek M.F., Caldwell S., Barb D., et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797–835. DOI: 10.1097/HEP.0000000000000323</mixed-citation></citation-alternatives></ref><ref id="cit130"><label>130</label><citation-alternatives><mixed-citation xml:lang="ru">Zelber-Sagi S., Salomone F., Mlynarsky L. The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: Evidence and plausible mechanisms. Liver Int. 2017;37(7):936–49. DOI: 10.1111/liv.13435</mixed-citation><mixed-citation xml:lang="en">Zelber-Sagi S., Salomone F., Mlynarsky L. The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: Evidence and plausible mechanisms. Liver Int. 2017;37(7):936–49. DOI: 10.1111/liv.13435</mixed-citation></citation-alternatives></ref><ref id="cit131"><label>131</label><citation-alternatives><mixed-citation xml:lang="ru">Haigh L., Kirk C., El Gendy K., Gallacher J., Errington L., Mathers J.C., et al. The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis. Clin Nutr. 2022;41(9):1913–31. DOI: 10.1016/j.clnu.2022.06.037</mixed-citation><mixed-citation xml:lang="en">Haigh L., Kirk C., El Gendy K., Gallacher J., Errington L., Mathers J.C., et al. The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis. Clin Nutr. 2022;41(9):1913–31. DOI: 10.1016/j.clnu.2022.06.037</mixed-citation></citation-alternatives></ref><ref id="cit132"><label>132</label><citation-alternatives><mixed-citation xml:lang="ru">Younossi Z.M., Corey K.E., Lim J.K. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: Expert review. Gastroenterology. 2021;160(3):912–8. DOI: 10.1053/j.gastro.2020.11.051</mixed-citation><mixed-citation xml:lang="en">Younossi Z.M., Corey K.E., Lim J.K. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: Expert review. Gastroenterology. 2021;160(3):912–8. DOI: 10.1053/j.gastro.2020.11.051</mixed-citation></citation-alternatives></ref><ref id="cit133"><label>133</label><citation-alternatives><mixed-citation xml:lang="ru">Panchal S.K., Poudyal H., Brown L. Quercetin ameliorates cardiovascular, hepatic, and metabolic changes in diet-induced metabolic syndrome in rats. J Nutr. 2012;142(6):1026–32. DOI: 10.3945/jn.111.157263</mixed-citation><mixed-citation xml:lang="en">Panchal S.K., Poudyal H., Brown L. Quercetin ameliorates cardiovascular, hepatic, and metabolic changes in diet-induced metabolic syndrome in rats. J Nutr. 2012;142(6):1026–32. DOI: 10.3945/jn.111.157263</mixed-citation></citation-alternatives></ref><ref id="cit134"><label>134</label><citation-alternatives><mixed-citation xml:lang="ru">Aller R., Izaola O., de la Fuente B., De Luis Román D.A. Mediterranean diet is associated with liver histology in patients with non alcoholic fatty liver disease. Nutr Hosp. 2015;32(6):2518–24. DOI: 10.3305/nh.2015.32.6.10074</mixed-citation><mixed-citation xml:lang="en">Aller R., Izaola O., de la Fuente B., De Luis Román D.A. Mediterranean diet is associated with liver histology in patients with non alcoholic fatty liver disease. Nutr Hosp. 2015;32(6):2518–24. DOI: 10.3305/nh.2015.32.6.10074</mixed-citation></citation-alternatives></ref><ref id="cit135"><label>135</label><citation-alternatives><mixed-citation xml:lang="ru">Abenavoli L., Greco M., Nazionale I., Peta V., Milic N., Accattato F., et al. Effects of Mediterranean diet supplemented with silybin-vitamin E-phospholipid complex in overweight patients with non-alcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2015;9(4):519–27. DOI: 10.1586/17474124.2015.1004312</mixed-citation><mixed-citation xml:lang="en">Abenavoli L., Greco M., Nazionale I., Peta V., Milic N., Accattato F., et al. Effects of Mediterranean diet supplemented with silybin-vitamin E-phospholipid complex in overweight patients with non-alcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2015;9(4):519–27. DOI: 10.1586/17474124.2015.1004312</mixed-citation></citation-alternatives></ref><ref id="cit136"><label>136</label><citation-alternatives><mixed-citation xml:lang="ru">Ryan M.C., Itsiopoulos C., Thodis T., Ward G., Trost N., Hofferberth S., et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol. 2013;59(1):138–43. DOI: 10.1016/j.jhep.2013.02.012</mixed-citation><mixed-citation xml:lang="en">Ryan M.C., Itsiopoulos C., Thodis T., Ward G., Trost N., Hofferberth S., et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol. 2013;59(1):138–43. DOI: 10.1016/j.jhep.2013.02.012</mixed-citation></citation-alternatives></ref><ref id="cit137"><label>137</label><citation-alternatives><mixed-citation xml:lang="ru">Trovato F.M., Martines G.F., Brischetto D., Trovato G., Catalano D. Neglected features of lifestyle: Their relevance in non-alcoholic fatty liver disease. World J Hepatol. 2016;8(33):1459–65. DOI: 10.4254/wjh.v8.i33.1459</mixed-citation><mixed-citation xml:lang="en">Trovato F.M., Martines G.F., Brischetto D., Trovato G., Catalano D. Neglected features of lifestyle: Their relevance in non-alcoholic fatty liver disease. World J Hepatol. 2016;8(33):1459–65. DOI: 10.4254/wjh.v8.i33.1459</mixed-citation></citation-alternatives></ref><ref id="cit138"><label>138</label><citation-alternatives><mixed-citation xml:lang="ru">Lee D., Chiavaroli L., Ayoub-Charette S., Khan T.A., Zurbau A., Au-Yeung F., et al. Important food sources of fructose-containing sugars and non-alcoholic fatty liver disease: A systematic review and meta-analysis of controlled trials. Nutrients. 2022;14(14):2846. DOI: 10.3390/nu14142846</mixed-citation><mixed-citation xml:lang="en">Lee D., Chiavaroli L., Ayoub-Charette S., Khan T.A., Zurbau A., Au-Yeung F., et al. Important food sources of fructose-containing sugars and non-alcoholic fatty liver disease: A systematic review and meta-analysis of controlled trials. Nutrients. 2022;14(14):2846. DOI: 10.3390/nu14142846</mixed-citation></citation-alternatives></ref><ref id="cit139"><label>139</label><citation-alternatives><mixed-citation xml:lang="ru">Liu W., Zhai D., Zhang T., Mudoti N.G., Chang Q., Liu Y., et al. Meta-analysis of the association between major foods with added fructose and non-alcoholic fatty liver disease. Food Funct. 2023;14(12):5551–61. DOI: 10.1039/d3fo00882g</mixed-citation><mixed-citation xml:lang="en">Liu W., Zhai D., Zhang T., Mudoti N.G., Chang Q., Liu Y., et al. Meta-analysis of the association between major foods with added fructose and non-alcoholic fatty liver disease. Food Funct. 2023;14(12):5551–61. DOI: 10.1039/d3fo00882g</mixed-citation></citation-alternatives></ref><ref id="cit140"><label>140</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang X.L., Wang T.Y., Targher G., Byrne C.D., Zheng M.H. Lifestyle interventions for non-obese patients both with, and at risk, of non-alcoholic fatty liver disease. Diabetes Metab J. 2022;46(3):391–401. DOI: 10.4093/dmj.2022.0048</mixed-citation><mixed-citation xml:lang="en">Zhang X.L., Wang T.Y., Targher G., Byrne C.D., Zheng M.H. Lifestyle interventions for non-obese patients both with, and at risk, of non-alcoholic fatty liver disease. Diabetes Metab J. 2022;46(3):391–401. DOI: 10.4093/dmj.2022.0048</mixed-citation></citation-alternatives></ref><ref id="cit141"><label>141</label><citation-alternatives><mixed-citation xml:lang="ru">Wong V.W., Wong G.L., Chan R.S., Shu S.S., Cheung B.H., Li L.S., et al. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. J Hepatol. 2018;69(6):1349–56. DOI: 10.1016/j.jhep.2018.08.011</mixed-citation><mixed-citation xml:lang="en">Wong V.W., Wong G.L., Chan R.S., Shu S.S., Cheung B.H., Li L.S., et al. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. J Hepatol. 2018;69(6):1349–56. DOI: 10.1016/j.jhep.2018.08.011</mixed-citation></citation-alternatives></ref><ref id="cit142"><label>142</label><citation-alternatives><mixed-citation xml:lang="ru">Long M.T., Noureddin M., Lim J.K. AGA clinical practice update: Diagnosis and management of nonalcoholic fatty liver disease in lean individuals: Expert review. Gastroenterology. 2022;163(3):764–74.e1. DOI: 10.1053/j.gastro.2022.06.023</mixed-citation><mixed-citation xml:lang="en">Long M.T., Noureddin M., Lim J.K. AGA clinical practice update: Diagnosis and management of nonalcoholic fatty liver disease in lean individuals: Expert review. Gastroenterology. 2022;163(3):764–74.e1. DOI: 10.1053/j.gastro.2022.06.023</mixed-citation></citation-alternatives></ref><ref id="cit143"><label>143</label><citation-alternatives><mixed-citation xml:lang="ru">Francque S.M., Marchesini G., Kautz A., Walmsley M., Dorner R., Lazarus J.V., et al. Non-alcoholic fatty liver disease: A patient guideline. JHEP Rep. 2021;3(5):100322. DOI: 10.1016/j.jhepr.2021.100322</mixed-citation><mixed-citation xml:lang="en">Francque S.M., Marchesini G., Kautz A., Walmsley M., Dorner R., Lazarus J.V., et al. Non-alcoholic fatty liver disease: A patient guideline. JHEP Rep. 2021;3(5):100322. DOI: 10.1016/j.jhepr.2021.100322</mixed-citation></citation-alternatives></ref><ref id="cit144"><label>144</label><citation-alternatives><mixed-citation xml:lang="ru">Jarvis H., O’Keefe H., Craig D., Stow D., Hanratty B., Anstee Q.M. Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis. BMJ Open. 2022;12(1):e049767. DOI: 10.1136/bmjopen-2021-049767</mixed-citation><mixed-citation xml:lang="en">Jarvis H., O’Keefe H., Craig D., Stow D., Hanratty B., Anstee Q.M. Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis. BMJ Open. 2022;12(1):e049767. DOI: 10.1136/bmjopen-2021-049767</mixed-citation></citation-alternatives></ref><ref id="cit145"><label>145</label><citation-alternatives><mixed-citation xml:lang="ru">Di Ciaula A., Bonfrate L., Krawczyk M., Frühbeck G., Portincasa P. Synergistic and detrimental effects of alcohol intake on progression of liver steatosis. Int J Mol Sci. 2022;23(5):2636. DOI: 10.3390/ijms23052636</mixed-citation><mixed-citation xml:lang="en">Di Ciaula A., Bonfrate L., Krawczyk M., Frühbeck G., Portincasa P. Synergistic and detrimental effects of alcohol intake on progression of liver steatosis. Int J Mol Sci. 2022;23(5):2636. DOI: 10.3390/ijms23052636</mixed-citation></citation-alternatives></ref><ref id="cit146"><label>146</label><citation-alternatives><mixed-citation xml:lang="ru">Long M.T., Massaro J.M., Hoffmann U., Benjamin E.J., Naimi T.S. Alcohol use is associated with hepatic steatosis among persons with presumed nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2020;18(8):1831–41.e5. DOI: 10.1016/j.cgh.2019.11.022</mixed-citation><mixed-citation xml:lang="en">Long M.T., Massaro J.M., Hoffmann U., Benjamin E.J., Naimi T.S. Alcohol use is associated with hepatic steatosis among persons with presumed nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2020;18(8):1831–41.e5. DOI: 10.1016/j.cgh.2019.11.022</mixed-citation></citation-alternatives></ref><ref id="cit147"><label>147</label><citation-alternatives><mixed-citation xml:lang="ru">El Hadi H., Di Vincenzo A., Vettor R., Rossato M. Cardio-metabolic disorders in non-alcoholic fatty liver disease. Int J Mol Sci. 2019;20(9):2215. DOI: 10.3390/ijms20092215</mixed-citation><mixed-citation xml:lang="en">El Hadi H., Di Vincenzo A., Vettor R., Rossato M. Cardio-metabolic disorders in non-alcoholic fatty liver disease. Int J Mol Sci. 2019;20(9):2215. DOI: 10.3390/ijms20092215</mixed-citation></citation-alternatives></ref><ref id="cit148"><label>148</label><citation-alternatives><mixed-citation xml:lang="ru">Lizardi-Cervera J., Aguilar-Zapata D. Nonalcoholic fatty liver disease and its association with cardiovascular disease. Ann Hepatol. 2009;8(Suppl. 1):S40–3. DOI: 10.1016/S1665-2681(19)31825-3</mixed-citation><mixed-citation xml:lang="en">Lizardi-Cervera J., Aguilar-Zapata D. Nonalcoholic fatty liver disease and its association with cardiovascular disease. Ann Hepatol. 2009;8(Suppl. 1):S40–3. DOI: 10.1016/S1665-2681(19)31825-3</mixed-citation></citation-alternatives></ref><ref id="cit149"><label>149</label><citation-alternatives><mixed-citation xml:lang="ru">Angulo P., Kleiner D.E., Dam-Larsen S., Adams L.A., Bjornsson E.S., Charatcharoenwitthaya P., et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389–97.e10. DOI: 10.1053/j.gastro.2015.04.043</mixed-citation><mixed-citation xml:lang="en">Angulo P., Kleiner D.E., Dam-Larsen S., Adams L.A., Bjornsson E.S., Charatcharoenwitthaya P., et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389–97.e10. DOI: 10.1053/j.gastro.2015.04.043</mixed-citation></citation-alternatives></ref><ref id="cit150"><label>150</label><citation-alternatives><mixed-citation xml:lang="ru">Kwo P.Y., Cohen S.M., Lim J.K. ACG clinical guideline: Evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017;112(1):18–35. DOI: 10.1038/ajg.2016.517</mixed-citation><mixed-citation xml:lang="en">Kwo P.Y., Cohen S.M., Lim J.K. ACG clinical guideline: Evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017;112(1):18–35. DOI: 10.1038/ajg.2016.517</mixed-citation></citation-alternatives></ref><ref id="cit151"><label>151</label><citation-alternatives><mixed-citation xml:lang="ru">Kim H.C., Nam C.M., Jee S.H., Han K.H., Oh D.K., Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: Prospective cohort study. BMJ. 2004;328(7446):983. DOI: 10.1136/bmj.38050.593634.63</mixed-citation><mixed-citation xml:lang="en">Kim H.C., Nam C.M., Jee S.H., Han K.H., Oh D.K., Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: Prospective cohort study. BMJ. 2004;328(7446):983. DOI: 10.1136/bmj.38050.593634.63</mixed-citation></citation-alternatives></ref><ref id="cit152"><label>152</label><citation-alternatives><mixed-citation xml:lang="ru">Lee T.H., Kim W.R., Benson J.T., Therneau T.M., Melton L.J. 3rd. Serum aminotransferase activity and mortality risk in a United States community. Hepatology. 2008;47(3):880–7. DOI: 10.1002/hep.22090</mixed-citation><mixed-citation xml:lang="en">Lee T.H., Kim W.R., Benson J.T., Therneau T.M., Melton L.J. 3rd. Serum aminotransferase activity and mortality risk in a United States community. Hepatology. 2008;47(3):880–7. DOI: 10.1002/hep.22090</mixed-citation></citation-alternatives></ref><ref id="cit153"><label>153</label><citation-alternatives><mixed-citation xml:lang="ru">Ruhl C.E., Everhart J.E. Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology. 2009;136(2):477–85.e11. DOI: 10.1053/j.gastro.2008.10.052</mixed-citation><mixed-citation xml:lang="en">Ruhl C.E., Everhart J.E. Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology. 2009;136(2):477–85.e11. DOI: 10.1053/j.gastro.2008.10.052</mixed-citation></citation-alternatives></ref><ref id="cit154"><label>154</label><citation-alternatives><mixed-citation xml:lang="ru">Ioannou G.N., Weiss N.S., Boyko E.J., Mozaffarian D., Lee S.P. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology. 2006;43(5):1145–51. DOI: 10.1002/hep.21171</mixed-citation><mixed-citation xml:lang="en">Ioannou G.N., Weiss N.S., Boyko E.J., Mozaffarian D., Lee S.P. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology. 2006;43(5):1145–51. DOI: 10.1002/hep.21171</mixed-citation></citation-alternatives></ref><ref id="cit155"><label>155</label><citation-alternatives><mixed-citation xml:lang="ru">Buzzetti E., Linden A., Best L.M., Madden A.M., Roberts D., Chase T.J.G., et al. Lifestyle modifications for nonalcohol-related fatty liver disease: A network meta-analysis. Cochrane Database Syst Rev. 2021;6(6):CD013156. DOI: 10.1002/14651858.CD013156.pub2</mixed-citation><mixed-citation xml:lang="en">Buzzetti E., Linden A., Best L.M., Madden A.M., Roberts D., Chase T.J.G., et al. Lifestyle modifications for nonalcohol-related fatty liver disease: A network meta-analysis. Cochrane Database Syst Rev. 2021;6(6):CD013156. DOI: 10.1002/14651858.CD013156.pub2</mixed-citation></citation-alternatives></ref><ref id="cit156"><label>156</label><citation-alternatives><mixed-citation xml:lang="ru">Komolafe O., Buzzetti E., Linden A., Best L.M., Madden A.M., Roberts D., et al. Nutritional supplementation for nonalcohol-related fatty liver disease: A network meta-analysis. Cochrane Database Syst Rev. 2021;7(7):CD013157. DOI: 10.1002/14651858.CD013157.pub2</mixed-citation><mixed-citation xml:lang="en">Komolafe O., Buzzetti E., Linden A., Best L.M., Madden A.M., Roberts D., et al. Nutritional supplementation for nonalcohol-related fatty liver disease: A network meta-analysis. Cochrane Database Syst Rev. 2021;7(7):CD013157. DOI: 10.1002/14651858.CD013157.pub2</mixed-citation></citation-alternatives></ref><ref id="cit157"><label>157</label><citation-alternatives><mixed-citation xml:lang="ru">Romero-Gómez M., Zelber-Sagi S., Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829–46. DOI: 10.1016/j.jhep.2017.05.016</mixed-citation><mixed-citation xml:lang="en">Romero-Gómez M., Zelber-Sagi S., Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829–46. DOI: 10.1016/j.jhep.2017.05.016</mixed-citation></citation-alternatives></ref><ref id="cit158"><label>158</label><citation-alternatives><mixed-citation xml:lang="ru">Peng L., Wang J., Li F. Weight reduction for non-alcoholic fatty liver disease. Cochrane Database Syst Rev. 2011;6:CD003619. DOI: 10.1002/14651858.CD003619.pub3</mixed-citation><mixed-citation xml:lang="en">Peng L., Wang J., Li F. Weight reduction for non-alcoholic fatty liver disease. Cochrane Database Syst Rev. 2011;6:CD003619. DOI: 10.1002/14651858.CD003619.pub3</mixed-citation></citation-alternatives></ref><ref id="cit159"><label>159</label><citation-alternatives><mixed-citation xml:lang="ru">Xiang Z., Chen Y.P., Ma K.F., Ye Y.F., Zheng L., Yang Y.D., et al. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: A systematic review. BMC Gastroenterol. 2013;13:140. DOI: 10.1186/1471-230X-13-140</mixed-citation><mixed-citation xml:lang="en">Xiang Z., Chen Y.P., Ma K.F., Ye Y.F., Zheng L., Yang Y.D., et al. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: A systematic review. BMC Gastroenterol. 2013;13:140. DOI: 10.1186/1471-230X-13-140</mixed-citation></citation-alternatives></ref><ref id="cit160"><label>160</label><citation-alternatives><mixed-citation xml:lang="ru">Simental-Mendía M., Sánchez-García A., Simental-Mendía L.E. Effect of ursodeoxycholic acid on liver markers: A systematic review and meta-analysis of randomized placebo-controlled clinical trials. Br J Clin Pharmacol. 2020;86(8):1476–88. DOI: 10.1111/bcp.14311</mixed-citation><mixed-citation xml:lang="en">Simental-Mendía M., Sánchez-García A., Simental-Mendía L.E. Effect of ursodeoxycholic acid on liver markers: A systematic review and meta-analysis of randomized placebo-controlled clinical trials. Br J Clin Pharmacol. 2020;86(8):1476–88. DOI: 10.1111/bcp.14311</mixed-citation></citation-alternatives></ref><ref id="cit161"><label>161</label><citation-alternatives><mixed-citation xml:lang="ru">Laurin J., Lindor K.D., Crippin J.S., Gossard A., Gores G.J., Ludwig J., et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study. Hepatology. 1996;23(6):1464–7. DOI: 10.1002/hep.510230624</mixed-citation><mixed-citation xml:lang="en">Laurin J., Lindor K.D., Crippin J.S., Gossard A., Gores G.J., Ludwig J., et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study. Hepatology. 1996;23(6):1464–7. DOI: 10.1002/hep.510230624</mixed-citation></citation-alternatives></ref><ref id="cit162"><label>162</label><citation-alternatives><mixed-citation xml:lang="ru">Ozel Coskun B.D., Yucesoy M., Gursoy S., Baskol M., Yurci A., Yagbasan A., et al. Effects of ursodeoxycholic acid therapy on carotid intima media thickness, apolipoprotein A1, apolipoprotein B, and apolipoprotein B/A1 ratio in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2015;27(2):142–9. DOI: 10.1097/MEG.0000000000000264</mixed-citation><mixed-citation xml:lang="en">Ozel Coskun B.D., Yucesoy M., Gursoy S., Baskol M., Yurci A., Yagbasan A., et al. Effects of ursodeoxycholic acid therapy on carotid intima media thickness, apolipoprotein A1, apolipoprotein B, and apolipoprotein B/A1 ratio in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2015;27(2):142–9. DOI: 10.1097/MEG.0000000000000264</mixed-citation></citation-alternatives></ref><ref id="cit163"><label>163</label><citation-alternatives><mixed-citation xml:lang="ru">Ratziu V., de Ledinghen V., Oberti F., Mathurin P., Wartelle-Bladou C., Renou C., et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol. 2011;54(5):1011–9. DOI: 10.1016/j.jhep.2010.08.030</mixed-citation><mixed-citation xml:lang="en">Ratziu V., de Ledinghen V., Oberti F., Mathurin P., Wartelle-Bladou C., Renou C., et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol. 2011;54(5):1011–9. DOI: 10.1016/j.jhep.2010.08.030</mixed-citation></citation-alternatives></ref><ref id="cit164"><label>164</label><citation-alternatives><mixed-citation xml:lang="ru">Павлов Ч.С., Варганова Д.Л., Семенистая М.Ч., Кузнецова Е.А., Усанова А.А., Свистунов А.А. Урсодезоксихолевая кислота: эффективность и безопасность в лечении неалкогольной жировой болезни печени (метаанализ). Вестник Российской академии медицинских наук. 2018;73(5):294–305. DOI: 10.15690/vramn975</mixed-citation><mixed-citation xml:lang="en">Pavlov Ch.S., Varganova D.L., Semenistaya M.Ch., Kuznetsova E.A., Usanova A.A., Svistunov A.A. Ursodeoxycholic acid: Efficacy and safety in the treatment of nonalcoholic fatty liver disease (meta-analysis). Annals of the Russian Academy of Medical Sciences. 2018;73(5):294–305. (In Russ.). DOI: 10.15690/vramn975</mixed-citation></citation-alternatives></ref><ref id="cit165"><label>165</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang W., Tang Y., Huang J., Hu H. Efficacy of ursodeoxycholic acid in nonalcoholic fatty liver disease: An updated meta-analysis of randomized controlled trials. Asia Pac J Clin Nutr. 2020;29(4):696–705. DOI: 10.6133/apjcn.202012_29(4).0004</mixed-citation><mixed-citation xml:lang="en">Zhang W., Tang Y., Huang J., Hu H. Efficacy of ursodeoxycholic acid in nonalcoholic fatty liver disease: An updated meta-analysis of randomized controlled trials. Asia Pac J Clin Nutr. 2020;29(4):696–705. DOI: 10.6133/apjcn.202012_29(4).0004</mixed-citation></citation-alternatives></ref><ref id="cit166"><label>166</label><citation-alternatives><mixed-citation xml:lang="ru">Lin X., Mai M., He T., Huang H., Zhang P., Xia E., et al. Efficiency of ursodeoxycholic acid for the treatment of nonalcoholic steatohepatitis: A systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2022;16(6):537–45. DOI: 10.1080/17474124.2022.2083605</mixed-citation><mixed-citation xml:lang="en">Lin X., Mai M., He T., Huang H., Zhang P., Xia E., et al. Efficiency of ursodeoxycholic acid for the treatment of nonalcoholic steatohepatitis: A systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2022;16(6):537–45. DOI: 10.1080/17474124.2022.2083605</mixed-citation></citation-alternatives></ref><ref id="cit167"><label>167</label><citation-alternatives><mixed-citation xml:lang="ru">Nadinskaia M., Maevskaya M., Ivashkin V., Kodzoeva K., Pirogova I., Chesnokov E., et al. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2021;27(10):959–75. DOI: 10.3748/wjg.v27.i10.959</mixed-citation><mixed-citation xml:lang="en">Nadinskaia M., Maevskaya M., Ivashkin V., Kodzoeva K., Pirogova I., Chesnokov E., et al. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2021;27(10):959–75. DOI: 10.3748/wjg.v27.i10.959</mixed-citation></citation-alternatives></ref><ref id="cit168"><label>168</label><citation-alternatives><mixed-citation xml:lang="ru">Byrnes K., Blessinger S., Bailey N.T., Scaife R., Liu G., Khambu B. Therapeutic regulation of autophagy in hepatic metabolism. Acta Pharm Sin B. 2022;12(1):33–49. DOI: 10.1016/j.apsb.2021.07.021</mixed-citation><mixed-citation xml:lang="en">Byrnes K., Blessinger S., Bailey N.T., Scaife R., Liu G., Khambu B. Therapeutic regulation of autophagy in hepatic metabolism. Acta Pharm Sin B. 2022;12(1):33–49. DOI: 10.1016/j.apsb.2021.07.021</mixed-citation></citation-alternatives></ref><ref id="cit169"><label>169</label><citation-alternatives><mixed-citation xml:lang="ru">Decuypere J.P., Parys J.B., Bultynck G. Regulation of the autophagic bcl-2/beclin 1 interaction. Cells. 2012;1(3):284–312. DOI: 10.3390/cells1030284</mixed-citation><mixed-citation xml:lang="en">Decuypere J.P., Parys J.B., Bultynck G. Regulation of the autophagic bcl-2/beclin 1 interaction. Cells. 2012;1(3):284–312. DOI: 10.3390/cells1030284</mixed-citation></citation-alternatives></ref><ref id="cit170"><label>170</label><citation-alternatives><mixed-citation xml:lang="ru">Carino A., Biagioli M., Marchianò S., Fiorucci C., Zampella A., Monti M.C., et al. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH. Biochim Biophys Acta Mol Cell Biol Lipids. 2019;1864(10):1422–37. DOI: 10.1016/j.bbalip.2019.07.006</mixed-citation><mixed-citation xml:lang="en">Carino A., Biagioli M., Marchianò S., Fiorucci C., Zampella A., Monti M.C., et al. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH. Biochim Biophys Acta Mol Cell Biol Lipids. 2019;1864(10):1422–37. DOI: 10.1016/j.bbalip.2019.07.006</mixed-citation></citation-alternatives></ref><ref id="cit171"><label>171</label><citation-alternatives><mixed-citation xml:lang="ru">Marchianò S., Biagioli M., Roselli R., Zampella A., Di Giorgio C., Bordoni M., et al. Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling. Biochim Biophys Acta Mol Cell Biol Lipids. 2022;1867(11):159218. DOI: 10.1016/j.bbalip.2022.159218</mixed-citation><mixed-citation xml:lang="en">Marchianò S., Biagioli M., Roselli R., Zampella A., Di Giorgio C., Bordoni M., et al. Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling. Biochim Biophys Acta Mol Cell Biol Lipids. 2022;1867(11):159218. DOI: 10.1016/j.bbalip.2022.159218</mixed-citation></citation-alternatives></ref><ref id="cit172"><label>172</label><citation-alternatives><mixed-citation xml:lang="ru">Karedath J., Javed H., Ahsan Talpur F., Lal B., Kumari A., Kivan H., et al. Effect of vitamin E on clinical outcomes in patients with non-alcoholic fatty liver disease: A meta-analysis. Cureus. 2022;14(12):e32764. DOI: 10.7759/cureus.32764</mixed-citation><mixed-citation xml:lang="en">Karedath J., Javed H., Ahsan Talpur F., Lal B., Kumari A., Kivan H., et al. Effect of vitamin E on clinical outcomes in patients with non-alcoholic fatty liver disease: A meta-analysis. Cureus. 2022;14(12):e32764. DOI: 10.7759/cureus.32764</mixed-citation></citation-alternatives></ref><ref id="cit173"><label>173</label><citation-alternatives><mixed-citation xml:lang="ru">Bril F., Biernacki D.M., Kalavalapalli S., Lomonaco R., Subbarayan S.K., Lai J., et al. Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: A randomized controlled trial. Diabetes Care. 2019;42(8):1481–8. DOI: 10.2337/dc19-0167</mixed-citation><mixed-citation xml:lang="en">Bril F., Biernacki D.M., Kalavalapalli S., Lomonaco R., Subbarayan S.K., Lai J., et al. Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: A randomized controlled trial. Diabetes Care. 2019;42(8):1481–8. DOI: 10.2337/dc19-0167</mixed-citation></citation-alternatives></ref><ref id="cit174"><label>174</label><citation-alternatives><mixed-citation xml:lang="ru">Xu R., Tao A., Zhang S., Deng Y., Chen G. Association between vitamin E and non-alcoholic steatohepatitis: A meta-analysis. Int J Clin Exp Med. 2015;8(3):3924–34.</mixed-citation><mixed-citation xml:lang="en">Xu R., Tao A., Zhang S., Deng Y., Chen G. Association between vitamin E and non-alcoholic steatohepatitis: A meta-analysis. Int J Clin Exp Med. 2015;8(3):3924–34.</mixed-citation></citation-alternatives></ref><ref id="cit175"><label>175</label><citation-alternatives><mixed-citation xml:lang="ru">Mazhar I.J., Yasir M., Sarfraz S., Shlaghya G., Narayana S.H., Mushtaq U., et al. Vitamin E and pioglitazone: A comprehensive systematic review of their efficacy in non-alcoholic fatty liver disease. Cureus. 2023;15(8):e43635. DOI: 10.7759/cureus.43635</mixed-citation><mixed-citation xml:lang="en">Mazhar I.J., Yasir M., Sarfraz S., Shlaghya G., Narayana S.H., Mushtaq U., et al. Vitamin E and pioglitazone: A comprehensive systematic review of their efficacy in non-alcoholic fatty liver disease. Cureus. 2023;15(8):e43635. DOI: 10.7759/cureus.43635</mixed-citation></citation-alternatives></ref><ref id="cit176"><label>176</label><citation-alternatives><mixed-citation xml:lang="ru">Vilar-Gomez E., Vuppalanchi R., Gawrieh S., Ghabril M., Saxena R., Cummings O.W., et al. Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis. Hepatology. 2020;71(2):495–509. DOI: 10.1002/hep.30368</mixed-citation><mixed-citation xml:lang="en">Vilar-Gomez E., Vuppalanchi R., Gawrieh S., Ghabril M., Saxena R., Cummings O.W., et al. Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis. Hepatology. 2020;71(2):495–509. DOI: 10.1002/hep.30368</mixed-citation></citation-alternatives></ref><ref id="cit177"><label>177</label><citation-alternatives><mixed-citation xml:lang="ru">European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–402. DOI: 10.1016/j.jhep.2015.11.004</mixed-citation><mixed-citation xml:lang="en">European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–402. DOI: 10.1016/j.jhep.2015.11.004</mixed-citation></citation-alternatives></ref><ref id="cit178"><label>178</label><citation-alternatives><mixed-citation xml:lang="ru">Chalasani N., Younossi Z., Lavine J.E., Charlton M., Cusi K., Rinella M., et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57. DOI: 10.1002/hep.29367</mixed-citation><mixed-citation xml:lang="en">Chalasani N., Younossi Z., Lavine J.E., Charlton M., Cusi K., Rinella M., et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57. DOI: 10.1002/hep.29367</mixed-citation></citation-alternatives></ref><ref id="cit179"><label>179</label><citation-alternatives><mixed-citation xml:lang="ru">Sanyal A.J., Chalasani N., Kowdley K.V., McCullough A., Diehl A.M., Bass N.M., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675–85. DOI: 10.1056/NEJMoa0907929</mixed-citation><mixed-citation xml:lang="en">Sanyal A.J., Chalasani N., Kowdley K.V., McCullough A., Diehl A.M., Bass N.M., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675–85. DOI: 10.1056/NEJMoa0907929</mixed-citation></citation-alternatives></ref><ref id="cit180"><label>180</label><citation-alternatives><mixed-citation xml:lang="ru">Ando Y., Jou J.H. Nonalcoholic fatty liver disease and recent guideline updates. Clin Liver Dis (Hoboken). 2021;17(1):23–8. DOI: 10.1002/cld.1045</mixed-citation><mixed-citation xml:lang="en">Ando Y., Jou J.H. Nonalcoholic fatty liver disease and recent guideline updates. Clin Liver Dis (Hoboken). 2021;17(1):23–8. DOI: 10.1002/cld.1045</mixed-citation></citation-alternatives></ref><ref id="cit181"><label>181</label><citation-alternatives><mixed-citation xml:lang="ru">Bjelakovic G., Nikolova D., Gluud C. Meta-regression analyses, meta-analyses, and trial sequential analyses of the effects of supplementation with beta-carotene, vitamin A, and vitamin E singly or in different combinations on all-cause mortality: Do we have evidence for lack of harm? PLoS One. 2013;8(9):e74558. DOI: 10.1371/journal.pone.0074558</mixed-citation><mixed-citation xml:lang="en">Bjelakovic G., Nikolova D., Gluud C. Meta-regression analyses, meta-analyses, and trial sequential analyses of the effects of supplementation with beta-carotene, vitamin A, and vitamin E singly or in different combinations on all-cause mortality: Do we have evidence for lack of harm? PLoS One. 2013;8(9):e74558. DOI: 10.1371/journal.pone.0074558</mixed-citation></citation-alternatives></ref><ref id="cit182"><label>182</label><citation-alternatives><mixed-citation xml:lang="ru">Miller E.R. 3rd, Pastor-Barriuso R., Dalal D., Riemersma R.A., Appel L.J., Guallar E. Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142(1):37–46. DOI: 10.7326/0003-4819-142-1-200501040-00110</mixed-citation><mixed-citation xml:lang="en">Miller E.R. 3rd, Pastor-Barriuso R., Dalal D., Riemersma R.A., Appel L.J., Guallar E. Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142(1):37–46. DOI: 10.7326/0003-4819-142-1-200501040-00110</mixed-citation></citation-alternatives></ref><ref id="cit183"><label>183</label><citation-alternatives><mixed-citation xml:lang="ru">Curtis A.J., Bullen M., Piccenna L., McNeil J.J. Vitamin E supplementation and mortality in healthy people: A meta-analysis of randomised controlled trials. Cardiovasc Drugs Ther. 2014;28(6):563–73. DOI: 10.1007/s10557-014-6560-7</mixed-citation><mixed-citation xml:lang="en">Curtis A.J., Bullen M., Piccenna L., McNeil J.J. Vitamin E supplementation and mortality in healthy people: A meta-analysis of randomised controlled trials. Cardiovasc Drugs Ther. 2014;28(6):563–73. DOI: 10.1007/s10557-014-6560-7</mixed-citation></citation-alternatives></ref><ref id="cit184"><label>184</label><citation-alternatives><mixed-citation xml:lang="ru">Vivarelli F., Canistro D., Cirillo S., Papi A., Spisni E., Vornoli A., et al. Co-carcinogenic effects of vitamin E in prostate. Sci Rep. 2019;9(1):11636. DOI: 10.1038/s41598-019-48213-1</mixed-citation><mixed-citation xml:lang="en">Vivarelli F., Canistro D., Cirillo S., Papi A., Spisni E., Vornoli A., et al. Co-carcinogenic effects of vitamin E in prostate. Sci Rep. 2019;9(1):11636. DOI: 10.1038/s41598-019-48213-1</mixed-citation></citation-alternatives></ref><ref id="cit185"><label>185</label><citation-alternatives><mixed-citation xml:lang="ru">Podszun M., Frank J. Vitamin E-drug interactions: Molecular basis and clinical relevance. Nutr Res Rev. 2014;27(2):215–31. DOI: 10.1017/S0954422414000146</mixed-citation><mixed-citation xml:lang="en">Podszun M., Frank J. Vitamin E-drug interactions: Molecular basis and clinical relevance. Nutr Res Rev. 2014;27(2):215–31. DOI: 10.1017/S0954422414000146</mixed-citation></citation-alternatives></ref><ref id="cit186"><label>186</label><citation-alternatives><mixed-citation xml:lang="ru">Noureddin M., Sander-Struckmeier S., Mato J.M. Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review. World J Hepatol. 2020;12(2):46–63. DOI: 10.4254/wjh.v12.i2.46</mixed-citation><mixed-citation xml:lang="en">Noureddin M., Sander-Struckmeier S., Mato J.M. Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review. World J Hepatol. 2020;12(2):46–63. DOI: 10.4254/wjh.v12.i2.46</mixed-citation></citation-alternatives></ref><ref id="cit187"><label>187</label><citation-alternatives><mixed-citation xml:lang="ru">Райхельсон К.Л., Кондрашина Э.А. Адеметионин в лечении повышенной утомляемости/слабости при заболеваниях печени: систематический обзор. Терапевтический архив. 2019;91(2):134–42. DOI: 10.26442/00403660.2019.02.000130</mixed-citation><mixed-citation xml:lang="en">Raikhelson K.L., Kondrashina E.A. Ademethionine in the treatment of fatigue in liver diseases: A systematic review. Terapevticheskii Arkhiv. 2019;91(2):134–42. (In Russ.). DOI: 10.26442/00403660.2019.02.000130</mixed-citation></citation-alternatives></ref><ref id="cit188"><label>188</label><citation-alternatives><mixed-citation xml:lang="ru">Барановский А.Ю., Райхельсон К.Л., Марченко Н.В. Применение S-аденозилметионина (Гептрала®) в терапии больных неалкогольным стеатогепатитом. Клинические перспективы гастроэнтерологии, гепатологии. 2010;9(1):3–10.</mixed-citation><mixed-citation xml:lang="en">Baranovsky A.Yu., Raykhelson K.L., Marchenko N.V. Application of S-adenosylmethionine (Heptral®) in treatment of patients with non-alcoholic steatohepatitis. Clinical Perspectives of Gastroenterology, Hepatology. 2010;9(1):3–10. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit189"><label>189</label><citation-alternatives><mixed-citation xml:lang="ru">Shankar R., Virukalpattigopalratnam M.P., Singh T. Heptral® (Ademetionine) in intrahepatic cholestasis due to chronic non-alcoholic liver disease: Subgroup analysis of results of a multicentre observational study in India. J Clin Exp Hepatol. 2014;4(Suppl. 2):S33. DOI: 10.1016/j.jceh.2014.02.071</mixed-citation><mixed-citation xml:lang="en">Shankar R., Virukalpattigopalratnam M.P., Singh T. Heptral® (Ademetionine) in intrahepatic cholestasis due to chronic non-alcoholic liver disease: Subgroup analysis of results of a multicentre observational study in India. J Clin Exp Hepatol. 2014;4(Suppl. 2):S33. DOI: 10.1016/j.jceh.2014.02.071</mixed-citation></citation-alternatives></ref><ref id="cit190"><label>190</label><citation-alternatives><mixed-citation xml:lang="ru">Li H., Liu N.N., Peng Z.G. Effect of bicyclol on blood biomarkers of NAFLD: A systematic review and meta-analysis. BMJ Open. 2020;10(12):e039700. DOI: 10.1136/bmjopen-2020-039700</mixed-citation><mixed-citation xml:lang="en">Li H., Liu N.N., Peng Z.G. Effect of bicyclol on blood biomarkers of NAFLD: A systematic review and meta-analysis. BMJ Open. 2020;10(12):e039700. DOI: 10.1136/bmjopen-2020-039700</mixed-citation></citation-alternatives></ref><ref id="cit191"><label>191</label><citation-alternatives><mixed-citation xml:lang="ru">Маевская М.В., Луньков В.Д., Гейвандова Н.И., Пальгова Л.К., Пирогова И.Ю., Прашнова М.К. и др. Бициклол в лечении пациентов с хроническими диффузными заболеваниями печени. Медицинский совет. 2020;(15):78–89. DOI: 10.21518/2079-701X-2020-15-78-89</mixed-citation><mixed-citation xml:lang="en">Maevskaya M.V., Lunkov V.D., Geyvandova N.I., Palgova L.K., Pirogova I.Yu., Prashnova M.K., et al. Bicyclol in the treatment of patients with chronic diffuse liver diseases. Medical Council. 2020;(15):78–89. (In Russ.). DOI: 10.21518/2079-701X-2020-15-78-89</mixed-citation></citation-alternatives></ref><ref id="cit192"><label>192</label><citation-alternatives><mixed-citation xml:lang="ru">Pan S.Y., Dong H., Yu Z.L., Zhao X.Y., Xiang C.J., Wang H., et al. Bicyclol, a synthetic dibenzocyclooctadiene derivative, decreases hepatic lipids but increases serum triglyceride level in normal and hypercholesterolaemic mice. J Pharm Pharmacol. 2007;59(12):1657–62. DOI: 10.1211/jpp.59.12.0007</mixed-citation><mixed-citation xml:lang="en">Pan S.Y., Dong H., Yu Z.L., Zhao X.Y., Xiang C.J., Wang H., et al. Bicyclol, a synthetic dibenzocyclooctadiene derivative, decreases hepatic lipids but increases serum triglyceride level in normal and hypercholesterolaemic mice. J Pharm Pharmacol. 2007;59(12):1657–62. DOI: 10.1211/jpp.59.12.0007</mixed-citation></citation-alternatives></ref><ref id="cit193"><label>193</label><citation-alternatives><mixed-citation xml:lang="ru">Pan S.Y., Yu Z.L., Dong H., Xiang C.J., Fong W.F., Ko K.M. Ethanol extract of fructus schisandrae decreases hepatic triglyceride level in mice fed with a high fat/cholesterol diet, with attention to acute toxicity. Evid Based Complement Alternat Med. 2011;2011:729412. DOI: 10.1093/ecam/nep070</mixed-citation><mixed-citation xml:lang="en">Pan S.Y., Yu Z.L., Dong H., Xiang C.J., Fong W.F., Ko K.M. Ethanol extract of fructus schisandrae decreases hepatic triglyceride level in mice fed with a high fat/cholesterol diet, with attention to acute toxicity. Evid Based Complement Alternat Med. 2011;2011:729412. DOI: 10.1093/ecam/nep070</mixed-citation></citation-alternatives></ref><ref id="cit194"><label>194</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao W., Yan Y., Xiao Z., Wang M., Xu M., Wang Z., et al. Bicyclol ameliorates nonalcoholic fatty liver disease in mice via inhibiting MAPKs and NF-κB signaling pathways. Biomed Pharmacother. 2021;141:111874. DOI: 10.1016/j.biopha.2021.111874</mixed-citation><mixed-citation xml:lang="en">Zhao W., Yan Y., Xiao Z., Wang M., Xu M., Wang Z., et al. Bicyclol ameliorates nonalcoholic fatty liver disease in mice via inhibiting MAPKs and NF-κB signaling pathways. Biomed Pharmacother. 2021;141:111874. DOI: 10.1016/j.biopha.2021.111874</mixed-citation></citation-alternatives></ref><ref id="cit195"><label>195</label><citation-alternatives><mixed-citation xml:lang="ru">Пирогова И.Ю., Яковлева С.В., Неуймина Т.В., Синицын С.П., Чулков В.С., Шамаева Т.Н. Эффективность и безопасность Бициклола при неалкогольной жировой болезни печени: результаты когортного исследования. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018;28(4):66–75. DOI: 10.22416/1382-4376-2018-28-4-66-75</mixed-citation><mixed-citation xml:lang="en">Pirogova I.Yu., Yakovleva S.V., Neuymina T.V., Sinitsyn S.P., Chulkov V.S., Shamaeva T.N. Efficacy and safety of bicyclol treatment for non-alcoholic fatty liver disease: Results of a cohort study. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(4):66–75. (In Russ.). DOI: 10.22416/1382-4376-2018-28-4-66-75</mixed-citation></citation-alternatives></ref><ref id="cit196"><label>196</label><citation-alternatives><mixed-citation xml:lang="ru">Оковитый С.В., Приходько В.А., Безбородкина Н.Н., Кудрявцев Б.Н. Гепатопротекторы: руководство для врачей. 2-е изд. М.: ГЭОТАР-Медиа; 2022. DOI: 10.33029/9704-6689-6-LIV-1-240</mixed-citation><mixed-citation xml:lang="en">Okovity S.V., Prikhodko V.A., Bezborodkina N.N., Kudryavtsev B.N. Hepatoprotectors: A guide for doctors. 2nd ed. Moscow: GEOTAR-Media Publ.; 2022. (In Russ.). DOI: 10.33029/9704-6689-6-LIV-1-240</mixed-citation></citation-alternatives></ref><ref id="cit197"><label>197</label><citation-alternatives><mixed-citation xml:lang="ru">Семисерин В.А., Каракозов А.Г., Малькута М.А., Золотарева Л.А., Левченко О.Б., Калягин И.Е. и др. Оценка эффективности гепатопротективной монотерапии неалкогольной жировой болезни печени в стадии стеатогепатита препаратом на основе янтарной кислоты и метионина. Терапевтический архив. 2016;88(2):58–63. DOI: 10.17116/terarkh201688258-63</mixed-citation><mixed-citation xml:lang="en">Semiserin V.A., Karakozov A.G., Malkuta M.A., Zolotareva L.A., Levchenko O.B., Kalyagin I.E., et al. Evaluation of the efficiency of hepatoprotective monotherapy using succinic acid and methionine for nonalcoholic fatty liver disease at the stage of steatohepatitis. Terapevticheskii Arkhiv. 2016;88(2):58–63. (In Russ.). DOI: 10.17116/terarkh201688258-63</mixed-citation></citation-alternatives></ref><ref id="cit198"><label>198</label><citation-alternatives><mixed-citation xml:lang="ru">Стельмах В.В., Козлов В.К., Баранов В.Л., Латария Э.Л., Некрасова А.С. Энерготропная патогенетически ориентированная терапия сукцинатсодержащими препаратами при неалкогольной жировой болезни печени: перспективы клинического применения. Медицинский алфавит. 2013;1(2):38–44.</mixed-citation><mixed-citation xml:lang="en">Stelmakh V.V., Kozlov V.K., Baranov V.L., Latariya E.L., Nekrasova A.S. Energy-tropic pathogenetically oriented therapy with succinate-containing drugs in non-alcoholic fatty liver disease: Prospects for clinical use. Medical Alphabet. 2013;1(2):38–44. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit199"><label>199</label><citation-alternatives><mixed-citation xml:lang="ru">Дударенко С.В., Коваленко А.Л., Прокопенко С.М., Белогурова Е.В. Применение ремаксола в терапии метаболического синдрома у пациентов с неалкогольным стеатогепатитом и сахарным диабетом 2 типа. Экспериментальная и клиническая гастроэнтерология. 2016;6:89–94.</mixed-citation><mixed-citation xml:lang="en">Dudorenko S.V., Kovalenko A.L., Prokopenko S.M., Belogurova E.V. The use of remaxol in the treatment of metabolic syndrome in patients with nonalcoholic steatohepatitis and diabetes mellitus 2 type. Experimental and Clinical Gastroenterology. 2016;6:89–94. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit200"><label>200</label><citation-alternatives><mixed-citation xml:lang="ru">Шиповская А.А., Дуданова О.П. Внутрипеченочный холестаз при неалкогольной жировой болезни печени. Терапевтический архив. 2018;90(2):69–74. DOI: 10.26442/terarkh201890269-74</mixed-citation><mixed-citation xml:lang="en">Shipovskaya A.A., Dudanova O.P. Intrahepatic cholestasis in nonalcoholic fatty liver disease. Terapevticheskii Arkhiv. 2018;90(2):69–74. (In Russ.). DOI: 10.26442/terarkh201890269-74</mixed-citation></citation-alternatives></ref><ref id="cit201"><label>201</label><citation-alternatives><mixed-citation xml:lang="ru">Pennisi G., Pipitone R.M., Grimaudo S., Spatola F., Di Martino V., Cammà C., et al. A cholestatic pattern predicts liver outcomes in patients with nonalcoholic fatty liver disease. Dig Liver Dis. 2021;53(Suppl. 1):S27. DOI: 10.1016/j.dld.2020.12.069</mixed-citation><mixed-citation xml:lang="en">Pennisi G., Pipitone R.M., Grimaudo S., Spatola F., Di Martino V., Cammà C., et al. A cholestatic pattern predicts liver outcomes in patients with nonalcoholic fatty liver disease. Dig Liver Dis. 2021;53(Suppl. 1):S27. DOI: 10.1016/j.dld.2020.12.069</mixed-citation></citation-alternatives></ref><ref id="cit202"><label>202</label><citation-alternatives><mixed-citation xml:lang="ru">Широкова Е.Н. Внутрипеченочный холестаз при неалкогольной жировой болезни печени: патогенез и роль адеметионина в терапии. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2023;33(2):79–86. DOI: 10.22416/1382-4376-2023-33-2-79-86</mixed-citation><mixed-citation xml:lang="en">Shirokova Ye.N. Intrahepatic cholestasis in non-alcoholic fatty liver disease: Pathogenesis and role of ademetionine in treatment. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2023;33(2):79–86. (In Russ.). DOI: 10.22416/1382-4376-2023-33-2-79-86</mixed-citation></citation-alternatives></ref><ref id="cit203"><label>203</label><citation-alternatives><mixed-citation xml:lang="ru">Anstee Q.M., Day C.P. S-adenosylmethionine (SAMe) therapy in liver disease: A review of current evidence and clinical utility. J Hepatol. 2012;57(5):1097–109. DOI: 10.1016/j.jhep.2012.04.041</mixed-citation><mixed-citation xml:lang="en">Anstee Q.M., Day C.P. S-adenosylmethionine (SAMe) therapy in liver disease: A review of current evidence and clinical utility. J Hepatol. 2012;57(5):1097–109. DOI: 10.1016/j.jhep.2012.04.041</mixed-citation></citation-alternatives></ref><ref id="cit204"><label>204</label><citation-alternatives><mixed-citation xml:lang="ru">Butterworth R.F., Kircheis G., Hilger N., McPhail M.J.W. Efficacy of l-ornithine l-aspartate for the treatment of hepatic encephalopathy and hyperammonemia in cirrhosis: Systematic review and meta-analysis of randomized controlled trials. J Clin Exp Hepatol. 2018;8(3):301–13. DOI: 10.1016/j.jceh.2018.05.004</mixed-citation><mixed-citation xml:lang="en">Butterworth R.F., Kircheis G., Hilger N., McPhail M.J.W. Efficacy of l-ornithine l-aspartate for the treatment of hepatic encephalopathy and hyperammonemia in cirrhosis: Systematic review and meta-analysis of randomized controlled trials. J Clin Exp Hepatol. 2018;8(3):301–13. DOI: 10.1016/j.jceh.2018.05.004</mixed-citation></citation-alternatives></ref><ref id="cit205"><label>205</label><citation-alternatives><mixed-citation xml:lang="ru">Ермолова Т.В., Ермолов С.Ю., Сологуб Т.В., Карев В.Е., Добкес А.Л., Апресян А.Г. Нарушения портопеченочной гемодинамики при хронических заболеваниях печени на начальных стадиях фиброза и их коррекция. Фарматека. 2016;(15):58–66.</mixed-citation><mixed-citation xml:lang="en">Ermolova T.V., Ermolov S.Yu., Sologub T.V., Karev V.E., Dobkes A.L., Apresyan A.G. Portohepatic hemodynamic disturbances in patients with chronic liver disease at the initial stages of fibrosis and their correction. Farmateka. 2016;(15):58–66. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit206"><label>206</label><citation-alternatives><mixed-citation xml:lang="ru">Зыкина Е.Ю., Симонова Ж.Г. Гипераммониемия у пациентов со стабильной стенокардией и неалкогольной жировой болезнью печени на стадии стеатоза. Экспериментальная и клиническая гастроэнтерология. 2023;8:57–65. DOI: 10.31146/1682-8658-ecg-216-8-57-65</mixed-citation><mixed-citation xml:lang="en">Zykina E.J., Simonova Zh.G. Hyperammonemia in patients with stable angina pectoris and nonalcoholic fatty liver disease at the steatosis stage. Experimental and Clinical Gastroenterology. 2023;8:57–65. (In Russ.). DOI: 10.31146/1682-8658-ecg-216-8-57-65</mixed-citation></citation-alternatives></ref><ref id="cit207"><label>207</label><citation-alternatives><mixed-citation xml:lang="ru">Гаранина Е.В. Влияние курсового приема L-орнитинL-аспартата на фиброз и стеатоз печени у больных ассоциированной с нарушениями метаболизма жировой болезнью печени (неалкогольной жировой болезнью печени), имеющих гипераммониемию. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(4):31–6. DOI: 10.22416/1382-4376-2021-31-4-31-36</mixed-citation><mixed-citation xml:lang="en">Garanina Е.V. Effect of L-ornithine-L-aspartate on liver fibrosis and steatosis in patients with metabolic-associated fatty liver disease (non-alcoholic fatty liver disease) and hyperammonaemia. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(4):31–6. (In Russ.). DOI: 10.22416/1382-4376-2021-31-4-31-36</mixed-citation></citation-alternatives></ref><ref id="cit208"><label>208</label><citation-alternatives><mixed-citation xml:lang="ru">Kaiser S., Gerok W., Häussinger D. Ammonia and glutamine metabolism in human liver slices: New aspects on the pathogenesis of hyperammonaemia in chronic liver disease. Eur J Clin Invest. 1988;18(5):535–42. DOI: 10.1111/j.1365-2362.1988.tb01053.x</mixed-citation><mixed-citation xml:lang="en">Kaiser S., Gerok W., Häussinger D. Ammonia and glutamine metabolism in human liver slices: New aspects on the pathogenesis of hyperammonaemia in chronic liver disease. Eur J Clin Invest. 1988;18(5):535–42. DOI: 10.1111/j.1365-2362.1988.tb01053.x</mixed-citation></citation-alternatives></ref><ref id="cit209"><label>209</label><citation-alternatives><mixed-citation xml:lang="ru">De Chiara F., Heebøll S., Marrone G., Montoliu C., Hamilton-Dutoit S., Ferrandez A., et al. Urea cycle dysregulation in non-alcoholic fatty liver disease. J Hepatol. 2018;69(4):905–15. DOI: 10.1016/j.jhep.2018.06.023</mixed-citation><mixed-citation xml:lang="en">De Chiara F., Heebøll S., Marrone G., Montoliu C., Hamilton-Dutoit S., Ferrandez A., et al. Urea cycle dysregulation in non-alcoholic fatty liver disease. J Hepatol. 2018;69(4):905–15. DOI: 10.1016/j.jhep.2018.06.023</mixed-citation></citation-alternatives></ref><ref id="cit210"><label>210</label><citation-alternatives><mixed-citation xml:lang="ru">Алексеенко С.А., Агеева Е.А., Полковникова О.П. Современные подходы к диагностике и лечению гипераммониемии у пациентов с хроническими заболеваниями печени на доцирротической стадии. РМЖ. Медицинское обозрение. 2018;2(7-1):19–23.</mixed-citation><mixed-citation xml:lang="en">Alekseenko S.A., Ageeva E.A., Polkovnikova О.P. Modern approaches to diagnostics and treatment of hyperammonemia in patients with chronic liver disease at a precirrhotic stage. RMJ. Medical Review. 2018;2(7-1):19–23. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit211"><label>211</label><citation-alternatives><mixed-citation xml:lang="ru">Tian L.Y., Lu L.G., Tang C.W., Xie Y., Luo H.S., Tan S.Y., et al. Aspartate-ornithine granules in the treatment of nonalcoholic steatohepatitis: A multiple-dose parallel controlled clinical trial. Zhonghua Gan Zang Bing Za Zhi. 2013;21(7):528–32. (In Chinese). DOI: 10.3760/cma.j.issn.1007-3418.2013.07.013</mixed-citation><mixed-citation xml:lang="en">Tian L.Y., Lu L.G., Tang C.W., Xie Y., Luo H.S., Tan S.Y., et al. Aspartate-ornithine granules in the treatment of nonalcoholic steatohepatitis: A multiple-dose parallel controlled clinical trial. Zhonghua Gan Zang Bing Za Zhi. 2013;21(7):528–32. (In Chinese). DOI: 10.3760/cma.j.issn.1007-3418.2013.07.013</mixed-citation></citation-alternatives></ref><ref id="cit212"><label>212</label><citation-alternatives><mixed-citation xml:lang="ru">Pichon C., Nachit M., Gillard J., Vande Velde G., Lanthier N., Leclercq I.A. Impact of L-ornithine L-aspartate on non-alcoholic steatohepatitis-associated hyperammonemia and muscle alterations. Front Nutr. 2022;9:1051157. DOI: 10.3389/fnut.2022.1051157</mixed-citation><mixed-citation xml:lang="en">Pichon C., Nachit M., Gillard J., Vande Velde G., Lanthier N., Leclercq I.A. Impact of L-ornithine L-aspartate on non-alcoholic steatohepatitis-associated hyperammonemia and muscle alterations. Front Nutr. 2022;9:1051157. DOI: 10.3389/fnut.2022.1051157</mixed-citation></citation-alternatives></ref><ref id="cit213"><label>213</label><citation-alternatives><mixed-citation xml:lang="ru">Приходько В.А., Сысоев Ю.И., Поверяева М.А., Бунят А.В., Карев В.Е., Ивкин Д.Ю. и др. Влияние эмпаглифлозина и L-орнитина L-аспартата на поведенческокогнитивные функции и физическую работоспособность при экспериментальном стеатогепатите. Вестник РГМУ. 2020;3:53–62. DOI: 10.24075/brsmu.2020.034</mixed-citation><mixed-citation xml:lang="en">Prikhodko V.A., Sysoev Yu.I., Poveryaeva M.A., Bunyat A.V., Karev V.E., Ivkin D.Yu., et al. Effects of empagliflozin and L-ornithine L-aspartate on behavior, cognitive functions, and physical performance in mice with experimentally induced steatohepatitis. Bulletin of Russian State Medical University. 2020;3:49–57. (In Russ.). DOI: 10.24075/brsmu.2020.034</mixed-citation></citation-alternatives></ref><ref id="cit214"><label>214</label><citation-alternatives><mixed-citation xml:lang="ru">Оковитый С.В., Райхельсон К.Л., Приходько В.А. Комбинированная гепатопротекторная фармакотерапия заболеваний печени. Экспериментальная и клиническая гастроэнтерология. 2022;7:5–20. DOI: 10.31146/1682-8658-ecg-203-7-5-20</mixed-citation><mixed-citation xml:lang="en">Okovityi S.V.,Raikhelson K.L., Prikhodko V.A. Combined hepatoprotective pharmacotherapy for liver disease. Experimental and Clinical Gastroenterology. 2022;7:5–20. (In Russ.). DOI: 10.31146/1682-8658-ecg-203-7-5-20</mixed-citation></citation-alternatives></ref><ref id="cit215"><label>215</label><citation-alternatives><mixed-citation xml:lang="ru">Dufour J.F., Oneta C.M., Gonvers J.J., Bihl F., Cerny A., Cereda J.M., et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2006;4(12):1537–43. DOI: 10.1016/j.cgh.2006.09.025</mixed-citation><mixed-citation xml:lang="en">Dufour J.F., Oneta C.M., Gonvers J.J., Bihl F., Cerny A., Cereda J.M., et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2006;4(12):1537–43. DOI: 10.1016/j.cgh.2006.09.025</mixed-citation></citation-alternatives></ref><ref id="cit216"><label>216</label><citation-alternatives><mixed-citation xml:lang="ru">Pietu F., Guillaud O., Walter T., Vallin M., Hervieu V., Scoazec J.Y., et al. Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: Long-term results. Clin Res Hepatol Gastroenterol. 2012;36(2):146–55. DOI: 10.1016/j.clinre.2011.10.011</mixed-citation><mixed-citation xml:lang="en">Pietu F., Guillaud O., Walter T., Vallin M., Hervieu V., Scoazec J.Y., et al. Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: Long-term results. Clin Res Hepatol Gastroenterol. 2012;36(2):146–55. DOI: 10.1016/j.clinre.2011.10.011</mixed-citation></citation-alternatives></ref><ref id="cit217"><label>217</label><citation-alternatives><mixed-citation xml:lang="ru">Balmer M.L., Siegrist K., Zimmermann A., Dufour J.F. Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. Liver Int. 2009;29(8):1184–8. DOI: 10.1111/j.1478-3231.2009.02037.x</mixed-citation><mixed-citation xml:lang="en">Balmer M.L., Siegrist K., Zimmermann A., Dufour J.F. Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. Liver Int. 2009;29(8):1184–8. DOI: 10.1111/j.1478-3231.2009.02037.x</mixed-citation></citation-alternatives></ref><ref id="cit218"><label>218</label><citation-alternatives><mixed-citation xml:lang="ru">Thomsen M.N., Skytte M.J., Samkani A., Carl M.H., Weber P., Astrup A., et al. Dietary carbohydrate restriction augments weight loss-induced improvements in glycaemic control and liver fat in individuals with type 2 diabetes: A randomised controlled trial. Diabetologia. 2022;65(3):506–17. DOI: 10.1007/s00125-021-05628-8</mixed-citation><mixed-citation xml:lang="en">Thomsen M.N., Skytte M.J., Samkani A., Carl M.H., Weber P., Astrup A., et al. Dietary carbohydrate restriction augments weight loss-induced improvements in glycaemic control and liver fat in individuals with type 2 diabetes: A randomised controlled trial. Diabetologia. 2022;65(3):506–17. DOI: 10.1007/s00125-021-05628-8</mixed-citation></citation-alternatives></ref><ref id="cit219"><label>219</label><citation-alternatives><mixed-citation xml:lang="ru">Vilar-Gomez E., Martinez-Perez Y., Calzadilla-Bertot L., Torres-Gonzalez A., Gra-Oramas B., Gonzalez-Fabian L., et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367–78.e5. DOI: 10.1053/j.gastro.2015.04.005</mixed-citation><mixed-citation xml:lang="en">Vilar-Gomez E., Martinez-Perez Y., Calzadilla-Bertot L., Torres-Gonzalez A., Gra-Oramas B., Gonzalez-Fabian L., et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367–78.e5. DOI: 10.1053/j.gastro.2015.04.005</mixed-citation></citation-alternatives></ref><ref id="cit220"><label>220</label><citation-alternatives><mixed-citation xml:lang="ru">Wong C., Lee M.H., Yaow C.Y.L., Chin Y.H., Goh X.L., Ng C.H., et al. Glucagon-like peptide-1 receptor agonists for non-alcoholic fatty liver disease in type 2 diabetes: A meta-analysis. Front Endocrinol (Lausanne). 2021;12:609110. DOI: 10.3389/fendo.2021.609110</mixed-citation><mixed-citation xml:lang="en">Wong C., Lee M.H., Yaow C.Y.L., Chin Y.H., Goh X.L., Ng C.H., et al. Glucagon-like peptide-1 receptor agonists for non-alcoholic fatty liver disease in type 2 diabetes: A meta-analysis. Front Endocrinol (Lausanne). 2021;12:609110. DOI: 10.3389/fendo.2021.609110</mixed-citation></citation-alternatives></ref><ref id="cit221"><label>221</label><citation-alternatives><mixed-citation xml:lang="ru">Fan S., Shi X., Yao J., Zhong M., Feng P. The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. Rev Esp Enferm Dig. 2020;112(8):627–35. DOI: 10.17235/reed.2020.6392/2019</mixed-citation><mixed-citation xml:lang="en">Fan S., Shi X., Yao J., Zhong M., Feng P. The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. Rev Esp Enferm Dig. 2020;112(8):627–35. DOI: 10.17235/reed.2020.6392/2019</mixed-citation></citation-alternatives></ref><ref id="cit222"><label>222</label><citation-alternatives><mixed-citation xml:lang="ru">Newsome P.N., Buchholtz K., Cusi K., Linder M., Okanoue T., Ratziu V., et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113–24. DOI: 10.1056/NEJMoa2028395</mixed-citation><mixed-citation xml:lang="en">Newsome P.N., Buchholtz K., Cusi K., Linder M., Okanoue T., Ratziu V., et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113–24. DOI: 10.1056/NEJMoa2028395</mixed-citation></citation-alternatives></ref><ref id="cit223"><label>223</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu K., Kakkar R., Chahal D., Yoshida E.M., Hussaini T. Efficacy and safety of semaglutide in non-alcoholic fatty liver disease. World J Gastroenterol. 2023;29(37):5327–38. DOI: 10.3748/wjg.v29.i37.5327</mixed-citation><mixed-citation xml:lang="en">Zhu K., Kakkar R., Chahal D., Yoshida E.M., Hussaini T. Efficacy and safety of semaglutide in non-alcoholic fatty liver disease. World J Gastroenterol. 2023;29(37):5327–38. DOI: 10.3748/wjg.v29.i37.5327</mixed-citation></citation-alternatives></ref><ref id="cit224"><label>224</label><citation-alternatives><mixed-citation xml:lang="ru">Bandyopadhyay S., Das S., Samajdar S.S., Joshi S.R. Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis. Diabetes Metab Syndr. 2023;17(10):102849. DOI: 10.1016/j.dsx.2023.102849</mixed-citation><mixed-citation xml:lang="en">Bandyopadhyay S., Das S., Samajdar S.S., Joshi S.R. Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis. Diabetes Metab Syndr. 2023;17(10):102849. DOI: 10.1016/j.dsx.2023.102849</mixed-citation></citation-alternatives></ref><ref id="cit225"><label>225</label><citation-alternatives><mixed-citation xml:lang="ru">Gu Y., Sun L., Zhang W., Kong T., Zhou R., He Y., et al. Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials. Front Pharmacol. 2023;14:1102792. DOI: 10.3389/fphar.2023.1102792</mixed-citation><mixed-citation xml:lang="en">Gu Y., Sun L., Zhang W., Kong T., Zhou R., He Y., et al. Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials. Front Pharmacol. 2023;14:1102792. DOI: 10.3389/fphar.2023.1102792</mixed-citation></citation-alternatives></ref><ref id="cit226"><label>226</label><citation-alternatives><mixed-citation xml:lang="ru">Parab P., Chaudhary P., Mukhtar S., Moradi A., Kodali A., Okoye C., et al. Role of glucagon-like peptide-1 (GLP-1) receptor agonists in cardiovascular risk management in patients with type 2 diabetes mellitus: A systematic review. Cureus. 2023;15(9):e45487. DOI: 10.7759/cureus.45487</mixed-citation><mixed-citation xml:lang="en">Parab P., Chaudhary P., Mukhtar S., Moradi A., Kodali A., Okoye C., et al. Role of glucagon-like peptide-1 (GLP-1) receptor agonists in cardiovascular risk management in patients with type 2 diabetes mellitus: A systematic review. Cureus. 2023;15(9):e45487. DOI: 10.7759/cureus.45487</mixed-citation></citation-alternatives></ref><ref id="cit227"><label>227</label><citation-alternatives><mixed-citation xml:lang="ru">Banerjee M., Pal R., Mukhopadhyay S., Nair K. GLP-1 receptor agonists and risk of adverse cerebrovascular outcomes in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2023;108(7):1806–12. DOI: 10.1210/clinem/dgad076</mixed-citation><mixed-citation xml:lang="en">Banerjee M., Pal R., Mukhopadhyay S., Nair K. GLP-1 receptor agonists and risk of adverse cerebrovascular outcomes in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2023;108(7):1806–12. DOI: 10.1210/clinem/dgad076</mixed-citation></citation-alternatives></ref><ref id="cit228"><label>228</label><citation-alternatives><mixed-citation xml:lang="ru">Gomes D.A., Presume J., de Araújo Gonçalves P., Almeida M.S., Mendes M., Ferreira J. Association between the magnitude of glycemic control and body weight loss with GLP-1 receptor agonists and risk of atherosclerotic cardiovascular disease: A systematic review and meta-analyses of randomized diabetes cardiovascular outcomes trials. Cardiovasc Drugs Ther. 2024. DOI: 10.1007/s10557-024-07547-3</mixed-citation><mixed-citation xml:lang="en">Gomes D.A., Presume J., de Araújo Gonçalves P., Almeida M.S., Mendes M., Ferreira J. Association between the magnitude of glycemic control and body weight loss with GLP-1 receptor agonists and risk of atherosclerotic cardiovascular disease: A systematic review and meta-analyses of randomized diabetes cardiovascular outcomes trials. Cardiovasc Drugs Ther. 2024. DOI: 10.1007/s10557-024-07547-3</mixed-citation></citation-alternatives></ref><ref id="cit229"><label>229</label><citation-alternatives><mixed-citation xml:lang="ru">Cusi K., Orsak B., Bril F., Lomonaco R., Hecht J., Ortiz-Lopez C., et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: A randomized trial. Ann Intern Med. 2016;165(5):305–15. DOI: 10.7326/M15-1774</mixed-citation><mixed-citation xml:lang="en">Cusi K., Orsak B., Bril F., Lomonaco R., Hecht J., Ortiz-Lopez C., et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: A randomized trial. Ann Intern Med. 2016;165(5):305–15. DOI: 10.7326/M15-1774</mixed-citation></citation-alternatives></ref><ref id="cit230"><label>230</label><citation-alternatives><mixed-citation xml:lang="ru">Musso G., Cassader M., Paschetta E., Gambino R. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: A meta-analysis. JAMA Intern Med. 2017;177(5):633–40. DOI: 10.1001/jamainternmed.2016.9607</mixed-citation><mixed-citation xml:lang="en">Musso G., Cassader M., Paschetta E., Gambino R. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: A meta-analysis. JAMA Intern Med. 2017;177(5):633–40. DOI: 10.1001/jamainternmed.2016.9607</mixed-citation></citation-alternatives></ref><ref id="cit231"><label>231</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao Y., Zhao W., Wang H., Zhao Y., Bu H., Takahashi H. Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs. Medicine (Baltimore). 2022;101(46):e31508. DOI: 10.1097/MD.0000000000031508</mixed-citation><mixed-citation xml:lang="en">Zhao Y., Zhao W., Wang H., Zhao Y., Bu H., Takahashi H. Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs. Medicine (Baltimore). 2022;101(46):e31508. DOI: 10.1097/MD.0000000000031508</mixed-citation></citation-alternatives></ref><ref id="cit232"><label>232</label><citation-alternatives><mixed-citation xml:lang="ru">Ndakotsu A., Vivekanandan G. The role of thiazolidinediones in the amelioration of nonalcoholic fatty liver disease: A systematic review. Cureus. 2022;14(5):e25380. DOI: 10.7759/cureus.25380</mixed-citation><mixed-citation xml:lang="en">Ndakotsu A., Vivekanandan G. The role of thiazolidinediones in the amelioration of nonalcoholic fatty liver disease: A systematic review. Cureus. 2022;14(5):e25380. DOI: 10.7759/cureus.25380</mixed-citation></citation-alternatives></ref><ref id="cit233"><label>233</label><citation-alternatives><mixed-citation xml:lang="ru">Budd J., Cusi K. Role of agents for the treatment of diabetes in the management of nonalcoholic fatty liver disease. Curr Diab Rep. 2020;20(11):59. DOI: 10.1007/s11892-020-01349-1</mixed-citation><mixed-citation xml:lang="en">Budd J., Cusi K. Role of agents for the treatment of diabetes in the management of nonalcoholic fatty liver disease. Curr Diab Rep. 2020;20(11):59. DOI: 10.1007/s11892-020-01349-1</mixed-citation></citation-alternatives></ref><ref id="cit234"><label>234</label><citation-alternatives><mixed-citation xml:lang="ru">Государственный реестр лекарственных средств. Пиоглар. Номер ЛС-001671, дата регистрации 16.07.2011. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=66ecaf50-2ba6-41a8-848f-de7e5b8c9220</mixed-citation><mixed-citation xml:lang="en">State Register of Medicines. Pioglar. Number LS001671, registration date 16.07.2011. (In Russ.). URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=66ecaf50-2ba6-41a8-848f-de7e5b8c9220</mixed-citation></citation-alternatives></ref><ref id="cit235"><label>235</label><citation-alternatives><mixed-citation xml:lang="ru">Gautam A., Agrawal P.K., Doneria J., Nigam A. Effects of canagliflozin on abnormal liver function tests in patients of type 2 diabetes with non-alcoholic fatty liver disease. J Assoc Physicians India. 2018;66(8):62–6.</mixed-citation><mixed-citation xml:lang="en">Gautam A., Agrawal P.K., Doneria J., Nigam A. Effects of canagliflozin on abnormal liver function tests in patients of type 2 diabetes with non-alcoholic fatty liver disease. J Assoc Physicians India. 2018;66(8):62–6.</mixed-citation></citation-alternatives></ref><ref id="cit236"><label>236</label><citation-alternatives><mixed-citation xml:lang="ru">Wei Q., Xu X., Guo L., Li J., Li L. Effect of SGLT2 inhibitors on type 2 diabetes mellitus with non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2021;12:635556. DOI: 10.3389/fendo.2021.635556</mixed-citation><mixed-citation xml:lang="en">Wei Q., Xu X., Guo L., Li J., Li L. Effect of SGLT2 inhibitors on type 2 diabetes mellitus with non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2021;12:635556. DOI: 10.3389/fendo.2021.635556</mixed-citation></citation-alternatives></ref><ref id="cit237"><label>237</label><citation-alternatives><mixed-citation xml:lang="ru">Приходько В.А., Оковитый С.В., Куликов А.Н. Глифлозины при неалкогольной жировой болезни печени: перспективы применения за границами диабета, кардио- и нефропротекции. Терапия. 2023;9(7):130–41. DOI: 10.18565/therapy.2023.7.130-141</mixed-citation><mixed-citation xml:lang="en">Prikhodko V.A., Okovity S.V., Kulikov A.N. Gliflozins in non-alcoholic fatty liver disease: Perspectives of use outside diabetes, cardiac and nephroprotection. Therapy. 2023;9(7):130–41. (In Russ.). DOI: 10.18565/therapy.2023.7.130-141</mixed-citation></citation-alternatives></ref><ref id="cit238"><label>238</label><citation-alternatives><mixed-citation xml:lang="ru">Mo M., Huang Z., Liang Y., Liao Y., Xia N. The safety and efficacy evaluation of sodium-glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty liver disease: An updated meta-analysis. Dig Liver Dis. 2022;54(4):461–8. DOI: 10.1016/j.dld.2021.08.017</mixed-citation><mixed-citation xml:lang="en">Mo M., Huang Z., Liang Y., Liao Y., Xia N. The safety and efficacy evaluation of sodium-glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty liver disease: An updated meta-analysis. Dig Liver Dis. 2022;54(4):461–8. DOI: 10.1016/j.dld.2021.08.017</mixed-citation></citation-alternatives></ref><ref id="cit239"><label>239</label><citation-alternatives><mixed-citation xml:lang="ru">Jin Z., Yuan Y., Zheng C., Liu S., Weng H. Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: An updated meta-analysis of randomized controlled trials. J Diabetes Complications. 2023;37(8):108558. DOI: 10.1016/j.jdiacomp.2023.108558</mixed-citation><mixed-citation xml:lang="en">Jin Z., Yuan Y., Zheng C., Liu S., Weng H. Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: An updated meta-analysis of randomized controlled trials. J Diabetes Complications. 2023;37(8):108558. DOI: 10.1016/j.jdiacomp.2023.108558</mixed-citation></citation-alternatives></ref><ref id="cit240"><label>240</label><citation-alternatives><mixed-citation xml:lang="ru">Ong Lopez A.M.C., Pajimna J.A.T. Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: An updated systematic review and meta-analysis. Sci Rep. 2024;14(1):2122. DOI: 10.1038/s41598-024-52603-5</mixed-citation><mixed-citation xml:lang="en">Ong Lopez A.M.C., Pajimna J.A.T. Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: An updated systematic review and meta-analysis. Sci Rep. 2024;14(1):2122. DOI: 10.1038/s41598-024-52603-5</mixed-citation></citation-alternatives></ref><ref id="cit241"><label>241</label><citation-alternatives><mixed-citation xml:lang="ru">Sánchez-García A., Sahebkar A., Simental-Mendía M., Simental-Mendía L.E. Effect of ursodeoxycholic acid on glycemic markers: A systematic review and meta-analysis of clinical trials. Pharmacol Res. 2018;135:144–9. DOI: 10.1016/j.phrs.2018.08.008</mixed-citation><mixed-citation xml:lang="en">Sánchez-García A., Sahebkar A., Simental-Mendía M., Simental-Mendía L.E. Effect of ursodeoxycholic acid on glycemic markers: A systematic review and meta-analysis of clinical trials. Pharmacol Res. 2018;135:144–9. DOI: 10.1016/j.phrs.2018.08.008</mixed-citation></citation-alternatives></ref><ref id="cit242"><label>242</label><citation-alternatives><mixed-citation xml:lang="ru">Elhini S.H., Wahsh E.A., Elberry A.A., El Ameen N.F., Abdelfadil Saedii A., Refaie S.M., et al. The impact of an SGLT2 inhibitor versus ursodeoxycholic acid on liver steatosis in diabetic patients. Pharmaceuticals (Basel). 2022;15(12):1516. DOI: 10.3390/ph15121516</mixed-citation><mixed-citation xml:lang="en">Elhini S.H., Wahsh E.A., Elberry A.A., El Ameen N.F., Abdelfadil Saedii A., Refaie S.M., et al. The impact of an SGLT2 inhibitor versus ursodeoxycholic acid on liver steatosis in diabetic patients. Pharmaceuticals (Basel). 2022;15(12):1516. DOI: 10.3390/ph15121516</mixed-citation></citation-alternatives></ref><ref id="cit243"><label>243</label><citation-alternatives><mixed-citation xml:lang="ru">Houttu V., Csader S., Nieuwdorp M., Holleboom A.G., Schwab U. Dietary interventions in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. Front Nutr. 2021;8:716783. DOI: 10.3389/fnut.2021.716783</mixed-citation><mixed-citation xml:lang="en">Houttu V., Csader S., Nieuwdorp M., Holleboom A.G., Schwab U. Dietary interventions in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. Front Nutr. 2021;8:716783. DOI: 10.3389/fnut.2021.716783</mixed-citation></citation-alternatives></ref><ref id="cit244"><label>244</label><citation-alternatives><mixed-citation xml:lang="ru">Koutoukidis D.A., Astbury N.M., Tudor K.E., Morris E., Henry J.A., Noreik M., et al. Association of weight loss interventions with changes in biomarkers of nonalcoholic fatty liver disease: A systematic review and meta-analysis. JAMA Intern Med. 2019;179(9):1262–71. DOI: 10.1001/jamainternmed.2019.2248</mixed-citation><mixed-citation xml:lang="en">Koutoukidis D.A., Astbury N.M., Tudor K.E., Morris E., Henry J.A., Noreik M., et al. Association of weight loss interventions with changes in biomarkers of nonalcoholic fatty liver disease: A systematic review and meta-analysis. JAMA Intern Med. 2019;179(9):1262–71. DOI: 10.1001/jamainternmed.2019.2248</mixed-citation></citation-alternatives></ref><ref id="cit245"><label>245</label><citation-alternatives><mixed-citation xml:lang="ru">Ezpeleta M., Gabel K., Cienfuegos S., Kalam F., Lin S., Pavlou V., et al. Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: A randomized controlled trial. Cell Metab. 2023;35(1):56–70.e3. DOI: 10.1016/j.cmet.2022.12.001</mixed-citation><mixed-citation xml:lang="en">Ezpeleta M., Gabel K., Cienfuegos S., Kalam F., Lin S., Pavlou V., et al. Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: A randomized controlled trial. Cell Metab. 2023;35(1):56–70.e3. DOI: 10.1016/j.cmet.2022.12.001</mixed-citation></citation-alternatives></ref><ref id="cit246"><label>246</label><citation-alternatives><mixed-citation xml:lang="ru">Haufe S., Engeli S., Kast P., Böhnke J., Utz W., Haas V., et al. Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology. 2011;53(5):1504–14. DOI: 10.1002/hep.24242</mixed-citation><mixed-citation xml:lang="en">Haufe S., Engeli S., Kast P., Böhnke J., Utz W., Haas V., et al. Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology. 2011;53(5):1504–14. DOI: 10.1002/hep.24242</mixed-citation></citation-alternatives></ref><ref id="cit247"><label>247</label><citation-alternatives><mixed-citation xml:lang="ru">Asrih M., Jornayvaz F.R. Diets and nonalcoholic fatty liver disease: The good and the bad. Clin Nutr. 2014;33(2):186–90. DOI: 10.1016/j.clnu.2013.11.003</mixed-citation><mixed-citation xml:lang="en">Asrih M., Jornayvaz F.R. Diets and nonalcoholic fatty liver disease: The good and the bad. Clin Nutr. 2014;33(2):186–90. DOI: 10.1016/j.clnu.2013.11.003</mixed-citation></citation-alternatives></ref><ref id="cit248"><label>248</label><citation-alternatives><mixed-citation xml:lang="ru">Lemstra M., Bird Y., Nwankwo C., Rogers M., Moraros J. Weight loss intervention adherence and factors promoting adherence: A meta-analysis. Patient Prefer Adherence. 2016;10:1547–59. DOI: 10.2147/PPA.S103649</mixed-citation><mixed-citation xml:lang="en">Lemstra M., Bird Y., Nwankwo C., Rogers M., Moraros J. Weight loss intervention adherence and factors promoting adherence: A meta-analysis. Patient Prefer Adherence. 2016;10:1547–59. DOI: 10.2147/PPA.S103649</mixed-citation></citation-alternatives></ref><ref id="cit249"><label>249</label><citation-alternatives><mixed-citation xml:lang="ru">Scragg J., Hallsworth K., Taylor G., Cassidy S., Haigh L., Boyle M., et al. Factors associated with engagement and adherence to a low-energy diet to promote 10 % weight loss in patients with clinically significant non-alcoholic fatty liver disease. BMJ Open Gastroenterol. 2021;8(1):e000678. DOI: 10.1136/bmjgast-2021-000678</mixed-citation><mixed-citation xml:lang="en">Scragg J., Hallsworth K., Taylor G., Cassidy S., Haigh L., Boyle M., et al. Factors associated with engagement and adherence to a low-energy diet to promote 10 % weight loss in patients with clinically significant non-alcoholic fatty liver disease. BMJ Open Gastroenterol. 2021;8(1):e000678. DOI: 10.1136/bmjgast-2021-000678</mixed-citation></citation-alternatives></ref><ref id="cit250"><label>250</label><citation-alternatives><mixed-citation xml:lang="ru">Armstrong M.J., Gaunt P., Aithal G.P., Barton D., Hull D., Parker R., et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679–90. DOI: 10.1016/S0140-6736(15)00803-X</mixed-citation><mixed-citation xml:lang="en">Armstrong M.J., Gaunt P., Aithal G.P., Barton D., Hull D., Parker R., et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679–90. DOI: 10.1016/S0140-6736(15)00803-X</mixed-citation></citation-alternatives></ref><ref id="cit251"><label>251</label><citation-alternatives><mixed-citation xml:lang="ru">Vilsbøll T., Christensen M., Junker A.E., Knop F.K., Gluud L.L. Effects of glucagon-like peptide-1 receptor agonists on weight loss: Systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771. DOI: 10.1136/bmj.d7771</mixed-citation><mixed-citation xml:lang="en">Vilsbøll T., Christensen M., Junker A.E., Knop F.K., Gluud L.L. Effects of glucagon-like peptide-1 receptor agonists on weight loss: Systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771. DOI: 10.1136/bmj.d7771</mixed-citation></citation-alternatives></ref><ref id="cit252"><label>252</label><citation-alternatives><mixed-citation xml:lang="ru">Stokes C.S., Gluud L.L., Casper M., Lammert F. Ursodeoxycholic acid and diets higher in fat prevent gallbladder stones during weight loss: A meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol. 2014;12(7):1090–100.e2. DOI: 10.1016/j.cgh.2013.11.031</mixed-citation><mixed-citation xml:lang="en">Stokes C.S., Gluud L.L., Casper M., Lammert F. Ursodeoxycholic acid and diets higher in fat prevent gallbladder stones during weight loss: A meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol. 2014;12(7):1090–100.e2. DOI: 10.1016/j.cgh.2013.11.031</mixed-citation></citation-alternatives></ref><ref id="cit253"><label>253</label><citation-alternatives><mixed-citation xml:lang="ru">Fearon N.M., Kearns E.C., Kennedy C.A., Conneely J.B., Heneghan H.M. The impact of ursodeoxycholic acid on gallstone disease after bariatric surgery: A meta-analysis of randomized control trials. Surg Obes Relat Dis. 2022;18(1):77–84. DOI: 10.1016/j.soard.2021.10.004</mixed-citation><mixed-citation xml:lang="en">Fearon N.M., Kearns E.C., Kennedy C.A., Conneely J.B., Heneghan H.M. The impact of ursodeoxycholic acid on gallstone disease after bariatric surgery: A meta-analysis of randomized control trials. Surg Obes Relat Dis. 2022;18(1):77–84. DOI: 10.1016/j.soard.2021.10.004</mixed-citation></citation-alternatives></ref><ref id="cit254"><label>254</label><citation-alternatives><mixed-citation xml:lang="ru">Mulliri A., Menahem B., Alves A., Dupont B. Ursodeoxycholic acid for the prevention of gallstones and subsequent cholecystectomy after bariatric surgery: A meta-analysis of randomized controlled trials. J Gastroenterol. 2022;57(8):529–39. DOI: 10.1007/s00535-022-01886-4</mixed-citation><mixed-citation xml:lang="en">Mulliri A., Menahem B., Alves A., Dupont B. Ursodeoxycholic acid for the prevention of gallstones and subsequent cholecystectomy after bariatric surgery: A meta-analysis of randomized controlled trials. J Gastroenterol. 2022;57(8):529–39. DOI: 10.1007/s00535-022-01886-4</mixed-citation></citation-alternatives></ref><ref id="cit255"><label>255</label><citation-alternatives><mixed-citation xml:lang="ru">Machado F.H.F., Castro Filho H.F., Babadopulos R.F.A.L., Rocha H.A.L., Rocha J.L.C., Moraes Filho M.O. Ursodeoxycholic acid in the prevention of gallstones in patients subjected to Roux-en-Y gastric bypass1. Acta Cir Bras. 2019;34(1):e20190010000009. DOI: 10.1590/s0102-865020190010000009</mixed-citation><mixed-citation xml:lang="en">Machado F.H.F., Castro Filho H.F., Babadopulos R.F.A.L., Rocha H.A.L., Rocha J.L.C., Moraes Filho M.O. Ursodeoxycholic acid in the prevention of gallstones in patients subjected to Roux-en-Y gastric bypass1. Acta Cir Bras. 2019;34(1):e20190010000009. DOI: 10.1590/s0102-865020190010000009</mixed-citation></citation-alternatives></ref><ref id="cit256"><label>256</label><citation-alternatives><mixed-citation xml:lang="ru">Johansson K., Sundström J., Marcus C., Hemmingsson E., Neovius M. Risk of symptomatic gallstones and cholecystectomy after a very-low-calorie diet or low-calorie diet in a commercial weight loss program: 1-year matched cohort study. Int J Obes (Lond). 2014;38(2):279–84. DOI: 10.1038/ijo.2013.83</mixed-citation><mixed-citation xml:lang="en">Johansson K., Sundström J., Marcus C., Hemmingsson E., Neovius M. Risk of symptomatic gallstones and cholecystectomy after a very-low-calorie diet or low-calorie diet in a commercial weight loss program: 1-year matched cohort study. Int J Obes (Lond). 2014;38(2):279–84. DOI: 10.1038/ijo.2013.83</mixed-citation></citation-alternatives></ref><ref id="cit257"><label>257</label><citation-alternatives><mixed-citation xml:lang="ru">European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol. 2016;65(1):146–81. DOI: 10.1016/j.jhep.2016.03.005</mixed-citation><mixed-citation xml:lang="en">European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol. 2016;65(1):146–81. DOI: 10.1016/j.jhep.2016.03.005</mixed-citation></citation-alternatives></ref><ref id="cit258"><label>258</label><citation-alternatives><mixed-citation xml:lang="ru">Uy M.C., Talingdan-Te M.C., Espinosa W.Z., Daez M.L., Ong J.P. Ursodeoxycholic acid in the prevention of gallstone formation after bariatric surgery: A meta-analysis. Obes Surg. 2008;18(12):1532–8. DOI: 10.1007/s11695-008-9587-7</mixed-citation><mixed-citation xml:lang="en">Uy M.C., Talingdan-Te M.C., Espinosa W.Z., Daez M.L., Ong J.P. Ursodeoxycholic acid in the prevention of gallstone formation after bariatric surgery: A meta-analysis. Obes Surg. 2008;18(12):1532–8. DOI: 10.1007/s11695-008-9587-7</mixed-citation></citation-alternatives></ref><ref id="cit259"><label>259</label><citation-alternatives><mixed-citation xml:lang="ru">Dongiovanni P., Petta S., Mannisto V., Mancina R.M., Pipitone R., Karja V., et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol. 2015;63(3):705–12. DOI: 10.1016/j.jhep.2015.05.006</mixed-citation><mixed-citation xml:lang="en">Dongiovanni P., Petta S., Mannisto V., Mancina R.M., Pipitone R., Karja V., et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol. 2015;63(3):705–12. DOI: 10.1016/j.jhep.2015.05.006</mixed-citation></citation-alternatives></ref><ref id="cit260"><label>260</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou H., Toshiyoshi M., Zhao W., Zhao Y., Zhao Y. Statins on nonalcoholic fatty liver disease: A systematic review and meta-analysis of 14 RCTs. Medicine (Baltimore). 2023;102(26):e33981. DOI: 10.1097/MD.0000000000033981</mixed-citation><mixed-citation xml:lang="en">Zhou H., Toshiyoshi M., Zhao W., Zhao Y., Zhao Y. Statins on nonalcoholic fatty liver disease: A systematic review and meta-analysis of 14 RCTs. Medicine (Baltimore). 2023;102(26):e33981. DOI: 10.1097/MD.0000000000033981</mixed-citation></citation-alternatives></ref><ref id="cit261"><label>261</label><citation-alternatives><mixed-citation xml:lang="ru">Pastori D., Sciacqua A., Marcucci R., Del Ben M., Baratta F., Violi F., et al. Non-alcoholic fatty liver disease (NAFLD), metabolic syndrome and cardiovascular events in atrial fibrillation. A prospective multicenter cohort study. Intern Emerg Med. 2021;16(8):2063–8. DOI: 10.1007/s11739-021-02682-3</mixed-citation><mixed-citation xml:lang="en">Pastori D., Sciacqua A., Marcucci R., Del Ben M., Baratta F., Violi F., et al. Non-alcoholic fatty liver disease (NAFLD), metabolic syndrome and cardiovascular events in atrial fibrillation. A prospective multicenter cohort study. Intern Emerg Med. 2021;16(8):2063–8. DOI: 10.1007/s11739-021-02682-3</mixed-citation></citation-alternatives></ref><ref id="cit262"><label>262</label><citation-alternatives><mixed-citation xml:lang="ru">Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L., et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88. DOI: 10.1093/eurheartj/ehz455</mixed-citation><mixed-citation xml:lang="en">Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L., et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88. DOI: 10.1093/eurheartj/ehz455</mixed-citation></citation-alternatives></ref><ref id="cit263"><label>263</label><citation-alternatives><mixed-citation xml:lang="ru">Pastori D., Pani A., Di Rocco A., Menichelli D., Gazzaniga G., Farcomeni A., et al. Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis. Br J Clin Pharmacol. 2022;88(2):441–51. DOI: 10.1111/bcp.14943</mixed-citation><mixed-citation xml:lang="en">Pastori D., Pani A., Di Rocco A., Menichelli D., Gazzaniga G., Farcomeni A., et al. Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis. Br J Clin Pharmacol. 2022;88(2):441–51. DOI: 10.1111/bcp.14943</mixed-citation></citation-alternatives></ref><ref id="cit264"><label>264</label><citation-alternatives><mixed-citation xml:lang="ru">Abdallah M., Brown L., Provenza J., Tariq R., Gowda S., Singal A.K. Safety and efficacy of dyslipidemia treatment in NAFLD patients: A meta-analysis of randomized controlled trials. Ann Hepatol. 2022;27(6):100738. DOI: 10.1016/j.aohep.2022.100738</mixed-citation><mixed-citation xml:lang="en">Abdallah M., Brown L., Provenza J., Tariq R., Gowda S., Singal A.K. Safety and efficacy of dyslipidemia treatment in NAFLD patients: A meta-analysis of randomized controlled trials. Ann Hepatol. 2022;27(6):100738. DOI: 10.1016/j.aohep.2022.100738</mixed-citation></citation-alternatives></ref><ref id="cit265"><label>265</label><citation-alternatives><mixed-citation xml:lang="ru">Athyros V.G., Boutari C., Stavropoulos K., Anagnostis P., Imprialos K.P., Doumas M., et al. Statins: An under-appreciated asset for the prevention and the treatment of NAFLD or NASH and the related cardiovascular risk. Curr Vasc Pharmacol. 2018;16(3):246–53. DOI: 10.2174/1570161115666170621082910</mixed-citation><mixed-citation xml:lang="en">Athyros V.G., Boutari C., Stavropoulos K., Anagnostis P., Imprialos K.P., Doumas M., et al. Statins: An under-appreciated asset for the prevention and the treatment of NAFLD or NASH and the related cardiovascular risk. Curr Vasc Pharmacol. 2018;16(3):246–53. DOI: 10.2174/1570161115666170621082910</mixed-citation></citation-alternatives></ref><ref id="cit266"><label>266</label><citation-alternatives><mixed-citation xml:lang="ru">Torres-Peña J.D., Martín-Piedra L., Fuentes-Jiménez F. Statins in non-alcoholic steatohepatitis. Front Cardiovasc Med. 2021;8:777131. DOI: 10.3389/fcvm.2021.777131</mixed-citation><mixed-citation xml:lang="en">Torres-Peña J.D., Martín-Piedra L., Fuentes-Jiménez F. Statins in non-alcoholic steatohepatitis. Front Cardiovasc Med. 2021;8:777131. DOI: 10.3389/fcvm.2021.777131</mixed-citation></citation-alternatives></ref><ref id="cit267"><label>267</label><citation-alternatives><mixed-citation xml:lang="ru">Aithal G.P., Watkins P.B., Andrade R.J., Larrey D., Molokhia M., Takikawa H., et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89(6):806–15. DOI: 10.1038/clpt.2011.58</mixed-citation><mixed-citation xml:lang="en">Aithal G.P., Watkins P.B., Andrade R.J., Larrey D., Molokhia M., Takikawa H., et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89(6):806–15. DOI: 10.1038/clpt.2011.58</mixed-citation></citation-alternatives></ref><ref id="cit268"><label>268</label><citation-alternatives><mixed-citation xml:lang="ru">Марцевич С.Ю., Кутишенко Н.П., Дроздова Л.Ю., Лерман О.В., Невзорова В.А., Резник И.И. и др. Исследование РАКУРС: повышение эффективности и безопасности терапии статинами у больных с заболеваниями печени, желчного пузыря и (или) желчевыводящих путей с помощью урсодеоксихолевой кислоты. Терапевтический архив. 2014;86(12):48–52. DOI: 10.17116/terarkh2014861248-52</mixed-citation><mixed-citation xml:lang="en">Martsevich S.Yu., Kutishenko N.P., Drozdova L.Yu., Lerman O.V., Nevzorova V.A., Reznik I.I., et al. Ursodeoxycholic acid-enhanced efficiency and safety of statin therapy in patients with liver, gallbladder, and/or biliary tract diseases: The RACURS study. Terapevticheskii Arkhiv. 2014;86(12):48–52. (In Russ.). DOI: 10.17116/terarkh2014861248-52</mixed-citation></citation-alternatives></ref><ref id="cit269"><label>269</label><citation-alternatives><mixed-citation xml:lang="ru">Nadinskaya M., Martsevich S., Kutishenko N., Balashov I., Lerman O. P0624 Ursodeoxycholic acid influence on efficacy and safety of statin therapy in patients with high risk of cardiovascular events and nonalcoholic fatty liver disease: The RACURS study (post-hoc analysis). United European Gastroenterol J. 2015;3(Suppl. 5):P0624. DOI: 10.1177/2050640615601623</mixed-citation><mixed-citation xml:lang="en">Nadinskaya M., Martsevich S., Kutishenko N., Balashov I., Lerman O. P0624 Ursodeoxycholic acid influence on efficacy and safety of statin therapy in patients with high risk of cardiovascular events and nonalcoholic fatty liver disease: The RACURS study (post-hoc analysis). United European Gastroenterol J. 2015;3(Suppl. 5):P0624. DOI: 10.1177/2050640615601623</mixed-citation></citation-alternatives></ref><ref id="cit270"><label>270</label><citation-alternatives><mixed-citation xml:lang="ru">Cabezas Gelabert R. Effect of ursodeoxycholic acid combined with statins in hypercholesterolemia treatment: A prospective clinical trial. Rev Clin Esp. 2004;204(12):632–5. (In Spanish). DOI: 10.1016/s0014-2565(04)71566-0</mixed-citation><mixed-citation xml:lang="en">Cabezas Gelabert R. Effect of ursodeoxycholic acid combined with statins in hypercholesterolemia treatment: A prospective clinical trial. Rev Clin Esp. 2004;204(12):632–5. (In Spanish). DOI: 10.1016/s0014-2565(04)71566-0</mixed-citation></citation-alternatives></ref><ref id="cit271"><label>271</label><citation-alternatives><mixed-citation xml:lang="ru">Seo S.H., Lee D.H., Lee Y.S., Cho K.J., Park H.J., Lee H.W., et al. Co-administration of ursodeoxycholic acid with rosuvastatin/ezetimibe in a non-alcoholic fatty liver disease model. Gastroenterol Rep (Oxf). 2022;10:goac037. DOI: 10.1093/gastro/goac037</mixed-citation><mixed-citation xml:lang="en">Seo S.H., Lee D.H., Lee Y.S., Cho K.J., Park H.J., Lee H.W., et al. Co-administration of ursodeoxycholic acid with rosuvastatin/ezetimibe in a non-alcoholic fatty liver disease model. Gastroenterol Rep (Oxf). 2022;10:goac037. DOI: 10.1093/gastro/goac037</mixed-citation></citation-alternatives></ref><ref id="cit272"><label>272</label><citation-alternatives><mixed-citation xml:lang="ru">Nakade Y., Murotani K., Inoue T., Kobayashi Y., Yamamoto T., Ishii N., et al. Ezetimibe for the treatment of non-alcoholic fatty liver disease: A meta-analysis. Hepatol Res. 2017;47(13):1417–28. DOI: 10.1111/hepr.12887</mixed-citation><mixed-citation xml:lang="en">Nakade Y., Murotani K., Inoue T., Kobayashi Y., Yamamoto T., Ishii N., et al. Ezetimibe for the treatment of non-alcoholic fatty liver disease: A meta-analysis. Hepatol Res. 2017;47(13):1417–28. DOI: 10.1111/hepr.12887</mixed-citation></citation-alternatives></ref><ref id="cit273"><label>273</label><citation-alternatives><mixed-citation xml:lang="ru">Lee H.Y., Jun D.W., Kim H.J., Oh H., Saeed W.K., Ahn H., et al. Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis. Korean J Intern Med. 2019;34(2):296–304. DOI: 10.3904/kjim.2017.194</mixed-citation><mixed-citation xml:lang="en">Lee H.Y., Jun D.W., Kim H.J., Oh H., Saeed W.K., Ahn H., et al. Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis. Korean J Intern Med. 2019;34(2):296–304. DOI: 10.3904/kjim.2017.194</mixed-citation></citation-alternatives></ref><ref id="cit274"><label>274</label><citation-alternatives><mixed-citation xml:lang="ru">Cho Y., Rhee H., Kim Y.E., Lee M., Lee B.W., Kang E.S., et al. Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: An open-label randomized controlled trial (ESSENTIAL study). BMC Med. 2022;20(1):93. DOI: 10.1186/s12916-022-02288-2</mixed-citation><mixed-citation xml:lang="en">Cho Y., Rhee H., Kim Y.E., Lee M., Lee B.W., Kang E.S., et al. Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: An open-label randomized controlled trial (ESSENTIAL study). BMC Med. 2022;20(1):93. DOI: 10.1186/s12916-022-02288-2</mixed-citation></citation-alternatives></ref><ref id="cit275"><label>275</label><citation-alternatives><mixed-citation xml:lang="ru">Scorletti E., Bhatia L., McCormick K.G., Clough G.F., Nash K., Hodson L., et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: Results from the Welcome* study. Hepatology. 2014;60(4):1211–21. DOI: 10.1002/hep.27289</mixed-citation><mixed-citation xml:lang="en">Scorletti E., Bhatia L., McCormick K.G., Clough G.F., Nash K., Hodson L., et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: Results from the Welcome* study. Hepatology. 2014;60(4):1211–21. DOI: 10.1002/hep.27289</mixed-citation></citation-alternatives></ref><ref id="cit276"><label>276</label><citation-alternatives><mixed-citation xml:lang="ru">Maciejewska-Markiewicz D., Stachowska E., Hawryłkowicz V., Stachowska L., Prowans P. The role of resolvins, protectins and marensins in non-alcoholic fatty liver disease (NAFLD). Biomolecules. 2021;11(7):937. DOI: 10.3390/biom11070937</mixed-citation><mixed-citation xml:lang="en">Maciejewska-Markiewicz D., Stachowska E., Hawryłkowicz V., Stachowska L., Prowans P. The role of resolvins, protectins and marensins in non-alcoholic fatty liver disease (NAFLD). Biomolecules. 2021;11(7):937. DOI: 10.3390/biom11070937</mixed-citation></citation-alternatives></ref><ref id="cit277"><label>277</label><citation-alternatives><mixed-citation xml:lang="ru">Bhatt D.L., Steg P.G., Miller M., Brinton E.A., Jacobson T.A., Ketchum S.B., et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22. DOI: 10.1056/NEJMoa1812792</mixed-citation><mixed-citation xml:lang="en">Bhatt D.L., Steg P.G., Miller M., Brinton E.A., Jacobson T.A., Ketchum S.B., et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22. DOI: 10.1056/NEJMoa1812792</mixed-citation></citation-alternatives></ref><ref id="cit278"><label>278</label><citation-alternatives><mixed-citation xml:lang="ru">Sanyal A.J., Abdelmalek M.F., Suzuki A., Cummings O.W., Chojkier M. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology. 2014;147(2):377–84.e1. DOI: 10.1053/j.gastro.2014.04.046</mixed-citation><mixed-citation xml:lang="en">Sanyal A.J., Abdelmalek M.F., Suzuki A., Cummings O.W., Chojkier M. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology. 2014;147(2):377–84.e1. DOI: 10.1053/j.gastro.2014.04.046</mixed-citation></citation-alternatives></ref><ref id="cit279"><label>279</label><citation-alternatives><mixed-citation xml:lang="ru">Lee C.H., Fu Y., Yang S.J., Chi C.C. Effects of omega-3 polyunsaturated fatty acid supplementation on non-alcoholic fatty liver: A systematic review and meta-analysis. Nutrients. 2020;12(9):2769. DOI: 10.3390/nu12092769</mixed-citation><mixed-citation xml:lang="en">Lee C.H., Fu Y., Yang S.J., Chi C.C. Effects of omega-3 polyunsaturated fatty acid supplementation on non-alcoholic fatty liver: A systematic review and meta-analysis. Nutrients. 2020;12(9):2769. DOI: 10.3390/nu12092769</mixed-citation></citation-alternatives></ref><ref id="cit280"><label>280</label><citation-alternatives><mixed-citation xml:lang="ru">Musazadeh V., Karimi A., Malekahmadi M., Ahrabi S.S., Dehghan P. Omega-3 polyunsaturated fatty acids in the treatment of non-alcoholic fatty liver disease: An umbrella systematic review and meta-analysis. Clin Exp Pharmacol Physiol. 2023;50(5):327–34. DOI: 10.1111/1440-1681.13750</mixed-citation><mixed-citation xml:lang="en">Musazadeh V., Karimi A., Malekahmadi M., Ahrabi S.S., Dehghan P. Omega-3 polyunsaturated fatty acids in the treatment of non-alcoholic fatty liver disease: An umbrella systematic review and meta-analysis. Clin Exp Pharmacol Physiol. 2023;50(5):327–34. DOI: 10.1111/1440-1681.13750</mixed-citation></citation-alternatives></ref><ref id="cit281"><label>281</label><citation-alternatives><mixed-citation xml:lang="ru">Yan J.H., Guan B.J., Gao H.Y., Peng X.E. Omega-3 polyunsaturated fatty acid supplementation and non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018;97(37):e12271. DOI: 10.1097/MD.0000000000012271</mixed-citation><mixed-citation xml:lang="en">Yan J.H., Guan B.J., Gao H.Y., Peng X.E. Omega-3 polyunsaturated fatty acid supplementation and non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018;97(37):e12271. DOI: 10.1097/MD.0000000000012271</mixed-citation></citation-alternatives></ref><ref id="cit282"><label>282</label><citation-alternatives><mixed-citation xml:lang="ru">Hilleman D.E., Wiggins B.S., Bottorff M.B. Critical differences between dietary supplement and prescription omega-3 fatty acids: A narrative review. Adv Ther. 2020;37(2):656–70. DOI: 10.1007/s12325-019-01211-1</mixed-citation><mixed-citation xml:lang="en">Hilleman D.E., Wiggins B.S., Bottorff M.B. Critical differences between dietary supplement and prescription omega-3 fatty acids: A narrative review. Adv Ther. 2020;37(2):656–70. DOI: 10.1007/s12325-019-01211-1</mixed-citation></citation-alternatives></ref><ref id="cit283"><label>283</label><citation-alternatives><mixed-citation xml:lang="ru">Fernández-Miranda C., Pérez-Carreras M., Colina F., López-Alonso G., Vargas C., Solís-Herruzo J.A. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis. 2008;40(3):200–5. DOI: 10.1016/j.dld.2007.10.002</mixed-citation><mixed-citation xml:lang="en">Fernández-Miranda C., Pérez-Carreras M., Colina F., López-Alonso G., Vargas C., Solís-Herruzo J.A. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis. 2008;40(3):200–5. DOI: 10.1016/j.dld.2007.10.002</mixed-citation></citation-alternatives></ref><ref id="cit284"><label>284</label><citation-alternatives><mixed-citation xml:lang="ru">Mahmoudi A., Moallem S.A., Johnston T.P., Sahebkar A. Liver protective effect of fenofibrate in NASH/NAFLD animal models. PPAR Res. 2022;2022:5805398. DOI: 10.1155/2022/5805398</mixed-citation><mixed-citation xml:lang="en">Mahmoudi A., Moallem S.A., Johnston T.P., Sahebkar A. Liver protective effect of fenofibrate in NASH/NAFLD animal models. PPAR Res. 2022;2022:5805398. DOI: 10.1155/2022/5805398</mixed-citation></citation-alternatives></ref><ref id="cit285"><label>285</label><citation-alternatives><mixed-citation xml:lang="ru">Lawitz E.J., Bhandari B.R., Ruane P.J., Kohli A., Harting E., Ding D., et al. Fenofibrate mitigates hypertriglyceridemia in nonalcoholic steatohepatitis patients treated with cilofexor/firsocostat. Clin Gastroenterol Hepatol. 2023;21(1):143–52.e3. DOI: 10.1016/j.cgh.2021.12.044</mixed-citation><mixed-citation xml:lang="en">Lawitz E.J., Bhandari B.R., Ruane P.J., Kohli A., Harting E., Ding D., et al. Fenofibrate mitigates hypertriglyceridemia in nonalcoholic steatohepatitis patients treated with cilofexor/firsocostat. Clin Gastroenterol Hepatol. 2023;21(1):143–52.e3. DOI: 10.1016/j.cgh.2021.12.044</mixed-citation></citation-alternatives></ref><ref id="cit286"><label>286</label><citation-alternatives><mixed-citation xml:lang="ru">Maev I.V., Samsonov A.A., Palgova L.K., Pavlov C.S., Shirokova E.N., Vovk E.I., et al. Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: Real-life observational study from Russia. BMJ Open Gastroenterol. 2020;7(1):e000368. DOI: 10.1136/bmjgast-2019-000368</mixed-citation><mixed-citation xml:lang="en">Maev I.V., Samsonov A.A., Palgova L.K., Pavlov C.S., Shirokova E.N., Vovk E.I., et al. Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: Real-life observational study from Russia. BMJ Open Gastroenterol. 2020;7(1):e000368. DOI: 10.1136/bmjgast-2019-000368</mixed-citation></citation-alternatives></ref><ref id="cit287"><label>287</label><citation-alternatives><mixed-citation xml:lang="ru">Dajani A.I, Popovic B. Essential phospholipids for nonalcoholic fatty liver disease associated with metabolic syndrome: A systematic review and network meta-analysis. World J Clin Cases. 2020;8(21):5235–49. DOI: 10.12998/wjcc.v8.i21.5235</mixed-citation><mixed-citation xml:lang="en">Dajani A.I, Popovic B. Essential phospholipids for nonalcoholic fatty liver disease associated with metabolic syndrome: A systematic review and network meta-analysis. World J Clin Cases. 2020;8(21):5235–49. DOI: 10.12998/wjcc.v8.i21.5235</mixed-citation></citation-alternatives></ref><ref id="cit288"><label>288</label><citation-alternatives><mixed-citation xml:lang="ru">Kuche K., Bhargavi N., Dora C.P., Jain S. Drug-phospholipid complex — a go through strategy for enhanced oral bioavailability. AAPS PharmSciTech. 2019;20(2):43. DOI: 10.1208/s12249-018-1252-4</mixed-citation><mixed-citation xml:lang="en">Kuche K., Bhargavi N., Dora C.P., Jain S. Drug-phospholipid complex — a go through strategy for enhanced oral bioavailability. AAPS PharmSciTech. 2019;20(2):43. DOI: 10.1208/s12249-018-1252-4</mixed-citation></citation-alternatives></ref><ref id="cit289"><label>289</label><citation-alternatives><mixed-citation xml:lang="ru">Оковитый С.В., Болотова В.Ц., Анисимова Н.А., Ивкин Д.Ю., Титович И.А., Сысоев Ю.И. и др. Перспективы применения растительных извлечений для коррекции нарушений жирового и углеводного обмена. Фармация. 2020;69(2):17–22. DOI: 10.29296/25419218-2020-02-03</mixed-citation><mixed-citation xml:lang="en">Okovityi S.V., Bolotova V.Ts., Anisimova N.A., Ivkin D.Yu., Titovich I.A., Sysoev Yu.I., et al. Prospects for using plant extracts to correct fat and carbohydrate metabolism disorders. Pharmacy. 2020;69(2):17–22. (In Russ.). DOI: 10.29296/25419218-2020-02-03</mixed-citation></citation-alternatives></ref><ref id="cit290"><label>290</label><citation-alternatives><mixed-citation xml:lang="ru">Dimakopoulou A., Sfikas G., Athyros V. PCSK9 administration ameliorates non alcoholic fatty disease in patients with heterozygous familial hyperlipidemia. Hell J Atheroscler. 2018;9(2):12. DOI: 10.23803/HJA.V9I2.175.G150</mixed-citation><mixed-citation xml:lang="en">Dimakopoulou A., Sfikas G., Athyros V. PCSK9 administration ameliorates non alcoholic fatty disease in patients with heterozygous familial hyperlipidemia. Hell J Atheroscler. 2018;9(2):12. DOI: 10.23803/HJA.V9I2.175.G150</mixed-citation></citation-alternatives></ref><ref id="cit291"><label>291</label><citation-alternatives><mixed-citation xml:lang="ru">Rimbert A., Smati S., Dijk W., Le May C., Cariou B. Genetic inhibition of PCSK9 and liver function. JAMA Cardiol. 2021;6(3):353–4. DOI: 10.1001/jamacardio.2020.5341</mixed-citation><mixed-citation xml:lang="en">Rimbert A., Smati S., Dijk W., Le May C., Cariou B. Genetic inhibition of PCSK9 and liver function. JAMA Cardiol. 2021;6(3):353–4. DOI: 10.1001/jamacardio.2020.5341</mixed-citation></citation-alternatives></ref><ref id="cit292"><label>292</label><citation-alternatives><mixed-citation xml:lang="ru">Jang H.R., Kang D., Sinn D.H., Gu S., Cho S.J., Lee J.E., et al. Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: A cohort study. Sci Rep. 2018;8(1):4718. DOI: 10.1038/s41598-018-23014-0</mixed-citation><mixed-citation xml:lang="en">Jang H.R., Kang D., Sinn D.H., Gu S., Cho S.J., Lee J.E., et al. Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: A cohort study. Sci Rep. 2018;8(1):4718. DOI: 10.1038/s41598-018-23014-0</mixed-citation></citation-alternatives></ref><ref id="cit293"><label>293</label><citation-alternatives><mixed-citation xml:lang="ru">Musso G., Gambino R., Tabibian J.H., Ekstedt M., Kechagias S., Hamaguchi M., et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: A systematic review and meta-analysis. PLoS Med. 2014;11(7):e1001680. DOI: 10.1371/journal.pmed.1001680</mixed-citation><mixed-citation xml:lang="en">Musso G., Gambino R., Tabibian J.H., Ekstedt M., Kechagias S., Hamaguchi M., et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: A systematic review and meta-analysis. PLoS Med. 2014;11(7):e1001680. DOI: 10.1371/journal.pmed.1001680</mixed-citation></citation-alternatives></ref><ref id="cit294"><label>294</label><citation-alternatives><mixed-citation xml:lang="ru">Targher G., Chonchol M., Bertolini L., Rodella S., Zenari L., Lippi G., et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol. 2008;19(8):1564–70. DOI: 10.1681/ASN.2007101155</mixed-citation><mixed-citation xml:lang="en">Targher G., Chonchol M., Bertolini L., Rodella S., Zenari L., Lippi G., et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol. 2008;19(8):1564–70. DOI: 10.1681/ASN.2007101155</mixed-citation></citation-alternatives></ref><ref id="cit295"><label>295</label><citation-alternatives><mixed-citation xml:lang="ru">Heda R., Yazawa M., Shi M., Bhaskaran M., Aloor F.Z., Thuluvath P.J., et al. Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect. World J Gastroenterol. 2021;27(17):1864–82. DOI: 10.3748/wjg.v27.i17.1864</mixed-citation><mixed-citation xml:lang="en">Heda R., Yazawa M., Shi M., Bhaskaran M., Aloor F.Z., Thuluvath P.J., et al. Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect. World J Gastroenterol. 2021;27(17):1864–82. DOI: 10.3748/wjg.v27.i17.1864</mixed-citation></citation-alternatives></ref><ref id="cit296"><label>296</label><citation-alternatives><mixed-citation xml:lang="ru">Monteillet L., Gjorgjieva M., Silva M., Verzieux V., Imikirene L., Duchampt A., et al. Intracellular lipids are an independent cause of liver injury and chronic kidney disease in non alcoholic fatty liver disease-like context. Mol Metab. 2018;16:100–15. DOI: 10.1016/j.molmet.2018.07.006</mixed-citation><mixed-citation xml:lang="en">Monteillet L., Gjorgjieva M., Silva M., Verzieux V., Imikirene L., Duchampt A., et al. Intracellular lipids are an independent cause of liver injury and chronic kidney disease in non alcoholic fatty liver disease-like context. Mol Metab. 2018;16:100–15. DOI: 10.1016/j.molmet.2018.07.006</mixed-citation></citation-alternatives></ref><ref id="cit297"><label>297</label><citation-alternatives><mixed-citation xml:lang="ru">Shimano H., Sato R. SREBP-regulated lipid metabolism: Convergent physiology — divergent pathophysiology. Nat Rev Endocrinol. 2017;13(12):710–30. DOI: 10.1038/nrendo.2017.91</mixed-citation><mixed-citation xml:lang="en">Shimano H., Sato R. SREBP-regulated lipid metabolism: Convergent physiology — divergent pathophysiology. Nat Rev Endocrinol. 2017;13(12):710–30. DOI: 10.1038/nrendo.2017.91</mixed-citation></citation-alternatives></ref><ref id="cit298"><label>298</label><citation-alternatives><mixed-citation xml:lang="ru">Marcuccilli M., Chonchol M. NAFLD and chronic kidney disease. Int J Mol Sci. 2016;17(4):562. DOI: 10.3390/ijms17040562</mixed-citation><mixed-citation xml:lang="en">Marcuccilli M., Chonchol M. NAFLD and chronic kidney disease. Int J Mol Sci. 2016;17(4):562. DOI: 10.3390/ijms17040562</mixed-citation></citation-alternatives></ref><ref id="cit299"><label>299</label><citation-alternatives><mixed-citation xml:lang="ru">Kwon S.Y., Park J., Park S.H., Lee Y.B., Kim G., Hur K.Y., et al. MAFLD and NAFLD in the prediction of incident chronic kidney disease. Sci Rep. 2023;13(1):1796. DOI: 10.1038/s41598-023-27762-6</mixed-citation><mixed-citation xml:lang="en">Kwon S.Y., Park J., Park S.H., Lee Y.B., Kim G., Hur K.Y., et al. MAFLD and NAFLD in the prediction of incident chronic kidney disease. Sci Rep. 2023;13(1):1796. DOI: 10.1038/s41598-023-27762-6</mixed-citation></citation-alternatives></ref><ref id="cit300"><label>300</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang X., Wong G.L., Yip T.C., Tse Y.K., Liang L.Y., Hui V.W., et al. Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease. Hepatology. 2022;76(2):469–82. DOI: 10.1002/hep.32294</mixed-citation><mixed-citation xml:lang="en">Zhang X., Wong G.L., Yip T.C., Tse Y.K., Liang L.Y., Hui V.W., et al. Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease. Hepatology. 2022;76(2):469–82. DOI: 10.1002/hep.32294</mixed-citation></citation-alternatives></ref><ref id="cit301"><label>301</label><citation-alternatives><mixed-citation xml:lang="ru">Hirata T., Tomita K., Kawai T., Yokoyama H., Shimada A., Kikuchi M., et al. Effect of telmisartan or losartan for treatment of nonalcoholic fatty liver disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY). Int J Endocrinol. 2013:587140. DOI: 10.1155/2013/587140</mixed-citation><mixed-citation xml:lang="en">Hirata T., Tomita K., Kawai T., Yokoyama H., Shimada A., Kikuchi M., et al. Effect of telmisartan or losartan for treatment of nonalcoholic fatty liver disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY). Int J Endocrinol. 2013:587140. DOI: 10.1155/2013/587140</mixed-citation></citation-alternatives></ref><ref id="cit302"><label>302</label><citation-alternatives><mixed-citation xml:lang="ru">Georgescu E.F., Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis. 2007;16(1):39–46.</mixed-citation><mixed-citation xml:lang="en">Georgescu E.F., Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis. 2007;16(1):39–46.</mixed-citation></citation-alternatives></ref><ref id="cit303"><label>303</label><citation-alternatives><mixed-citation xml:lang="ru">Georgescu E.F., Ionescu R., Niculescu M., Mogoanta L., Vancica L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol. 2009;15(8):942–54. DOI: 10.3748/wjg.15.942</mixed-citation><mixed-citation xml:lang="en">Georgescu E.F., Ionescu R., Niculescu M., Mogoanta L., Vancica L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol. 2009;15(8):942–54. DOI: 10.3748/wjg.15.942</mixed-citation></citation-alternatives></ref><ref id="cit304"><label>304</label><citation-alternatives><mixed-citation xml:lang="ru">Yokohama S., Yoneda M., Haneda M., Okamoto S., Okada M., Aso K., et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology. 2004;40(5):1222–5. DOI: 10.1002/hep.20420</mixed-citation><mixed-citation xml:lang="en">Yokohama S., Yoneda M., Haneda M., Okamoto S., Okada M., Aso K., et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology. 2004;40(5):1222–5. DOI: 10.1002/hep.20420</mixed-citation></citation-alternatives></ref><ref id="cit305"><label>305</label><citation-alternatives><mixed-citation xml:lang="ru">Osterreicher C.H., Taura K., De Minicis S., Seki E., Penz-Osterreicher M., Kodama Y., et al. Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice. Hepatology. 2009;50(3):929–38. DOI: 10.1002/hep.23104</mixed-citation><mixed-citation xml:lang="en">Osterreicher C.H., Taura K., De Minicis S., Seki E., Penz-Osterreicher M., Kodama Y., et al. Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice. Hepatology. 2009;50(3):929–38. DOI: 10.1002/hep.23104</mixed-citation></citation-alternatives></ref><ref id="cit306"><label>306</label><citation-alternatives><mixed-citation xml:lang="ru">Ala M. SGLT2 inhibition for cardiovascular diseases, chronic kidney disease, and NAFLD. Endocrinology. 2021;162(12):bqab157. DOI: 10.1210/endocr/bqab157</mixed-citation><mixed-citation xml:lang="en">Ala M. SGLT2 inhibition for cardiovascular diseases, chronic kidney disease, and NAFLD. Endocrinology. 2021;162(12):bqab157. DOI: 10.1210/endocr/bqab157</mixed-citation></citation-alternatives></ref><ref id="cit307"><label>307</label><citation-alternatives><mixed-citation xml:lang="ru">Toyama T., Neuen B.L., Jun M., Ohkuma T., Neal B., Jardine M.J., et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. Diabetes Obes Metab. 2019;21(5):1237–50. DOI: 10.1111/dom.13648</mixed-citation><mixed-citation xml:lang="en">Toyama T., Neuen B.L., Jun M., Ohkuma T., Neal B., Jardine M.J., et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. Diabetes Obes Metab. 2019;21(5):1237–50. DOI: 10.1111/dom.13648</mixed-citation></citation-alternatives></ref><ref id="cit308"><label>308</label><citation-alternatives><mixed-citation xml:lang="ru">Sarafidis P., Ferro C.J., Morales E., Ortiz A., Malyszko J., Hojs R., et al. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrol Dial Transplant. 2019;34(2):208–30. DOI: 10.1093/ndt/gfy407</mixed-citation><mixed-citation xml:lang="en">Sarafidis P., Ferro C.J., Morales E., Ortiz A., Malyszko J., Hojs R., et al. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrol Dial Transplant. 2019;34(2):208–30. DOI: 10.1093/ndt/gfy407</mixed-citation></citation-alternatives></ref><ref id="cit309"><label>309</label><citation-alternatives><mixed-citation xml:lang="ru">Musso G., Cassader M., Cohney S., De Michieli F., Pinach S., Saba F., et al. Fatty liver and chronic kidney disease: Novel mechanistic insights and therapeutic opportunities. Diabetes Care. 2016;39(10):1830–45. DOI: 10.2337/dc15-1182</mixed-citation><mixed-citation xml:lang="en">Musso G., Cassader M., Cohney S., De Michieli F., Pinach S., Saba F., et al. Fatty liver and chronic kidney disease: Novel mechanistic insights and therapeutic opportunities. Diabetes Care. 2016;39(10):1830–45. DOI: 10.2337/dc15-1182</mixed-citation></citation-alternatives></ref><ref id="cit310"><label>310</label><citation-alternatives><mixed-citation xml:lang="ru">Heerspink H.J.L., Stefánsson B.V., Correa-Rotter R., Chertow G.M., Greene T., Hou F.F., et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46. DOI: 10.1056/NEJMoa2024816</mixed-citation><mixed-citation xml:lang="en">Heerspink H.J.L., Stefánsson B.V., Correa-Rotter R., Chertow G.M., Greene T., Hou F.F., et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46. DOI: 10.1056/NEJMoa2024816</mixed-citation></citation-alternatives></ref><ref id="cit311"><label>311</label><citation-alternatives><mixed-citation xml:lang="ru">Herrington W.G., Staplin N., Wanner C., Green J.B., Hauske S.J., Emberson J.R., et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117–27. DOI: 10.1056/NEJMoa2204233</mixed-citation><mixed-citation xml:lang="en">Herrington W.G., Staplin N., Wanner C., Green J.B., Hauske S.J., Emberson J.R., et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117–27. DOI: 10.1056/NEJMoa2204233</mixed-citation></citation-alternatives></ref><ref id="cit312"><label>312</label><citation-alternatives><mixed-citation xml:lang="ru">Palmer S.C., Tendal B., Mustafa R.A., Vandvik P.O., Li S., Hao Q., et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: Systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372:m4573. DOI: 10.1136/bmj.m4573</mixed-citation><mixed-citation xml:lang="en">Palmer S.C., Tendal B., Mustafa R.A., Vandvik P.O., Li S., Hao Q., et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: Systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372:m4573. DOI: 10.1136/bmj.m4573</mixed-citation></citation-alternatives></ref><ref id="cit313"><label>313</label><citation-alternatives><mixed-citation xml:lang="ru">Greco E.V., Russo G., Giandalia A., Viazzi F., Pontremoli R., De Cosmo S. GLP-1 receptor agonists and kidney protection. Medicina (Kaunas). 2019;55(6):233. DOI: 10.3390/medicina55060233</mixed-citation><mixed-citation xml:lang="en">Greco E.V., Russo G., Giandalia A., Viazzi F., Pontremoli R., De Cosmo S. GLP-1 receptor agonists and kidney protection. Medicina (Kaunas). 2019;55(6):233. DOI: 10.3390/medicina55060233</mixed-citation></citation-alternatives></ref><ref id="cit314"><label>314</label><citation-alternatives><mixed-citation xml:lang="ru">Marso S.P., Daniels G.H., Brown-Frandsen K., Kristensen P., Mann J.F., Nauck M.A., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22. DOI: 10.1056/NEJMoa1603827</mixed-citation><mixed-citation xml:lang="en">Marso S.P., Daniels G.H., Brown-Frandsen K., Kristensen P., Mann J.F., Nauck M.A., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22. DOI: 10.1056/NEJMoa1603827</mixed-citation></citation-alternatives></ref><ref id="cit315"><label>315</label><citation-alternatives><mixed-citation xml:lang="ru">Marso S.P., Bain S.C., Consoli A., Eliaschewitz F.G., Jódar E., Leiter L.A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44. DOI: 10.1056/NEJMoa1607141</mixed-citation><mixed-citation xml:lang="en">Marso S.P., Bain S.C., Consoli A., Eliaschewitz F.G., Jódar E., Leiter L.A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44. DOI: 10.1056/NEJMoa1607141</mixed-citation></citation-alternatives></ref><ref id="cit316"><label>316</label><citation-alternatives><mixed-citation xml:lang="ru">Gerstein H.C., Colhoun H.M., Dagenais G.R., Diaz R., Lakshmanan M., Pais P., et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–30. DOI: 10.1016/S0140-6736(19)31149-3</mixed-citation><mixed-citation xml:lang="en">Gerstein H.C., Colhoun H.M., Dagenais G.R., Diaz R., Lakshmanan M., Pais P., et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–30. DOI: 10.1016/S0140-6736(19)31149-3</mixed-citation></citation-alternatives></ref><ref id="cit317"><label>317</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Y., Jiang L., Wang J., Wang T., Chien C., Huang W., et al. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. Cardiovasc Diabetol. 2022;21(1):232. DOI: 10.1186/s12933-022-01676-5</mixed-citation><mixed-citation xml:lang="en">Zhang Y., Jiang L., Wang J., Wang T., Chien C., Huang W., et al. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. Cardiovasc Diabetol. 2022;21(1):232. DOI: 10.1186/s12933-022-01676-5</mixed-citation></citation-alternatives></ref><ref id="cit318"><label>318</label><citation-alternatives><mixed-citation xml:lang="ru">Ludwig J., Viggiano T.R., McGill D.B., Oh B.J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55(7):434–8.</mixed-citation><mixed-citation xml:lang="en">Ludwig J., Viggiano T.R., McGill D.B., Oh B.J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55(7):434–8.</mixed-citation></citation-alternatives></ref><ref id="cit319"><label>319</label><citation-alternatives><mixed-citation xml:lang="ru">Powell E.E., Cooksley W.G., Hanson R., Searle J., Halliday J.W., Powell L.W. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11(1):74–80. DOI: 10.1002/hep.1840110114</mixed-citation><mixed-citation xml:lang="en">Powell E.E., Cooksley W.G., Hanson R., Searle J., Halliday J.W., Powell L.W. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11(1):74–80. DOI: 10.1002/hep.1840110114</mixed-citation></citation-alternatives></ref><ref id="cit320"><label>320</label><citation-alternatives><mixed-citation xml:lang="ru">Ajmera V., Belt P., Wilson L.A., Gill R.M., Loomba R., Kleiner D.E., et al. Among patients with nonalcoholic fatty liver disease, modest alcohol use is associated with less improvement in histologic steatosis and steatohepatitis. Clin Gastroenterol Hepatol. 2018;16(9):1511–20.e5. DOI: 10.1016/j.cgh.2018.01.026</mixed-citation><mixed-citation xml:lang="en">Ajmera V., Belt P., Wilson L.A., Gill R.M., Loomba R., Kleiner D.E., et al. Among patients with nonalcoholic fatty liver disease, modest alcohol use is associated with less improvement in histologic steatosis and steatohepatitis. Clin Gastroenterol Hepatol. 2018;16(9):1511–20.e5. DOI: 10.1016/j.cgh.2018.01.026</mixed-citation></citation-alternatives></ref><ref id="cit321"><label>321</label><citation-alternatives><mixed-citation xml:lang="ru">Kimura T., Tanaka N., Fujimori N., Sugiura A., Yamazaki T., Joshita S., et al. Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis. World J Gastroenterol. 2018;24(13):1440–50. DOI: 10.3748/wjg.v24.i13.1440</mixed-citation><mixed-citation xml:lang="en">Kimura T., Tanaka N., Fujimori N., Sugiura A., Yamazaki T., Joshita S., et al. Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis. World J Gastroenterol. 2018;24(13):1440–50. DOI: 10.3748/wjg.v24.i13.1440</mixed-citation></citation-alternatives></ref><ref id="cit322"><label>322</label><citation-alternatives><mixed-citation xml:lang="ru">Younossi Z.M., Stepanova M., Ong J., Yilmaz Y., Duseja A., Eguchi Y., et al. Effects of alcohol consumption and metabolic syndrome on mortality in patients with nonalcoholic and alcohol-related fatty liver disease. Clin Gastroenterol Hepatol. 2019;17(8):1625–33.e1. DOI: 10.1016/j.cgh.2018.11.033</mixed-citation><mixed-citation xml:lang="en">Younossi Z.M., Stepanova M., Ong J., Yilmaz Y., Duseja A., Eguchi Y., et al. Effects of alcohol consumption and metabolic syndrome on mortality in patients with nonalcoholic and alcohol-related fatty liver disease. Clin Gastroenterol Hepatol. 2019;17(8):1625–33.e1. DOI: 10.1016/j.cgh.2018.11.033</mixed-citation></citation-alternatives></ref><ref id="cit323"><label>323</label><citation-alternatives><mixed-citation xml:lang="ru">Ekstedt M., Franzén L.E., Holmqvist M., Bendtsen P., Mathiesen U.L., Bodemar G., et al. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease. Scand J Gastroenterol. 2009;44(3):366–74. DOI: 10.1080/00365520802555991</mixed-citation><mixed-citation xml:lang="en">Ekstedt M., Franzén L.E., Holmqvist M., Bendtsen P., Mathiesen U.L., Bodemar G., et al. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease. Scand J Gastroenterol. 2009;44(3):366–74. DOI: 10.1080/00365520802555991</mixed-citation></citation-alternatives></ref><ref id="cit324"><label>324</label><citation-alternatives><mixed-citation xml:lang="ru">Sookoian S., Castaño G.O., Pirola C.J. Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease: A meta-analysis of 43,175 individuals. Gut. 2014;63(3):530–2. DOI: 10.1136/gutjnl-2013-305718</mixed-citation><mixed-citation xml:lang="en">Sookoian S., Castaño G.O., Pirola C.J. Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease: A meta-analysis of 43,175 individuals. Gut. 2014;63(3):530–2. DOI: 10.1136/gutjnl-2013-305718</mixed-citation></citation-alternatives></ref><ref id="cit325"><label>325</label><citation-alternatives><mixed-citation xml:lang="ru">Cao G., Yi T., Liu Q., Wang M., Tang S. Alcohol consumption and risk of fatty liver disease: A meta-analysis. PeerJ. 2016;4:e2633. DOI: 10.7717/peerj.2633</mixed-citation><mixed-citation xml:lang="en">Cao G., Yi T., Liu Q., Wang M., Tang S. Alcohol consumption and risk of fatty liver disease: A meta-analysis. PeerJ. 2016;4:e2633. DOI: 10.7717/peerj.2633</mixed-citation></citation-alternatives></ref><ref id="cit326"><label>326</label><citation-alternatives><mixed-citation xml:lang="ru">Chang Y., Cho Y.K., Kim Y., Sung E., Ahn J., Jung H.S., et al. Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease: A cohort study. Hepatology. 2019;69(1):64–75. DOI: 10.1002/hep.30170</mixed-citation><mixed-citation xml:lang="en">Chang Y., Cho Y.K., Kim Y., Sung E., Ahn J., Jung H.S., et al. Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease: A cohort study. Hepatology. 2019;69(1):64–75. DOI: 10.1002/hep.30170</mixed-citation></citation-alternatives></ref><ref id="cit327"><label>327</label><citation-alternatives><mixed-citation xml:lang="ru">Blomdahl J., Nasr P., Ekstedt M., Kechagias S. Moderate alcohol consumption is associated with significant fibrosis progression in NAFLD. Hepatol Commun. 2023;7(1):e0003. DOI: 10.1097/HC9.0000000000000003</mixed-citation><mixed-citation xml:lang="en">Blomdahl J., Nasr P., Ekstedt M., Kechagias S. Moderate alcohol consumption is associated with significant fibrosis progression in NAFLD. Hepatol Commun. 2023;7(1):e0003. DOI: 10.1097/HC9.0000000000000003</mixed-citation></citation-alternatives></ref><ref id="cit328"><label>328</label><citation-alternatives><mixed-citation xml:lang="ru">Ивашкин В.Т., Жаркова М.С., Корочанская Н.В., Хлынов И.Б., Успенский Ю.П. Фенотипы неалкогольной жировой болезни печени в различных регионах Российской Федерации, диагностические и лечебные подходы в клинической практике. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2023;33(2):7–18. DOI: 10.22416/1382-4376-2023-33-2-7-18</mixed-citation><mixed-citation xml:lang="en">Ivashkin V.T., Zharkova M.S., Korochanskaya N.V., Khlynov I.B., Uspensky Yu.P. Phenotypes of non-alcoholic fatty liver disease in different regions of the Russian Federation, diagnostic and therapeutic approach in clinical practice. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2023;33(2):7–18. (In Russ.). DOI: 10.22416/1382-4376-2023-33-2-7-18</mixed-citation></citation-alternatives></ref><ref id="cit329"><label>329</label><citation-alternatives><mixed-citation xml:lang="ru">Mato J.M., Cámara J., Fernández de Paz J., Caballería L., Coll S., Caballero A., et al. S-adenosylmethionine in alcoholic liver cirrhosis: A randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol. 1999;30(6):1081–9. DOI: 10.1016/s0168-8278(99)80263-3</mixed-citation><mixed-citation xml:lang="en">Mato J.M., Cámara J., Fernández de Paz J., Caballería L., Coll S., Caballero A., et al. S-adenosylmethionine in alcoholic liver cirrhosis: A randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol. 1999;30(6):1081–9. DOI: 10.1016/s0168-8278(99)80263-3</mixed-citation></citation-alternatives></ref><ref id="cit330"><label>330</label><citation-alternatives><mixed-citation xml:lang="ru">Rambaldi A., Gluud C. S-adenosyl-L-methionine for alcoholic liver diseases. Cochrane Database Syst Rev. 2006;2:CD002235. DOI: 10.1002/14651858.CD002235.pub2</mixed-citation><mixed-citation xml:lang="en">Rambaldi A., Gluud C. S-adenosyl-L-methionine for alcoholic liver diseases. Cochrane Database Syst Rev. 2006;2:CD002235. DOI: 10.1002/14651858.CD002235.pub2</mixed-citation></citation-alternatives></ref><ref id="cit331"><label>331</label><citation-alternatives><mixed-citation xml:lang="ru">Lassailly G., Caiazzo R., Buob D., Pigeyre M., Verkindt H., Labreuche J., et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology. 2015;149(2):379–88. DOI: 10.1053/j.gastro.2015.04.014</mixed-citation><mixed-citation xml:lang="en">Lassailly G., Caiazzo R., Buob D., Pigeyre M., Verkindt H., Labreuche J., et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology. 2015;149(2):379–88. DOI: 10.1053/j.gastro.2015.04.014</mixed-citation></citation-alternatives></ref><ref id="cit332"><label>332</label><citation-alternatives><mixed-citation xml:lang="ru">Bower G., Toma T., Harling L., Jiao L.R., Efthimiou E., Darzi A., et al. Bariatric surgery and non-alcoholic fatty liver disease: A systematic review of liver biochemistry and histology. Obes Surg. 2015;25(12):2280–9. DOI: 10.1007/s11695-015-1691-x</mixed-citation><mixed-citation xml:lang="en">Bower G., Toma T., Harling L., Jiao L.R., Efthimiou E., Darzi A., et al. Bariatric surgery and non-alcoholic fatty liver disease: A systematic review of liver biochemistry and histology. Obes Surg. 2015;25(12):2280–9. DOI: 10.1007/s11695-015-1691-x</mixed-citation></citation-alternatives></ref><ref id="cit333"><label>333</label><citation-alternatives><mixed-citation xml:lang="ru">Lee Y., Doumouras A.G., Yu J., Brar K., Banfield L., Gmora S., et al. Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17(6):1040–60.e11. DOI: 10.1016/j.cgh.2018.10.017</mixed-citation><mixed-citation xml:lang="en">Lee Y., Doumouras A.G., Yu J., Brar K., Banfield L., Gmora S., et al. Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17(6):1040–60.e11. DOI: 10.1016/j.cgh.2018.10.017</mixed-citation></citation-alternatives></ref><ref id="cit334"><label>334</label><citation-alternatives><mixed-citation xml:lang="ru">Fakhry T.K., Mhaskar R., Schwitalla T., Muradova E., Gonzalvo J.P., Murr M.M. Bariatric surgery improves nonalcoholic fatty liver disease: A contemporary systematic review and meta-analysis. Surg Obes Relat Dis. 2019;15(3):502–11. DOI: 10.1016/j.soard.2018.12.002</mixed-citation><mixed-citation xml:lang="en">Fakhry T.K., Mhaskar R., Schwitalla T., Muradova E., Gonzalvo J.P., Murr M.M. Bariatric surgery improves nonalcoholic fatty liver disease: A contemporary systematic review and meta-analysis. Surg Obes Relat Dis. 2019;15(3):502–11. DOI: 10.1016/j.soard.2018.12.002</mixed-citation></citation-alternatives></ref><ref id="cit335"><label>335</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou H., Luo P., Li P., Wang G., Yi X., Fu Z., et al. Bariatric surgery improves nonalcoholic fatty liver disease: Systematic review and meta-analysis. Obes Surg. 2022;32(6):1872–83. DOI: 10.1007/s11695-022-06011-1</mixed-citation><mixed-citation xml:lang="en">Zhou H., Luo P., Li P., Wang G., Yi X., Fu Z., et al. Bariatric surgery improves nonalcoholic fatty liver disease: Systematic review and meta-analysis. Obes Surg. 2022;32(6):1872–83. DOI: 10.1007/s11695-022-06011-1</mixed-citation></citation-alternatives></ref><ref id="cit336"><label>336</label><citation-alternatives><mixed-citation xml:lang="ru">Lazarus J.V., Mark H.E., Anstee Q.M., Arab J.P., Batterham R.L., Castera L., et al. Advancing the global public health agenda for NAFLD: A consensus statement. Nat Rev Gastroenterol Hepatol. 2022;19(1):60–78. DOI: 10.1038/s41575-021-00523-4</mixed-citation><mixed-citation xml:lang="en">Lazarus J.V., Mark H.E., Anstee Q.M., Arab J.P., Batterham R.L., Castera L., et al. Advancing the global public health agenda for NAFLD: A consensus statement. Nat Rev Gastroenterol Hepatol. 2022;19(1):60–78. DOI: 10.1038/s41575-021-00523-4</mixed-citation></citation-alternatives></ref><ref id="cit337"><label>337</label><citation-alternatives><mixed-citation xml:lang="ru">European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Obes Facts. 2016;9(2):65–90. DOI: 10.1159/000443344</mixed-citation><mixed-citation xml:lang="en">European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Obes Facts. 2016;9(2):65–90. DOI: 10.1159/000443344</mixed-citation></citation-alternatives></ref><ref id="cit338"><label>338</label><citation-alternatives><mixed-citation xml:lang="ru">Fernández T., Viñuela M., Vidal C., Barrera F. Lifestyle changes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. PLoS One. 2022;17(2):e0263931. DOI: 10.1371/journal.pone.0263931</mixed-citation><mixed-citation xml:lang="en">Fernández T., Viñuela M., Vidal C., Barrera F. Lifestyle changes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. PLoS One. 2022;17(2):e0263931. DOI: 10.1371/journal.pone.0263931</mixed-citation></citation-alternatives></ref><ref id="cit339"><label>339</label><citation-alternatives><mixed-citation xml:lang="ru">Glass L.M., Hunt C.M., Fuchs M., Su G.L. Comorbidities and nonalcoholic fatty liver disease: The chicken, the egg, or both? Fed Pract. 2019;36(2):64–71.</mixed-citation><mixed-citation xml:lang="en">Glass L.M., Hunt C.M., Fuchs M., Su G.L. Comorbidities and nonalcoholic fatty liver disease: The chicken, the egg, or both? Fed Pract. 2019;36(2):64–71.</mixed-citation></citation-alternatives></ref><ref id="cit340"><label>340</label><citation-alternatives><mixed-citation xml:lang="ru">Singh S., Singh P.P., Singh A.G., Murad M.H., Sanchez W. Anti-diabetic medications and the risk of hepatocellular cancer: A systematic review and meta-analysis. Am J Gastroenterol. 2013;108(6):881–91. DOI: 10.1038/ajg.2013.5</mixed-citation><mixed-citation xml:lang="en">Singh S., Singh P.P., Singh A.G., Murad M.H., Sanchez W. Anti-diabetic medications and the risk of hepatocellular cancer: A systematic review and meta-analysis. Am J Gastroenterol. 2013;108(6):881–91. DOI: 10.1038/ajg.2013.5</mixed-citation></citation-alternatives></ref><ref id="cit341"><label>341</label><citation-alternatives><mixed-citation xml:lang="ru">Ma S., Zheng Y., Xiao Y., Zhou P., Tan H. Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients. Medicine (Baltimore). 2017;96(19):e6888. DOI: 10.1097/MD.0000000000006888</mixed-citation><mixed-citation xml:lang="en">Ma S., Zheng Y., Xiao Y., Zhou P., Tan H. Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients. Medicine (Baltimore). 2017;96(19):e6888. DOI: 10.1097/MD.0000000000006888</mixed-citation></citation-alternatives></ref><ref id="cit342"><label>342</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou Y.Y., Zhu G.Q., Liu T., Zheng J.N., Cheng Z., Zou T.T., et al. Systematic review with network meta-analysis: Antidiabetic medication and risk of hepatocellular carcinoma. Sci Rep. 2016;6:33743. DOI: 10.1038/srep33743</mixed-citation><mixed-citation xml:lang="en">Zhou Y.Y., Zhu G.Q., Liu T., Zheng J.N., Cheng Z., Zou T.T., et al. Systematic review with network meta-analysis: Antidiabetic medication and risk of hepatocellular carcinoma. Sci Rep. 2016;6:33743. DOI: 10.1038/srep33743</mixed-citation></citation-alternatives></ref><ref id="cit343"><label>343</label><citation-alternatives><mixed-citation xml:lang="ru">Singh S., Singh P.P., Singh A.G., Murad M.H., Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: A systematic review and meta-analysis. Gastroenterology. 2013;144(2):323–32. DOI: 10.1053/j.gastro.2012.10.005</mixed-citation><mixed-citation xml:lang="en">Singh S., Singh P.P., Singh A.G., Murad M.H., Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: A systematic review and meta-analysis. Gastroenterology. 2013;144(2):323–32. DOI: 10.1053/j.gastro.2012.10.005</mixed-citation></citation-alternatives></ref><ref id="cit344"><label>344</label><citation-alternatives><mixed-citation xml:lang="ru">Singal A., Volk M.L., Waljee A., Salgia R., Higgins P., Rogers M.A., et al. Meta-analysis: Surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30(1):37–47. DOI: 10.1111/j.1365-2036.2009.04014.x</mixed-citation><mixed-citation xml:lang="en">Singal A., Volk M.L., Waljee A., Salgia R., Higgins P., Rogers M.A., et al. Meta-analysis: Surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30(1):37–47. DOI: 10.1111/j.1365-2036.2009.04014.x</mixed-citation></citation-alternatives></ref><ref id="cit345"><label>345</label><citation-alternatives><mixed-citation xml:lang="ru">European Association for the Study of the Liver. EASL clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. DOI: 10.1016/j.jhep.2018.03.019</mixed-citation><mixed-citation xml:lang="en">European Association for the Study of the Liver. EASL clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. DOI: 10.1016/j.jhep.2018.03.019</mixed-citation></citation-alternatives></ref><ref id="cit346"><label>346</label><citation-alternatives><mixed-citation xml:lang="ru">Machado M.V. The growing landscape of NAFLD-associated hepatocellular carcinoma and its impact in surveillance. GE Port J Gastroenterol. 2023;31(1):14–23. DOI: 10.1159/000531397</mixed-citation><mixed-citation xml:lang="en">Machado M.V. The growing landscape of NAFLD-associated hepatocellular carcinoma and its impact in surveillance. GE Port J Gastroenterol. 2023;31(1):14–23. DOI: 10.1159/000531397</mixed-citation></citation-alternatives></ref><ref id="cit347"><label>347</label><citation-alternatives><mixed-citation xml:lang="ru">Younossi Z., Stepanova M., Ong J.P., Jacobson I.M., Bugianesi E., Duseja A., et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2019;17(4):748–55.e3. DOI: 10.1016/j.cgh.2018.05.057</mixed-citation><mixed-citation xml:lang="en">Younossi Z., Stepanova M., Ong J.P., Jacobson I.M., Bugianesi E., Duseja A., et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2019;17(4):748–55.e3. DOI: 10.1016/j.cgh.2018.05.057</mixed-citation></citation-alternatives></ref><ref id="cit348"><label>348</label><citation-alternatives><mixed-citation xml:lang="ru">Ducreux M., Abou-Alfa G.K., Bekaii-Saab T., Berlin J., Cervantes A., de Baere T., et al. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022. ESMO Open. 2023;8(3):101567. DOI: 10.1016/j.esmoop.2023.101567</mixed-citation><mixed-citation xml:lang="en">Ducreux M., Abou-Alfa G.K., Bekaii-Saab T., Berlin J., Cervantes A., de Baere T., et al. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022. ESMO Open. 2023;8(3):101567. DOI: 10.1016/j.esmoop.2023.101567</mixed-citation></citation-alternatives></ref><ref id="cit349"><label>349</label><citation-alternatives><mixed-citation xml:lang="ru">Adams L.A., Lymp J.F., St Sauver J., Sanderson S.O., Lindor K.D., Feldstein A., et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology. 2005;129(1):113–21. DOI: 10.1053/j.gastro.2005.04.014</mixed-citation><mixed-citation xml:lang="en">Adams L.A., Lymp J.F., St Sauver J., Sanderson S.O., Lindor K.D., Feldstein A., et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology. 2005;129(1):113–21. DOI: 10.1053/j.gastro.2005.04.014</mixed-citation></citation-alternatives></ref><ref id="cit350"><label>350</label><citation-alternatives><mixed-citation xml:lang="ru">Hashimoto E., Yatsuji S., Tobari M., Taniai M., Torii N., Tokushige K., et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol. 2009;44(Suppl. 19):89–95. DOI: 10.1007/s00535-008-2262-x</mixed-citation><mixed-citation xml:lang="en">Hashimoto E., Yatsuji S., Tobari M., Taniai M., Torii N., Tokushige K., et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol. 2009;44(Suppl. 19):89–95. DOI: 10.1007/s00535-008-2262-x</mixed-citation></citation-alternatives></ref><ref id="cit351"><label>351</label><citation-alternatives><mixed-citation xml:lang="ru">Ascha M.S., Hanouneh I.A., Lopez R., Tamimi T.A., Feldstein A.F., Zein N.N. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51(6):1972–8. DOI: 10.1002/hep.23527</mixed-citation><mixed-citation xml:lang="en">Ascha M.S., Hanouneh I.A., Lopez R., Tamimi T.A., Feldstein A.F., Zein N.N. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51(6):1972–8. DOI: 10.1002/hep.23527</mixed-citation></citation-alternatives></ref><ref id="cit352"><label>352</label><citation-alternatives><mixed-citation xml:lang="ru">Bertot L.C., Jeffrey G.P., Wallace M., MacQuillan G., Garas G., Ching H.L., et al. Nonalcoholic fatty liver disease-related cirrhosis is commonly unrecognized and associated with hepatocellular carcinoma. Hepatol Commun. 2017;1(1):53–60. DOI: 10.1002/hep4.1018</mixed-citation><mixed-citation xml:lang="en">Bertot L.C., Jeffrey G.P., Wallace M., MacQuillan G., Garas G., Ching H.L., et al. Nonalcoholic fatty liver disease-related cirrhosis is commonly unrecognized and associated with hepatocellular carcinoma. Hepatol Commun. 2017;1(1):53–60. DOI: 10.1002/hep4.1018</mixed-citation></citation-alternatives></ref><ref id="cit353"><label>353</label><citation-alternatives><mixed-citation xml:lang="ru">Than N.N., Ghazanfar A., Hodson J., Tehami N., Coldham C., Mergental H., et al. Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease. QJM. 2017;110(2):73–81. DOI: 10.1093/qjmed/hcw151</mixed-citation><mixed-citation xml:lang="en">Than N.N., Ghazanfar A., Hodson J., Tehami N., Coldham C., Mergental H., et al. Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease. QJM. 2017;110(2):73–81. DOI: 10.1093/qjmed/hcw151</mixed-citation></citation-alternatives></ref><ref id="cit354"><label>354</label><citation-alternatives><mixed-citation xml:lang="ru">Yoo J.J., Park M.Y., Cho E.J., Yu S.J., Kim S.G., Kim Y.J., et al. Smoking increases the risk of hepatocellular carcinoma and cardiovascular disease in patients with metabolic-associated fatty liver disease. J Clin Med. 2023;12(9):3336. DOI: 10.3390/jcm12093336</mixed-citation><mixed-citation xml:lang="en">Yoo J.J., Park M.Y., Cho E.J., Yu S.J., Kim S.G., Kim Y.J., et al. Smoking increases the risk of hepatocellular carcinoma and cardiovascular disease in patients with metabolic-associated fatty liver disease. J Clin Med. 2023;12(9):3336. DOI: 10.3390/jcm12093336</mixed-citation></citation-alternatives></ref><ref id="cit355"><label>355</label><citation-alternatives><mixed-citation xml:lang="ru">Caussy C., Soni M., Cui J., Bettencourt R., Schork N., Chen C.H., et al. Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. J Clin Invest. 2017;127(7):2697–704. DOI: 10.1172/JCI93465</mixed-citation><mixed-citation xml:lang="en">Caussy C., Soni M., Cui J., Bettencourt R., Schork N., Chen C.H., et al. Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. J Clin Invest. 2017;127(7):2697–704. DOI: 10.1172/JCI93465</mixed-citation></citation-alternatives></ref><ref id="cit356"><label>356</label><citation-alternatives><mixed-citation xml:lang="ru">Wijarnpreecha K., Thongprayoon C., Ungprasert P. Coffee consumption and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017;29(2):e8–12. DOI: 10.1097/MEG.0000000000000776</mixed-citation><mixed-citation xml:lang="en">Wijarnpreecha K., Thongprayoon C., Ungprasert P. Coffee consumption and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017;29(2):e8–12. DOI: 10.1097/MEG.0000000000000776</mixed-citation></citation-alternatives></ref><ref id="cit357"><label>357</label><citation-alternatives><mixed-citation xml:lang="ru">Hayat U., Siddiqui A.A., Okut H., Afroz S., Tasleem S., Haris A. The effect of coffee consumption on the non-alcoholic fatty liver disease and liver fibrosis: A meta-analysis of 11 epidemiological studies. Ann Hepatol. 2021;20:100254. DOI: 10.1016/j.aohep.2020.08.071</mixed-citation><mixed-citation xml:lang="en">Hayat U., Siddiqui A.A., Okut H., Afroz S., Tasleem S., Haris A. The effect of coffee consumption on the non-alcoholic fatty liver disease and liver fibrosis: A meta-analysis of 11 epidemiological studies. Ann Hepatol. 2021;20:100254. DOI: 10.1016/j.aohep.2020.08.071</mixed-citation></citation-alternatives></ref><ref id="cit358"><label>358</label><citation-alternatives><mixed-citation xml:lang="ru">Kennedy O.J., Roderick P., Buchanan R., Fallowfield J.A., Hayes P.C., Parkes J. Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: A systematic review and dose-response meta-analysis. BMJ Open. 2017;7(5):e013739. DOI: 10.1136/bmjopen-2016-013739</mixed-citation><mixed-citation xml:lang="en">Kennedy O.J., Roderick P., Buchanan R., Fallowfield J.A., Hayes P.C., Parkes J. Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: A systematic review and dose-response meta-analysis. BMJ Open. 2017;7(5):e013739. DOI: 10.1136/bmjopen-2016-013739</mixed-citation></citation-alternatives></ref><ref id="cit359"><label>359</label><citation-alternatives><mixed-citation xml:lang="ru">Shen H., Rodriguez A.C., Shiani A., Lipka S., Shahzad G., Kumar A., et al. Association between caffeine consumption and nonalcoholic fatty liver disease: A systemic review and meta-analysis. Therap Adv Gastroenterol. 2016;9(1):113–20. DOI: 10.1177/1756283X15593700</mixed-citation><mixed-citation xml:lang="en">Shen H., Rodriguez A.C., Shiani A., Lipka S., Shahzad G., Kumar A., et al. Association between caffeine consumption and nonalcoholic fatty liver disease: A systemic review and meta-analysis. Therap Adv Gastroenterol. 2016;9(1):113–20. DOI: 10.1177/1756283X15593700</mixed-citation></citation-alternatives></ref><ref id="cit360"><label>360</label><citation-alternatives><mixed-citation xml:lang="ru">Chen Y.P., Lu F.B., Hu Y.B., Xu L.M., Zheng M.H., Hu E.D. A systematic review and a dose-response meta-analysis of coffee dose and nonalcoholic fatty liver disease. Clin Nutr. 2019;38(6):2552–7. DOI: 10.1016/j.clnu.2018.11.030</mixed-citation><mixed-citation xml:lang="en">Chen Y.P., Lu F.B., Hu Y.B., Xu L.M., Zheng M.H., Hu E.D. A systematic review and a dose-response meta-analysis of coffee dose and nonalcoholic fatty liver disease. Clin Nutr. 2019;38(6):2552–7. DOI: 10.1016/j.clnu.2018.11.030</mixed-citation></citation-alternatives></ref><ref id="cit361"><label>361</label><citation-alternatives><mixed-citation xml:lang="ru">Marventano S., Salomone F., Godos J., Pluchinotta F., Del Rio D., Mistretta A., et al. Coffee and tea consumption in relation with non-alcoholic fatty liver and metabolic syndrome: A systematic review and meta-analysis of observational studies. Clin Nutr. 2016;35(6):1269–81. DOI: 10.1016/j.clnu.2016.03.012</mixed-citation><mixed-citation xml:lang="en">Marventano S., Salomone F., Godos J., Pluchinotta F., Del Rio D., Mistretta A., et al. Coffee and tea consumption in relation with non-alcoholic fatty liver and metabolic syndrome: A systematic review and meta-analysis of observational studies. Clin Nutr. 2016;35(6):1269–81. DOI: 10.1016/j.clnu.2016.03.012</mixed-citation></citation-alternatives></ref><ref id="cit362"><label>362</label><citation-alternatives><mixed-citation xml:lang="ru">Ebadi M., Ip S., Bhanji R.A., Montano-Loza A.J. Effect of coffee consumption on non-alcoholic fatty liver disease incidence, prevalence and risk of significant liver fibrosis: Systematic review with meta-analysis of observational studies. Nutrients. 2021;13(9):3042. DOI: 10.3390/nu13093042</mixed-citation><mixed-citation xml:lang="en">Ebadi M., Ip S., Bhanji R.A., Montano-Loza A.J. Effect of coffee consumption on non-alcoholic fatty liver disease incidence, prevalence and risk of significant liver fibrosis: Systematic review with meta-analysis of observational studies. Nutrients. 2021;13(9):3042. DOI: 10.3390/nu13093042</mixed-citation></citation-alternatives></ref><ref id="cit363"><label>363</label><citation-alternatives><mixed-citation xml:lang="ru">Birerdinc A., Stepanova M., Pawloski L., Younossi Z.M. Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2012;35(1):76–82. DOI: 10.1111/j.1365-2036.2011.04916.x</mixed-citation><mixed-citation xml:lang="en">Birerdinc A., Stepanova M., Pawloski L., Younossi Z.M. Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2012;35(1):76–82. DOI: 10.1111/j.1365-2036.2011.04916.x</mixed-citation></citation-alternatives></ref><ref id="cit364"><label>364</label><citation-alternatives><mixed-citation xml:lang="ru">Inoue M., Yoshimi I., Sobue T., Tsugane S. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: A prospective study in Japan. J Natl Cancer Inst. 2005;97(4):293–300. DOI: 10.1093/jnci/dji040</mixed-citation><mixed-citation xml:lang="en">Inoue M., Yoshimi I., Sobue T., Tsugane S. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: A prospective study in Japan. J Natl Cancer Inst. 2005;97(4):293–300. DOI: 10.1093/jnci/dji040</mixed-citation></citation-alternatives></ref><ref id="cit365"><label>365</label><citation-alternatives><mixed-citation xml:lang="ru">Johnson S., Koh W.P., Wang R., Govindarajan S., Yu M.C., Yuan J.M. Coffee consumption and reduced risk of hepatocellular carcinoma: Findings from the Singapore Chinese Health Study. Cancer Causes Control. 2011;22(3):503–10. DOI: 10.1007/s10552-010-9725-0</mixed-citation><mixed-citation xml:lang="en">Johnson S., Koh W.P., Wang R., Govindarajan S., Yu M.C., Yuan J.M. Coffee consumption and reduced risk of hepatocellular carcinoma: Findings from the Singapore Chinese Health Study. Cancer Causes Control. 2011;22(3):503–10. DOI: 10.1007/s10552-010-9725-0</mixed-citation></citation-alternatives></ref><ref id="cit366"><label>366</label><citation-alternatives><mixed-citation xml:lang="ru">Hu G., Tuomilehto J., Pukkala E., Hakulinen T., Antikainen R., Vartiainen E., et al. Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer. Hepatology. 2008;48(1):129–36. DOI: 10.1002/hep.22320</mixed-citation><mixed-citation xml:lang="en">Hu G., Tuomilehto J., Pukkala E., Hakulinen T., Antikainen R., Vartiainen E., et al. Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer. Hepatology. 2008;48(1):129–36. DOI: 10.1002/hep.22320</mixed-citation></citation-alternatives></ref><ref id="cit367"><label>367</label><citation-alternatives><mixed-citation xml:lang="ru">Tanaka K., Hara M., Sakamoto T., Higaki Y., Mizuta T., Eguchi Y., et al. Inverse association between coffee drinking and the risk of hepatocellular carcinoma: A case-control study in Japan. Cancer Sci. 2007;98(2):214–8. DOI: 10.1111/j.1349-7006.2006.00368.x</mixed-citation><mixed-citation xml:lang="en">Tanaka K., Hara M., Sakamoto T., Higaki Y., Mizuta T., Eguchi Y., et al. Inverse association between coffee drinking and the risk of hepatocellular carcinoma: A case-control study in Japan. Cancer Sci. 2007;98(2):214–8. DOI: 10.1111/j.1349-7006.2006.00368.x</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
